



chain nodes :
7
ring nodes :
1 2 3 4 5 6 8 9 10 11 12 13
chain bonds :
6-7 7-8
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 6-7 7-8 8-9 8-13 9-10 10-11 11-12 12-13

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom

L1 STRUCTURE UPLOADED

=> d ;1
L1 HAS NO ANSWERS
L1 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

1 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 14:14:30 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1449 TO ITERATE

69.0% PROCESSED 1000 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 26697 TO 31263
PROJECTED ANSWERS: 5331 TO 7477

L2 50 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 14:14:35 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 28303 TO ITERATE

100.0% PROCESSED 28303 ITERATIONS 7113 ANSWERS
SEARCH TIME: 00.00.01

L3 7113 SEA SSS FUL L1

=>
Uploading C:\Program Files\Stnexp\Queries\168pt2.str





chain nodes :
15 16 17
ring nodes :
1 2 3 4 5 6 9 10 11 12 13 14
chain bonds :
6-9 13-15 15-16 16-17
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 6-9 9-10 9-14 10-11 11-12 12-13 13-14 13-15 15-16
16-17

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 9:Atom 10:Atom 11:Atom 12:Atom
13:Atom 14:CLASS 15:CLASS 16:CLASS 17:CLASS

L4 STRUCTURE UPLOADED

=> d l4
L4 HAS NO ANSWERS
L4 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l4
SAMPLE SEARCH INITIATED 14:18:59 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    212 TO ITERATE

100.0% PROCESSED     212 ITERATIONS                          22 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         3367 TO     5113
PROJECTED ANSWERS:             159 TO      721

L5            22 SEA SSS SAM L4

=> s l4 full
FULL SEARCH INITIATED 14:19:05 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   4548 TO ITERATE

100.0% PROCESSED    4548 ITERATIONS                         546 ANSWERS
SEARCH TIME: 00.00.01

L6           546 SEA SSS FUL L4

=> fil caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               325.67     325.88

FILE 'CAPLUS' ENTERED AT 14:19:12 ON 24 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 24 Jun 2005  VOL 143 ISS 1
FILE LAST UPDATED: 23 Jun 2005  (20050623/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.

=> s l6
L7            87 L6

=> d ed abs ibib hitstr 1-87
```

L7 ANSWER 1 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 02 Jul 2004
GI



I



II

AB Title compds. I [R1 = (un)substituted-alkyl, -alkenyl, -alkynyl, -cycloalkyl, etc., or R1 and X taken together from a saturated, partially saturated, or aromatic 5-6 membered ring having 0-3 heteroatoms selected from O, P, S or N fused to ring A; R2 = OH, halo, (un)substituted-alkyl, -alkynyl, -heteroaryl, etc., optionally two adjacent R2s taken together form a fused, saturated, partially saturated or aromatic 5-6 membered ring having 0-3 heteroatoms selected from O, P, S, or N, or two geminal R2s optionally taken together from a (un)substituted spiro, saturated, partially saturated or aromatic 5-6 membered ring having 0-3 heteroatoms selected from O, P, S or N, said fused or spiro ring being optionally substituted; X = (un)substituted-alkylene chain which optionally may have 0-3 heteroatoms selected from O, P, S or N; A = saturated, partially saturated, or aromatic 3-7 monocyclic or 8-10 membered bicyclic ring having one ring nitrogen and 0-4 addnl. heteroatoms selected from O, P, S or N ; Ring B contains an oxygen atom in addition to depicted N; R3 = H, amine, CF3, halo, (un)substituted alkyl, etc., Y = alkyl, alkenyl, alkynyl, carbonyl, thiocarbonyl, etc.; m = 0-1, n = 0-5] and their pharmaceutically acceptable salts are prepared and disclosed as CCR5 antagonists. Thus, II was prepared by reaction of [3-(2,2-dimethylpropanoyl)-6-phenyl-1,3-oxazinan-6-yl]acetaldehyde (preparation given) with 1-[(1R,5S)-8-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1H-benzimidazole dihydrochloride. I have pIC50 values of ≥5 in assays for CCR5 antagonism. As CCR5 antagonists, I are useful for the treatment of viral infections (particularly HIV infection).
ACCESSION NUMBER: 2004:534199 CAPLUS

L7 ANSWER 1 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
DOCUMENT NUMBER: 141:89094
TITLE: Preparation of oxazine and morpholine derivatives as CCR5 antagonists
INVENTOR(S): Aquino, Christopher Joseph; Chong, Pek Yong; Duan, Maosheng; Kazmierski, Wieslaw Mieczyslaw
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004055011	A1	20040701	WO 2003-US39740	20031212

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-433410P P 20021213
OTHER SOURCE(S): MARPAT 141:89094
IT **716324-21-9P 716324-24-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazine and morpholine derivs. as CCR5 antagonists)
RN 716324-21-9 CAPLUS
CN Morpholine, 4-(3-hydroxy-2,2-dimethyl-1-oxopropyl)-2-[2-[(3-endo)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl]-2-phenyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 716324-24-2 CAPLUS
CN Morpholine, 4-(2,2-dimethyl-1-oxopropyl)-2-[2-[(3-endo)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl]-2-phenyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L7 ANSWER 1 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 25 Jun 2004
GI



I II



III

AB Title compds. I [A = C-X, N; B = C-Y, N; R1 = H, alkyl; R2 = H, alkyl; X = H, OH, CONH2, etc.; Y = H, OH, NH2, etc.; Z = H, OH, F, etc.] their enantiomers and pharmaceutically acceptable salts were prepared For example, BH3-THF reduction of lactam II, e.g., prepared from 3-methoxybenzaldehyde in 5-steps, afforded 2-phenylmorpholine III in 84% yield. Compds. I expressed EC50 values < 1000 nM with 10-fold selectivity for D3 over D2, e.g., one example of compound I exhibited an EC50 value of 7.6 nM and 1315.8 fold selectivity for D3 over D2. Compds. I are claimed useful for the treatment of sexual dysfunction, e.g., hypoactive sexual activity, orgasmic disorders, erectile dysfunction, etc.
ACCESSION NUMBER: 2004:513545 CAPLUS
DOCUMENT NUMBER: 141:71567
TITLE: Preparation of 2-phenylmorpholines and related compounds as dopamine agonists in the treatment of sexual dysfunction.
INVENTOR(S): Allerton, Charlotte Moria Norfor; Baxter, Andrew Douglas; Cook, Andrew Simon; Hepworth, David; Wong, Stephen Kwok-fung
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 121 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004052372	A1	20040624	WO 2003-IB5683	20031202

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,

L7 ANSWER 2 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004259874	A1	20041223	US 2003-727168	20031202
NL 1024983	A1	20040611	NL 2003-1024983	20031210
NL 1024983	C2	20050201		

PRIORITY APPLN. INFO.:

GB 2002-28787	A	20021210
GB 2003-8460	A	20030411
GB 2003-13606	A	20030612
US 2003-438476P	P	20030107
US 2003-470950P	P	20030515
US 2003-501512P	P	20030908

OTHER SOURCE(S): MARPAT 141:71567

IT **547770-26-3P**, 2-(4-Benzyloxyphenyl)-4-propylmorpholine **547770-27-4P**, 4-(4-Propylmorpholin-2-yl)phenol **547770-28-5P**, 2-Bromo-4-(4-propylmorpholin-2-yl)phenol **547770-29-6P**, 2-(4-Benzyloxy-3-bromophenyl)-4-propylmorpholine **547770-30-9P**, 2-Benzyloxy-5-(4-propylmorpholin-2-yl)benzoic acid methyl ester **547770-31-0P**, 2-Benzyloxy-5-(4-propylmorpholin-2-yl)benzoic acid **547770-32-1P**, 2-Benzyloxy-5-(4-propylmorpholin-2-yl)benzamide **547770-34-3P**, 2-Nitro-4-(4-propylmorpholin-2-yl)phenol **547770-39-8P**, 6-(6-(2,5-Dimethylpyrrol-1-yl)pyridin-3-yl]-4-propylmorpholine **710653-57-9P** **710653-62-6P** **710653-83-1P** **710653-89-7P** **710654-25-4P**, 6-(4-Chloro-3-methoxyphenyl)-4-propylmorpholine **710654-58-3P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 2-phenylmorpholines and related compds. as dopamine agonists in the treatment of sexual dysfunction.)

RN 547770-26-3 CAPLUS
CN Morpholine, 2-[4-(phenylmethoxy)phenyl]-4-propyl- (9CI) (CA INDEX NAME)



RN 547770-27-4 CAPLUS
CN Phenol, 4-(4-propyl-2-morpholinyl)- (9CI) (CA INDEX NAME)



RN 547770-28-5 CAPLUS
CN Phenol, 2-bromo-4-(4-propyl-2-morpholinyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 2 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 547770-29-6 CAPLUS
CN Morpholine, 2-[3-bromo-4-(phenylmethoxy)phenyl]-4-propyl- (9CI) (CA INDEX NAME)



RN 547770-30-9 CAPLUS
CN Benzoic acid, 2-(phenylmethoxy)-5-(4-propyl-2-morpholinyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 547770-31-0 CAPLUS
CN Benzoic acid, 2-(phenylmethoxy)-5-(4-propyl-2-morpholinyl)- (9CI) (CA INDEX NAME)



RN 547770-32-1 CAPLUS
CN Benzamide, 2-(phenylmethoxy)-5-(4-propyl-2-morpholinyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 2 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 547770-34-3 CAPLUS
CN Phenol, 2-nitro-4-(4-propyl-2-morpholinyl)- (9CI) (CA INDEX NAME)



RN 547770-39-8 CAPLUS
CN Morpholine, 2-[6-(2,5-dimethyl-1H-pyrrol-1-yl)-3-pyridinyl]-4-propyl- (9CI) (CA INDEX NAME)



RN 710653-57-9 CAPLUS
CN Morpholine, 2-ethyl-6-(3-methoxyphenyl)-4-propyl-, (2R,6S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 710653-62-6 CAPLUS
CN Morpholine, 2-ethyl-6-(3-methoxyphenyl)-4-propyl-, (2R,6R)-rel- (9CI) (CA INDEX NAME)

L7 ANSWER 2 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Relative stereochemistry.



RN 710653-83-1 CAPLUS
CN Morpholine, 2-(3-methoxyphenyl)-6-methyl-4-propyl-, (2R,6S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 710653-89-7 CAPLUS
CN Morpholine, 2-(3-methoxyphenyl)-6-methyl-4-propyl-, (2R,6R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 710654-25-4 CAPLUS
CN Morpholine, 2-(4-chloro-3-methoxyphenyl)-4-propyl- (9CI) (CA INDEX NAME)



L7 ANSWER 2 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 710654-58-3 CAPLUS
CN Morpholine, 2-(3-methoxyphenyl)-5-methyl-4-propyl-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **142363-72-2P**, 2-(3-Methoxyphenyl)-4-propylmorpholine
547770-05-8P 547770-06-9P 547770-07-0P
547770-12-7P, 2-(3,5-Dimethoxyphenyl)-4-propylmorpholine
547770-13-8P 547770-14-9P 547770-20-7P,
2-(4-Fluoro-3-methoxyphenyl)-4-propylmorpholine **547770-33-2P**,
2-Hydroxy-5-(4-propylmorpholin-2-yl)benzamide **547770-35-4P**,
2-Amino-4-(4-propylmorpholin-2-yl)phenol **710652-35-0P**
710652-39-4P 710653-32-0P, 5-(4-Propylmorpholin-2-yl)pyridin-2-ylamine **710653-37-5P 710653-43-3P**
710653-68-2P 710653-73-9P 710653-95-5P
710654-00-5P 710654-30-1P 710654-62-9P
710654-68-5P 710654-74-3P 710655-10-0P
710655-15-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-phenylmorpholines and related compds. as dopamine agonists in the treatment of sexual dysfunction.)
RN 142363-72-2 CAPLUS
CN Morpholine, 2-(3-methoxyphenyl)-4-propyl- (9CI) (CA INDEX NAME)



RN 547770-05-8 CAPLUS
CN Phenol, 3-[(2R)-4-propyl-2-morpholinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 2 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 547770-06-9 CAPLUS
CN Phenol, 3-[(2S)-4-propyl-2-morpholinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 547770-07-0 CAPLUS
CN Phenol, 3-[(2R)-4-propyl-2-morpholinyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 547770-12-7 CAPLUS
CN Morpholine, 2-(3,5-dimethoxyphenyl)-4-propyl- (9CI) (CA INDEX NAME)



RN 547770-13-8 CAPLUS
CN 1,3-Benzenediol, 5-[(2R)-4-propyl-2-morpholinyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 2 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.



RN 547770-14-9 CAPLUS
CN 1,3-Benzenediol, 5-[(2S)-4-propyl-2-morpholinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 547770-20-7 CAPLUS
CN Morpholine, 2-(4-fluoro-3-methoxyphenyl)-4-propyl- (9CI) (CA INDEX NAME)



RN 547770-33-2 CAPLUS
CN Benzamide, 2-hydroxy-5-(4-propyl-2-morpholinyl)- (9CI) (CA INDEX NAME)



RN 547770-35-4 CAPLUS
CN Phenol, 2-amino-4-(4-propyl-2-morpholinyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 2 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 710652-35-0 CAPLUS
CN Morpholine, 2-(4-fluoro-3-methoxyphenyl)-4-propyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 710652-39-4 CAPLUS
CN Morpholine, 2-(4-fluoro-3-methoxyphenyl)-4-propyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 710653-32-0 CAPLUS
CN 2-Pyridinamine, 5-(4-propyl-2-morpholinyl)- (9CI) (CA INDEX NAME)



RN 710653-37-5 CAPLUS
CN 2-Pyridinamine, 5-(4-propyl-2-morpholinyl)-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).

L7 ANSWER 2 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 710653-43-3 CAPLUS
CN 2-Pyridinamine, 5-(4-propyl-2-morpholinyl)-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 710653-68-2 CAPLUS
CN Phenol, 3-[(2R,6S)-6-ethyl-4-propyl-2-morpholinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 710653-73-9 CAPLUS
CN Phenol, 3-[(2R,6R)-6-ethyl-4-propyl-2-morpholinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L7 ANSWER 2 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 710653-95-5 CAPLUS
CN Phenol, 3-[(2R,6S)-6-methyl-4-propyl-2-morpholinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 710654-00-5 CAPLUS
CN Phenol, 3-[(2R,6R)-6-methyl-4-propyl-2-morpholinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 710654-30-1 CAPLUS
CN Phenol, 2-chloro-5-(4-propyl-2-morpholinyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 2 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 710654-62-9 CAPLUS
CN Phenol, 3-[(5S)-5-methyl-4-propyl-2-morpholinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710654-68-5 CAPLUS
CN Phenol, 3-[(2R,5R)-5-methyl-4-propyl-2-morpholinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710654-74-3 CAPLUS
CN Phenol, 3-[(2R,5S)-5-methyl-4-propyl-2-morpholinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710655-10-0 CAPLUS
CN 2-Pyridinamine, 5-[(2S,5S)-5-methyl-4-propyl-2-morpholinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

L7 ANSWER 2 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 710655-15-5 CAPLUS
CN 2-Pyridinamine, 5-[(2R,5S)-5-methyl-4-propyl-2-morpholinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **142363-68-6P**, 6-(3-Methoxyphenyl)-4-propylmorpholin-3-one
547770-11-6P, 6-(3,5-Dimethoxyphenyl)-4-propylmorpholin-3-one
547770-19-4P, 6-(4-Fluoro-3-methoxyphenyl)-4-propylmorpholin-3-one
547770-25-2P, 6-(4-Benzyloxyphenyl)-4-propylmorpholin-3-one
547770-38-7P **710653-47-7P**, 2-Ethyl-6-(3-methoxyphenyl)-4-propylmorpholin-3-one **710653-77-3P**, 2-Methyl-6-(3-methoxyphenyl)-4-propylmorpholin-3-one **710654-16-3P**, 6-(4-Chloro-3-methoxyphenyl)-4-propylmorpholin-3-one **710654-53-8P** **710654-89-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 2-phenylmorpholines and related compds. as dopamine agonists in the treatment of sexual dysfunction.)

RN 142363-68-6 CAPLUS
CN 3-Morpholinone, 6-(3-methoxyphenyl)-4-propyl- (9CI) (CA INDEX NAME)



RN 547770-11-6 CAPLUS
CN 3-Morpholinone, 6-(3,5-dimethoxyphenyl)-4-propyl- (9CI) (CA INDEX NAME)

L7 ANSWER 2 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 547770-19-4 CAPLUS
CN 3-Morpholinone, 6-(4-fluoro-3-methoxyphenyl)-4-propyl- (9CI) (CA INDEX NAME)



RN 547770-25-2 CAPLUS
CN 3-Morpholinone, 6-[4-(phenylmethoxy)phenyl]-4-propyl- (9CI) (CA INDEX NAME)



RN 547770-38-7 CAPLUS
CN 3-Morpholinone, 6-[6-(2,5-dimethyl-1H-pyrrol-1-yl)-3-pyridinyl]-4-propyl- (9CI) (CA INDEX NAME)



RN 710653-47-7 CAPLUS
CN 3-Morpholinone, 2-ethyl-6-(3-methoxyphenyl)-4-propyl- (9CI) (CA INDEX NAME)

L7 ANSWER 2 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L7 ANSWER 2 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 710653-77-3 CAPLUS
CN 3-Morpholinone, 6-(3-methoxyphenyl)-2-methyl-4-propyl- (9CI) (CA INDEX NAME)



RN 710654-16-3 CAPLUS
CN 3-Morpholinone, 6-(4-chloro-3-methoxyphenyl)-4-propyl- (9CI) (CA INDEX NAME)



RN 710654-53-8 CAPLUS
CN 2-Morpholinol, 2-(3-methoxyphenyl)-5-methyl-4-propyl-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710654-89-0 CAPLUS
CN 2-Morpholinol, 2-[6-(2,5-dimethyl-1H-pyrrol-1-yl)-3-pyridinyl]-5-methyl-4-propyl-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 3 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 08 Dec 2003
GI



AB The development of new strategies for solid-phase synthesis of 3-aza-6,8-dioxabicyclo[3.2.1]octane scaffolds, named BTKs, e.g. I, is described. The preparation was made possible by the combination of three components: amines, α-halo-acetophenones, and sugar or tartaric acid derivs. By anchoring each of the three components it was possible to synthesize BTKs compds. either as amino alcs. or amido esters. The compatibility of the protocols with different classes of amines and substituted α-halo-acetophenones was demonstrated.

ACCESSION NUMBER: 2003:957358 CAPLUS
DOCUMENT NUMBER: 140:321342
TITLE: A solid-phase approach towards the development of 3-aza-6,8-dioxabicyclo[3.2.1]octane scaffolds
AUTHOR(S): Trabocchi, Andrea; Mancini, Francesco; Menchi, Gloria; Guarna, Antonio
CORPORATE SOURCE: Polo Scientifico di Sesto Fiorentino, Dipartimento di Chimica Organica 'Ugo Schiff', Universitadegli Studi di Firenze, Florence, Sesto Fiorentino, Italy
SOURCE: Molecular Diversity (2003), 6(3-4), 245-250
CODEN: MODIF4; ISSN: 1381-1991
PUBLISHER: Kluwer Academic Publishers
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **677353-54-7P 677353-62-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(solid-phase preparation of azadioxabicyclooctane scaffolds from amines, haloacetophenones, carbohydrate or tartaric acid derivs.)
RN 677353-54-7 CAPLUS
CN 6,8-Dioxa-3-azabicyclo[3.2.1]octane-7-methanol, 3-butyl-5-phenyl-, (1S,5S,7S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 677353-62-7 CAPLUS
CN 6,8-Dioxa-3-azabicyclo[3.2.1]octane-7-carboxylic acid, 3-butyl-5-(4-hydroxyphenyl)-2-oxo-, methyl ester, (1R,5S,7R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L7 ANSWER 3 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 27 Jun 2003
AB The use of a composition comprising a selective dopamine D3 receptor agonist is disclosed, wherein said dopamine D3 receptor agonist is at least about 15-times more functionally selective for a dopamine D3 receptor as compared with a dopamine D2 receptor when measured using the same functional assay, in the preparation of a medicament for the treatment and/or prevention of sexual dysfunction.
ACCESSION NUMBER: 2003:491050 CAPLUS
DOCUMENT NUMBER: 139:63348
TITLE: Selective dopamine D3 receptor agonists for the treatment of sexual dysfunction
INVENTOR(S): Van der Graaf, Pieter Hadewijn; Wayman, Christopher Peter; Baxter, Andrew Douglas; Cook, Andrew Simon; Wong, Stephen Kwok-Fung
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 247 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003051370	A1	20030626	WO 2002-GB5595	20021210
WO 2003051370	C1	20031002		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2470624	AA	20030626	CA 2002-2470624	20021210
EP 1463508	A1	20041006	EP 2002-788092	20021210
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002015064	A	20041013	BR 2002-15064	20021210
JP 2005516014	T2	20050602	JP 2003-552303	20021210

PRIORITY APPLN. INFO.: GB 2001-30219 A 20011218
WO 2002-GB5595 W 20021210

IT **142363-68-6P 142363-72-2P 547770-05-8P**
547770-06-9P 547770-07-0P 547770-11-6P
547770-12-7P 547770-13-8P 547770-14-9P
547770-19-4P 547770-20-7P 547770-21-8P
547770-22-9P 547770-25-2P 547770-26-3P
547770-27-4P 547770-28-5P 547770-29-6P
547770-30-9P 547770-31-0P 547770-32-1P
547770-33-2P 547770-34-3P 547770-35-4P
547770-38-7P 547770-39-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(selective dopamine D3 receptor agonists for the treatment of sexual dysfunction)
RN 142363-68-6 CAPLUS

L7 ANSWER 4 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 3-Morpholinone, 6-(3-methoxyphenyl)-4-propyl- (9CI) (CA INDEX NAME)



RN 142363-72-2 CAPLUS
CN Morpholine, 2-(3-methoxyphenyl)-4-propyl- (9CI) (CA INDEX NAME)



RN 547770-05-8 CAPLUS
CN Phenol, 3-[(2R)-4-propyl-2-morpholinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 547770-06-9 CAPLUS
CN Phenol, 3-[(2S)-4-propyl-2-morpholinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 547770-07-0 CAPLUS
CN Phenol, 3-[(2R)-4-propyl-2-morpholinyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 4 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 547770-11-6 CAPLUS
CN 3-Morpholinone, 6-(3,5-dimethoxyphenyl)-4-propyl- (9CI) (CA INDEX NAME)



RN 547770-12-7 CAPLUS
CN Morpholine, 2-(3,5-dimethoxyphenyl)-4-propyl- (9CI) (CA INDEX NAME)



RN 547770-13-8 CAPLUS
CN 1,3-Benzenediol, 5-[(2R)-4-propyl-2-morpholinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 547770-14-9 CAPLUS
CN 1,3-Benzenediol, 5-[(2S)-4-propyl-2-morpholinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 4 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 547770-19-4 CAPLUS
CN 3-Morpholinone, 6-(4-fluoro-3-methoxyphenyl)-4-propyl- (9CI) (CA INDEX NAME)



RN 547770-20-7 CAPLUS
CN Morpholine, 2-(4-fluoro-3-methoxyphenyl)-4-propyl- (9CI) (CA INDEX NAME)



RN 547770-21-8 CAPLUS
CN Phenol, 2-fluoro-5-[(2R)-4-propyl-2-morpholinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 547770-22-9 CAPLUS
CN Phenol, 2-fluoro-5-[(2S)-4-propyl-2-morpholinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 4 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 547770-25-2 CAPLUS
CN 3-Morpholinone, 6-[4-(phenylmethoxy)phenyl]-4-propyl- (9CI) (CA INDEX NAME)



RN 547770-26-3 CAPLUS
CN Morpholine, 2-[4-(phenylmethoxy)phenyl]-4-propyl- (9CI) (CA INDEX NAME)



RN 547770-27-4 CAPLUS
CN Phenol, 4-(4-propyl-2-morpholinyl)- (9CI) (CA INDEX NAME)



RN 547770-28-5 CAPLUS
CN Phenol, 2-bromo-4-(4-propyl-2-morpholinyl)- (9CI) (CA INDEX NAME)



RN 547770-29-6 CAPLUS
CN Morpholine, 2-[3-bromo-4-(phenylmethoxy)phenyl]-4-propyl- (9CI) (CA INDEX

L7 ANSWER 4 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
NAME)



RN 547770-30-9 CAPLUS
CN Benzoic acid, 2-(phenylmethoxy)-5-(4-propyl-2-morpholinyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 547770-31-0 CAPLUS
CN Benzoic acid, 2-(phenylmethoxy)-5-(4-propyl-2-morpholinyl)- (9CI) (CA INDEX NAME)



RN 547770-32-1 CAPLUS
CN Benzamide, 2-(phenylmethoxy)-5-(4-propyl-2-morpholinyl)- (9CI) (CA INDEX NAME)



RN 547770-33-2 CAPLUS
CN Benzamide, 2-hydroxy-5-(4-propyl-2-morpholinyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 4 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 547770-34-3 CAPLUS
CN Phenol, 2-nitro-4-(4-propyl-2-morpholinyl)- (9CI) (CA INDEX NAME)



RN 547770-35-4 CAPLUS
CN Phenol, 2-amino-4-(4-propyl-2-morpholinyl)- (9CI) (CA INDEX NAME)



RN 547770-38-7 CAPLUS
CN 3-Morpholinone, 6-[6-(2,5-dimethyl-1H-pyrrol-1-yl)-3-pyridinyl]-4-propyl- (9CI) (CA INDEX NAME)



RN 547770-39-8 CAPLUS
CN Morpholine, 2-[6-(2,5-dimethyl-1H-pyrrol-1-yl)-3-pyridinyl]-4-propyl- (9CI) (CA INDEX NAME)

L7 ANSWER 4 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 20 Mar 2003
GI



AB Enantiomerically pure bicyclic 1,4-oxazepinone I was obtained by the Cu(II)-catalyzed decomposition of an α-diazo carbonyl compound II tethered to a chiral morpholinone, through the cascade evolution of the spirocyclic ammonium ylide formed. LiAlH4 reduction and transesterification of the lactone moiety of the oxazepinone afforded pure chiral pyrrolidine III and 3-prolinone bicyclic hemiacetal IV, resp., both bearing a quaternary stereocenter.

ACCESSION NUMBER: 2003:215683 CAPLUS
DOCUMENT NUMBER: 139:133481
TITLE: Stereospecific [1,2]-rearrangement of a spirocyclic ammonium ylide with ring expansion sequence
AUTHOR(S): Saba, Antonio
CORPORATE SOURCE: Dipartimento di Chimica, Facolta di Scienze, Sassari, I-07100, Italy
SOURCE: Tetrahedron Letters (2003), 44(14), 2895-2898
CODEN: TELEAY; ISSN: 0040-4039
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:133481
IT **566189-01-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(asym. synthesis of pyrrolidine derivative and prolinone bicyclic hemiacetal via Cu-catalyzed stereoselective [1,2]-sigmatropic rearrangement of diazo(diphenyloxomorpholinyl)oxopentanoate)
RN 566189-01-3 CAPLUS
CN 4-Morpholinepentanoic acid, α-diazo-β,6-dioxo-2,3-diphenyl-, ethyl ester, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

L7 ANSWER 6 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 05 Jun 2002
AB The present study describes the synthesis and in vitro pharmacol. of a novel series of dopaminergic agents in which the classical phenylethylamine pharmacophore is replaced by a thienylethylamine moiety. In general, the novel compds. showed a moderate affinity for the dopamine (DA) D2 and D3 receptors. When the thienylethylamine moiety is fixed in a rigid system, the affinity for the DA receptor is significantly increased. However, in the tricyclic hexahydrothianaphthoxazine structure, the affinity for the DA receptors is diminished.

ACCESSION NUMBER: 2002:422015 CAPLUS
DOCUMENT NUMBER: 137:134484
TITLE: Further Characterization of Structural Requirements for Ligands at the Dopamine D2 and D3 Receptor: Exploring the Thiophene Moiety
AUTHOR(S): Dijkstra, Durk; Rodenhuis, Nienke; Vermeulen, Erik S.; Pugsley, Thomas A.; Wise, Lawrence D.; Wikstroem, Hkan V.
CORPORATE SOURCE: Department of Medicinal Chemistry, University of Groningen, Groningen, NL-9713, Neth.
SOURCE: Journal of Medicinal Chemistry (2002), 45(14), 3022-3031
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 137:134484
IT **444559-24-4P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and dopaminergic activity of thienylethylamines and tricyclic hexahydrothianaphthoxazines)
RN 444559-24-4 CAPLUS
CN 2H-Naphth[1,2-b]-1,4-oxazin-9-ol, 3,4,4a,5,6,10b-hexahydro-2-phenyl-4-propyl-, hydrochloride, (2R,4aR,10bR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

IT **444559-42-6P 444559-43-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and dopaminergic activity of thienylethylamines and tricyclic hexahydrothianaphthoxazines)
RN 444559-42-6 CAPLUS
CN 2H-Naphth[1,2-b]-1,4-oxazin-3(4H)-one, 4a,5,6,10b-tetrahydro-9-methoxy-2-phenyl-4-propyl-, (2R,4aR,10bR)-rel- (9CI) (CA INDEX NAME)

L7 ANSWER 6 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Relative stereochemistry.



RN 444559-43-7 CAPLUS
CN 2H-Naphth[1,2-b]-1,4-oxazine, 3,4,4a,5,6,10b-hexahydro-9-methoxy-2-phenyl-4-propyl-, hydrochloride, (2R,4aR,10bR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

IT **485816-14-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and dopaminergic activity of thienylethylamines and tricyclic hexahydrothianaphthoxazines)
RN 485816-14-6 CAPLUS
CN 2H-Naphth[1,2-b]-1,4-oxazin-3(4H)-one, 4a,5,6,10b-tetrahydro-9-methoxy-2-phenyl-4-propyl-, (2R,4aS,10bS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L7 ANSWER 6 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 05 Dec 2001
GI



AB Wittig reaction of Ph3P:CHCN with the lactone carbonyl of (5R,6S)-4-(benzyloxycarbonyl)-5,6-diphenyl-2,3,5,6-tetrahydro-4H-1,4-oxazin-2-one gave cyanomethylated adduct I, whose subsequent reduction afforded morpholinoethylamine II as a dihydrochloride salt in quant. yield with excellent diastereoselectivity. After having its primary amino group protected with Cbz, II was coupled with morpholinobutyl iodide III. The resulting adduct was hydrogenated to remove the Cbz groups and the chiral auxiliaries to afford hypusine (IV) as a dihydrochloride salt in an overall 53% yield.

ACCESSION NUMBER: 2001:874823 CAPLUS
DOCUMENT NUMBER: 136:151418
TITLE: Asymmetric Synthesis of (+)-Hypusine
AUTHOR(S): Jain, Rajendra P.; Albrecht, Brian K.; DeMong, Duane E.; Williams, Robert M.
CORPORATE SOURCE: Department of Chemistry, Colorado State University, Fort Collins, CO, 80523, USA
SOURCE: Organic Letters (2001), 3(26), 4287-4289
CODEN: ORLEF7; ISSN: 1523-7060
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 136:151418

IT **394251-34-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(asym. preparation of hypusine dihydrochloride)
RN 394251-34-4 CAPLUS
CN 4-Morpholinecarboxylic acid, 3-[4-[(2S,3R,6R)-2,3-diphenyl-6-[2-[[(phenylmethoxy)carbonyl]amino]ethyl]-4-morpholinyl]butyl]-2-oxo-5,6-diphenyl-, phenylmethyl ester, (3S,5S,6R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 7 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 07 Sep 2001
GI



I

AB Title compds. [e.g., I; RR = O or each R = H; R1 = (un)substituted Ph; R2 = H, Me, CH2Ph; R3 = (un)substituted phenyl(methyl), CH(CO2H)CH2Ph, allyl, etc.; R6 = H, Me, CO2H, CH2OH; Z = O or NH] were prepared Thus, PhCOCH2NHCH2Ph was N-acylated by 1,4-dioxane-2,3-dicarboxylic acid monomethyl ester and the product cyclized to give I (RR = O, R1 = R3 = CH2Ph, R2 = H, R6 = CO2Me, Z = O). The method is suitable for solid phase synthesis and the preparation of combinatorial libraries.

ACCESSION NUMBER: 2001:654699 CAPLUS
DOCUMENT NUMBER: 135:211044
TITLE: Preparation of 3-aza-6,8-dioxabicyclo[3.2.1]octanecarboxylates and analogs
INVENTOR(S): Guarna, Antonio; Menchi, Gloria; Occhiato, Ernesto Giovanni; Machetti, Fabrizio; Scarpi, Dina
PATENT ASSIGNEE(S): Universita Degli Studi di Firenze, Italy
SOURCE: Eur. Pat. Appl., 26 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1130022	A1	20010905	EP 2000-104135	20000229
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2401693	AA	20010907	CA 2001-2401693	20010227
WO 2001064686	A1	20010907	WO 2001-EP2185	20010227
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2003176414	A1	20030918	US 2002-220556	20021101
PRIORITY APPLN. INFO.:			EP 2000-104135 A	20000229
			WO 2001-EP2185 W	20010227

OTHER SOURCE(S): CASREACT 135:211044; MARPAT 135:211044
IT **357667-16-4P 357667-64-2P 357667-70-0P**

L7 ANSWER 8 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
357667-71-1P 357667-72-2P 357667-73-3P
357667-78-8P 357667-81-3P 357667-82-4P
357667-83-5P 357667-84-6P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of 3-aza-6,8-dioxabicyclo[3.2.1]octanecarboxylates and analogs)

RN 357667-16-4 CAPLUS
CN 6,8-Dioxa-3-azabicyclo[3.2.1]octane-7-carboxylic acid, 2-oxo-5-phenyl-3-propyl- (9CI) (CA INDEX NAME)



RN 357667-64-2 CAPLUS
CN 6,8-Dioxa-3-azabicyclo[3.2.1]octane-7-carboxylic acid, 5-(4-hydroxyphenyl)-2-oxo-3-propyl- (9CI) (CA INDEX NAME)



RN 357667-70-0 CAPLUS
CN 6,8-Dioxa-3-azabicyclo[3.2.1]octane-3-acetic acid, 7-carboxy-α-(1-hydroxyethyl)-2-oxo-5-phenyl- (9CI) (CA INDEX NAME)



RN 357667-71-1 CAPLUS
CN 6,8-Dioxa-3-azabicyclo[3.2.1]octane-3-acetic acid, 7-carboxy-α-[2-(methylthio)ethyl]-2-oxo-5-phenyl- (9CI) (CA INDEX NAME)

L7 ANSWER 8 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 357667-72-2 CAPLUS
CN 6,8-Dioxa-3-azabicyclo[3.2.1]octane-3-acetic acid, α-(3-aminopropyl)-7-carboxy-2-oxo-5-phenyl- (9CI) (CA INDEX NAME)



RN 357667-73-3 CAPLUS
CN Butanedioic acid, (7-carboxy-2-oxo-5-phenyl-6,8-dioxa-3-azabicyclo[3.2.1]oct-3-yl)- (9CI) (CA INDEX NAME)



RN 357667-78-8 CAPLUS
CN 6,8-Dioxa-3-azabicyclo[3.2.1]octane-3-acetic acid, 7-carboxy-5-(4-hydroxyphenyl)-α-(1-methylethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 357667-81-3 CAPLUS
CN 6,8-Dioxa-3-azabicyclo[3.2.1]octane-3-acetic acid, 7-carboxy-α-(1-hydroxyethyl)-5-(4-hydroxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)

L7 ANSWER 8 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 357667-82-4 CAPLUS
CN 6,8-Dioxa-3-azabicyclo[3.2.1]octane-3-acetic acid, 7-carboxy-5-(4-hydroxyphenyl)-α-[2-(methylthio)ethyl]-2-oxo- (9CI) (CA INDEX NAME)



RN 357667-83-5 CAPLUS
CN 6,8-Dioxa-3-azabicyclo[3.2.1]octane-3-acetic acid, α-(3-aminopropyl)-7-carboxy-5-(4-hydroxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 357667-84-6 CAPLUS
CN Butanedioic acid, [7-carboxy-5-(4-hydroxyphenyl)-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]oct-3-yl]- (9CI) (CA INDEX NAME)

L7 ANSWER 8 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 27 Mar 2001
GI



I



II

AB The authors have developed a route for an enantioselective construction of the simplified omuralide analog I in nine steps, with the use of (R)-atrolactic acid (II) as a recoverable chiral controller.

ACCESSION NUMBER: 2001:214617 CAPLUS
DOCUMENT NUMBER: 135:19883
TITLE: A Novel Enantioselective Synthetic Route to Omuralide Analogues with the Potential for Species Selectivity in Proteasome Inhibition
AUTHOR(S): Crane, Sheldon N.; Corey, E. J.
CORPORATE SOURCE: Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, 02138, USA
SOURCE: Organic Letters (2001), 3(9), 1395-1397
CODEN: ORLEF7; ISSN: 1523-7060
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 135:19883
IT **342797-11-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(novel enantioselective synthetic route to omuralide analogs with the potential for species selectivity in proteasome inhibition)
RN 342797-11-9 CAPLUS
CN 4-Morpholinepropanoic acid, α,α,2-trimethyl-β,3,6-trioxo-2-phenyl-, ethyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L7 ANSWER 10 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 12 Feb 2001
AB The solid-phase synthesis of 1,4-benzothiazin-3(4H)-ones and 1,4-benzoxazin-3(4H)-ones is reported. Alkylation of immobilized 4-hydroxy-3-nitrobenzamide and 3-nitro-4-sulfanylbenzamide, followed by reduction and cyclization gave resin-bound 1,4-benzoxazin-3(4H)-ones and 1,4-benzothiazin-3(4H)-ones, resp. Further alkylation and acylation was performed on the amide N in the presence of NaH followed by TFA cleavage.

ACCESSION NUMBER: 2001:102282 CAPLUS
DOCUMENT NUMBER: 134:326472
TITLE: Solid-phase combinatorial synthesis of 1,4-benzoxazin-3(4H)-one and 1,4-benzothiazin-3(4H)-one derivatives
AUTHOR(S): Lee, C. L.; Chan, K. P.; Lam, Y.; Lee, S. Y.
CORPORATE SOURCE: Department of Chemistry, National University of Singapore, 117543, Singapore
SOURCE: Tetrahedron Letters (2001), 42(6), 1167-1169
CODEN: TELEAY; ISSN: 0040-4039
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 134:326472
IT **336163-89-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(solid-phase combinatorial synthesis of benzoxazinones and benzothiazinones)
RN 336163-89-4 CAPLUS
CN 2H-1,4-Benzoxazine-6-carboxamide, 4-butyl-3,4-dihydro-3-oxo-2-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 11 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 27 Sep 2000

AB Inappropriate thrombus formation within blood vessels is the leading cause of mortality in the industrialized world. Factor Xa (FXa) is a trypsin-like serine protease that plays a key role in the blood coagulation cascade and represents an attractive target for anticoagulant drug development. From a high-throughput in vitro mass screen of our chemical library, we identified 4-[5-[(2R,6S)-2,6-dimethyltetrahydro-1(2H)-pyridinyl]pentyl]-2-phenyl-2H-1,4-benzoxazin-3(4H)-one as an inhibitor of FXa with an IC50 of 27 μM. Through a combination of SAR studies and mol. modeling, we synthesized 3-(4-[5-[(2R,6S)-2,6-dimethyltetrahydro-1(2H)-pyridinyl]pentyl]-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-2-yl)-1-benzenecarboximidamide which was a potent FXa inhibitor with an IC50 of 3 nM. This compound exhibited high selectivity for FXa over other related serine proteases and was efficacious when dosed i.v. in rabbit and dog antithrombotic models.

ACCESSION NUMBER: 2000:675083 CAPLUS
DOCUMENT NUMBER: 134:36674
TITLE: Rational Design, Synthesis, and Biological Activity of Benzoxazinones as Novel Factor Xa Inhibitors
AUTHOR(S): Dudley, Danette A.; Bunker, Amy M.; Chi, Liguo; Cody, Wayne L.; Holland, Debra R.; Ignasiak, Diane P.; Janiczek-Dolphin, Nancy; McClanahan, Thomas B.; Mertz, Thomas E.; Narasimhan, Lakshmi S.; Rapundalo, Stephen T.; Trautschold, Julia A.; van Huis, Chad A.; Edmunds, Jeremy J.
CORPORATE SOURCE: Pfizer Global Research and Development, Ann Arbor, MI, 48105, USA
SOURCE: Journal of Medicinal Chemistry (2000), 43(22), 4063-4070
CODEN: JMCMAR: ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 134:36674

IT **313220-95-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(rational design, synthesis, and biol. activity of benzoxazinones as novel factor Xa inhibitors)

RN 313220-95-0 CAPLUS

CN Benzenecarboximidamide, 3-[4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-N-hydroxy-, trihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●3 HCl

IT **244616-91-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(rational design, synthesis, and biol. activity of benzoxazinones as novel factor Xa inhibitors)

RN 244616-91-9 CAPLUS

CN Benzenecarboximidamide, 3-[4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

IT **313220-79-0P 313220-81-4P 313220-83-6P**
313220-84-7P 313220-85-8P 313220-86-9P
313220-88-1P 313220-90-5P 313220-91-6P
313220-93-8P 313220-94-9P 313220-97-2P
313220-98-3P 313220-99-4P 313221-00-0P
313221-01-1P 313221-03-3P 313221-04-4P
313221-05-5P 313221-06-6P 313221-07-7P
313221-08-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(rational design, synthesis, and biol. activity of benzoxazinones as novel factor Xa inhibitors)

RN 313220-79-0 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 2-(3,4-dichlorophenyl)-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-, rel-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313220-78-9
CMF C26 H32 Cl2 N2 O2

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 313220-81-4 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 2-(4-chlorophenyl)-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-, rel-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313220-80-3
CMF C26 H33 Cl N2 O2

L7 ANSWER 11 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 313220-83-6 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 2-(2-chlorophenyl)-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-, rel-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313220-82-5
CMF C26 H33 Cl N2 O2

Relative stereochemistry.



L7 ANSWER 11 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 313220-84-7 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-2-(4-methylphenyl)-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 313220-85-8 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-2-(4-methoxyphenyl)-, rel-, trifluoroacetate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 244616-88-4
CMF C27 H36 N2 O3

Relative stereochemistry.

L7 ANSWER 11 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313220-87-0
CMF C29 H40 N2 O5

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 313220-90-5 CAPLUS
CN Benzenecarbothioamide, 4-[4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-, rel-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313220-89-2
CMF C27 H35 N3 O2 S

Relative stereochemistry.

L7 ANSWER 11 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 313220-86-9 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 2-(3,4-dimethoxyphenyl)-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 313220-88-1 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-2-(3,4,5-trimethoxyphenyl)-, rel-,

L7 ANSWER 11 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 313220-91-6 CAPLUS
CN Benzenecarboximidamide, 4-[4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-N-hydroxy-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

L7 ANSWER 11 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 313220-93-8 CAPLUS
CN Benzenecarboximidamide, 4-[4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-, rel-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313220-92-7
CMF C27 H36 N4 O2

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 313220-94-9 CAPLUS
CN Benzenecarbothioamide, 3-[4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-, rel-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 244616-94-2
CMF C27 H35 N3 O2 S

Relative stereochemistry.

L7 ANSWER 11 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 313220-98-3 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-N-methyl-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 313220-99-4 CAPLUS
CN Morpholine, 4-[[3-[4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]phenyl]iminomethyl]-, trihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L7 ANSWER 11 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 313220-97-2 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 2-[3-(aminomethyl)phenyl]-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-, rel-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 244618-42-6
CMF C27 H37 N3 O2

Relative stereochemistry.



L7 ANSWER 11 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



●3 HCl

RN 313221-00-0 CAPLUS
CN Benzenecarboximidamide, 3-[4-[6-[(2R,6S)-2,6-dimethyl-1-piperidinyl]hexyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 313221-01-1 CAPLUS
CN Benzenecarboximidamide, 3-[4-[4-[(2R,6S)-2,6-dimethyl-1-piperidinyl]butyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L7 ANSWER 11 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



●2 HCl

RN 313221-03-3 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-[(2R,5S)-2,5-dimethyl-1-pyrrolidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-, rel-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313221-02-2
CMF C26 H34 N4 O2

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L7 ANSWER 11 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 313221-04-4 CAPLUS
CN Benzenecarboximidamide, 3-[3,4-dihydro-3-oxo-4-[5-(1-piperidinyl)pentyl]-2H-1,4-benzoxazin-2-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 313221-05-5 CAPLUS
CN Benzenecarboximidamide, 3-[3,4-dihydro-4-[5-(4-morpholinyl)pentyl]-3-oxo-2H-1,4-benzoxazin-2-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

L7 ANSWER 11 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 313221-06-6 CAPLUS
CN Benzenecarboximidamide, 3-[4-(5-aminopentyl)-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 313221-07-7 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-[bis(1-methylethyl)amino]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 313221-08-8 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-(dihexylamino)pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

L7 ANSWER 11 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

IT **313220-77-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(rational design, synthesis, and biol. activity of benzoxazinones as novel factor Xa inhibitors)
RN 313220-77-8 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-2-phenyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **244621-32-7P 244621-33-8P 244621-34-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(rational design, synthesis, and biol. activity of benzoxazinones as novel factor Xa inhibitors)
RN 244621-32-7 CAPLUS
CN Benzonitrile, 3-[4-(5-bromopentyl)-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)



RN 244621-33-8 CAPLUS
CN Benzonitrile, 3-[4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L7 ANSWER 11 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244621-34-9 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-N-[(trifluoroacetyl)oxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 12 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 2-phenylmorpholine derivs. as phosphodiesterase inhibitors)
RN 251315-75-0 CAPLUS
CN Morpholine, 2-[3-(cyclohexyloxy)-4-methoxyphenyl]-4-(2,2-dimethyl-1-oxopropyl)-2-phenyl- (9CI) (CA INDEX NAME)



L7 ANSWER 12 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 25 Nov 1999
GI



AB The title compds. [I; R1 = (un)substituted C1-8 alkyl or C3-7 cycloalkyl; R2 = C1-4 alkyl; R3 = H, (un)substituted C1-6 alkyl, (un)substituted aryl optionally containing ≥1 heteroatoms selected from O, N, and S; R4 = (un)substituted aryl optionally containing ≥1 heteroatoms selected from O, N, and S, CO2R5, CONHR5, C(S)OR5, C(S)NHR5, C(S)NR5R6, COR7; wherein R5, R6 = H, (un)substituted C1-6 alkyl, C3-7 cycloalkyl, or C2-6 alkenyl or alkynyl, (un)substituted aryl optionally containing ≥1 heteroatoms selected from O, N, and S, (un)substituted heterocyclyl optionally containing ≥1 heteroatoms selected from O, N, and S, N-monocyclic or polycyclic heterocyclyl; R7 = (un)substituted C1-6 alkyl, C2-6 alkenyl or alkynyl, (un)substituted aryl optionally containing ≥1 heteroatoms selected from O, N, and S] are prepared These compds. are useful for the treatment or prevention of inflammatory diseases and asthma or for the treatment of skin inflammations (dermatitis) such atopic dermatitis, contact dermatitis, psoriasis, and nettle rash (urticaria). Thus, a solution of 2-pyridinemethanol in THF was added dropwise to NaH in THF under ice-cooling and stirred at room temperature for 30 min, followed by adding a solution of 4-(chlorocarbonyl)-2-(3-cyclopentyloxy-4-methoxyphenyl)morpholine in THF dropwise under ice-cooling, and the resulting mixture was gradually warmed to room temperature and stirred for 3 h to give 2-(3-cyclopentyloxy-4-methoxyphenyl)-4-(4-pyridylmethoxycarbonyl)morpholine (II). II showed IC50 of 1.0 + 10-7 M against phosphodiesterase IV.

ACCESSION NUMBER: 1999:748650 CAPLUS
DOCUMENT NUMBER: 132:12315
TITLE: Preparation of 2-phenylmorpholine derivatives as phosphodiesterase inhibitors
INVENTOR(S): Akiyama, Toshihiko; Ine, Shinji; Yamana, Kenjirou; Takahama, Akane
PATENT ASSIGNEE(S): Nikken Chemicals Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 49 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11322730	A2	19991124	JP 1999-59696	19990308
PRIORITY APPLN. INFO.:			JP 1998-73059 A	19980309

OTHER SOURCE(S): MARPAT 132:12315
IT 251315-75-0P

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 08 Oct 1999
GI



AB Title compds. [I; R1 = cycloalkyl(alkyl), heterocyclyl(alkyl), aryl(alkyl), etc.; R2 = H or alkyl; R3R4 = (un)substituted CH:CHCH:CH, -N:CHCH:CH, -CH:NCH:CH, etc.; X = O, S, NH; Z = Z2Z3R5; R5 = H, (un)substituted (heteroatom-interrupted) alkyl or -cycloalkyl(alkyl)); Z1 = O, SO0-2, OCH2, SCH2, etc.; Z2 = bond or (heteroatom-interrupted) (cyclo)alkylene; Z3 = bond, (un)substituted heterocyclylene, -arylene] were prepared Thus, 4-(MeO)C6H4CH2CO2Me was α-brominated and the product etherified by 2-(O2N)C6H4OH to give, after reductive cyclization, I [R1 = C6H4(OMe)-4, R2 = H, R3R4 = CH:CHCH:CH, X = Z1 = O](II; Z = NH) which was N-alkylated by Br(CH2)Br and the product aminated by cis-2,6-dimethylpiperidine to give II [Z =N(CH2)5R5, R5 = cis-2,6-dimethyl-1-piperidinyl]. Data for biol. activity of I were given.

ACCESSION NUMBER: 1999:640847 CAPLUS
DOCUMENT NUMBER: 131:257572
TITLE: Preparation of benzoxazinones and -thiazinones as serine protease inhibitors
INVENTOR(S): Berryman, Kent Alan; Downing, Dennis Michael; Dudley, Danette Andrea; Edmunds, Jeremy John; Narasimhan, Lakshmi Sourirajan; Rapundalo, Stephen Taras
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: PCT Int. Appl., 175 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9950257	A1	19991007	WO 1998-US26708	19981215
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2319551	AA	19991007	CA 1998-2319551	19981215
AU 9919183	A1	19991018	AU 1999-19183	19981215
AU 765223	B2	20030911		
BR 9815784	A	20001121	BR 1998-15784	19981215
EP 1068191	A1	20010117	EP 1998-963965	19981215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002509925	T2	20020402	JP 2000-541161	19981215
NZ 506985	A	20031031	NZ 1998-506985	19981215
ZA 9902445	A	19991001	ZA 1999-2445	19990330
US 6509335	B1	20030121	US 2000-622265	20000814
NO 2000004698	A	20000920	NO 2000-4698	20000920
US 2003187256	A1	20031002	US 2002-292771	20021112

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
PRIORITY APPLN. INFO.: US 1998-80142P P 19980331
WO 1998-US26708 W 19981215
US 2000-622265 A3 20000814

OTHER SOURCE(S): MARPAT 131:257572
IT **244618-40-4P 244620-32-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of benzoxazinones and -thiazinones as serine protease inhibitors)
RN 244618-40-4 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-N-hydroxy-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 244620-32-4 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 4-(5-bromopentyl)-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



IT **30914-85-3P 30914-96-6P 30914-97-7P**
30914-98-8P 30914-99-9P 30915-00-5P
244616-88-4P 244616-89-5P 244616-90-8P
244616-91-9P 244616-94-2P 244616-95-3P
244616-96-4P 244618-38-0P 244618-39-1P
244618-41-5P 244618-42-6P 244618-43-7P
244618-44-8P 244618-45-9P 244618-46-0P
244618-60-8P 244618-61-9P 244618-62-0P
244618-65-3P 244618-66-4P 244618-95-9P
244618-96-0P 244618-98-2P 244619-06-5P
244619-07-6P 244619-08-7P 244619-09-8P

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
244619-10-1P 244619-11-2P 244619-12-3P
244619-13-4P 244619-14-5P 244619-15-6P
244619-16-7P 244619-17-8P 244619-18-9P
244619-19-0P 244619-20-3P 244619-21-4P
244619-22-5P 244619-23-6P 244619-24-7P
244619-25-8P 244619-26-9P 244619-27-0P
244619-28-1P 244619-29-2P 244619-30-5P
244619-31-6P 244619-32-7P 244619-33-8P
244619-34-9P 244619-35-0P 244619-36-1P
244619-37-2P 244619-38-3P 244619-39-4P
244619-40-7P 244619-41-8P 244619-42-9P
244619-43-0P 244619-44-1P 244619-45-2P
244619-46-3P 244619-47-4P 244619-48-5P
244619-49-6P 244619-50-9P 244619-51-0P
244619-52-1P 244619-53-2P 244619-54-3P
244619-55-4P 244619-56-5P 244619-57-6P
244619-58-7P 244619-59-8P 244619-60-1P
244619-61-2P 244619-62-3P 244619-63-4P
244619-64-5P 244619-65-6P 244619-66-7P
244619-67-8P 244619-68-9P 244619-69-0P
244619-70-3P 244619-71-4P 244619-72-5P
244619-73-6P 244619-74-7P 244619-75-8P
244619-76-9P 244619-77-0P 244619-78-1P
244619-79-2P 244619-80-5P 244619-81-6P
244619-82-7P 244619-83-8P 244619-84-9P
244619-85-0P 244619-86-1P 244619-87-2P
244619-88-3P 244619-89-4P 244619-90-7P
244619-91-8P 244619-92-9P 244619-93-0P
244619-94-1P 244619-95-2P 244619-96-3P
244619-98-5P 244620-00-6P 244620-01-7P
244620-02-8P 244620-03-9P 244620-04-0P
244620-05-1P 244620-07-3P 244620-08-4P
244620-09-5P 244620-10-8P 244620-11-9P
244620-12-0P 244620-13-1P 244620-14-2P
244620-15-3P 244620-16-4P 244620-18-6P
244620-19-7P 244620-20-0P 244620-21-1P
244620-22-2P 244620-23-3P 244620-24-4P
244620-25-5P 244620-27-7P 244620-28-8P
244620-29-9P 244620-30-2P 244620-31-3P
244620-34-6P 244620-35-7P 244620-36-8P
244620-37-9P 244620-38-0P 244620-39-1P
244620-41-5P 244620-43-7P 244620-47-1P
244620-48-2P 244620-49-3P 244620-50-6P
244620-51-7P 244620-52-8P 244620-53-9P
244620-54-0P 244620-55-1P 244620-56-2P
244620-57-3P 244620-58-4P 244620-59-5P
244620-60-8P 244620-63-1P 244620-64-2P
244620-65-3P 244620-68-6P 244620-69-7P
244620-70-0P 244620-71-1P 244620-72-2P
244620-73-3P 244620-74-4P 244620-75-5P
244620-76-6P 244620-78-8P 244620-81-3P
244620-82-4P 244620-84-6P 244620-87-9P
244621-17-8P 244621-18-9P 244621-19-0P
244621-20-3P 244623-37-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of benzoxazinones and -thiazinones as serine protease

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
inhibitors)
RN 30914-85-3 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[3-[bis(1-methylethyl)amino]propyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 30914-96-6 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[3-(2,5-dimethyl-1-pyrrolidinyl)propyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 30914-97-7 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[5-[bis(1-methylethyl)amino]pentyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 30914-98-8 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[5-(2,5-dimethyl-1-pyrrolidinyl)pentyl]-2-phenyl- (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 30914-99-9 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[5-(2,6-dimethyl-1-piperidinyl)pentyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 30915-00-5 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[3-(2,6-dimethyl-1-piperidinyl)propyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 244616-88-4 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-2-(4-methoxyphenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244616-89-5 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 244616-90-8 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-, rel-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 244616-89-5
CMF C27 H36 N4 O2

Relative stereochemistry.

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 244616-91-9 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 244616-94-2 CAPLUS
CN Benzenecarbothioamide, 3-[4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 244616-95-3 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-4-hydroxy-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 244616-96-4 CAPLUS
CN Benzenecarboximidamide, 3-[(2S)-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-4-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244618-38-0 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-4-methoxy-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 244618-39-1 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-2-(3-hydroxyphenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 244618-41-5 CAPLUS
CN Benzenecarboximidic acid, 3-[4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-, hydrazide, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 244618-42-6 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 2-[3-(aminomethyl)phenyl]-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 244618-43-7 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 2-(3-aminophenyl)-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244618-44-8 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-2-[3-(methylamino)phenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 244618-45-9 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 2-[3-(dimethylamino)phenyl]-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244618-46-0 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-4-hydroxy-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 244618-60-8 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-2-(3-pyridinyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 244618-61-9 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 2-(4-amino-3-pyridinyl)-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 244618-62-0 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 2-[4-(dimethylamino)-3-pyridinyl]-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 244618-65-3 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 2-(2-amino-4-pyridinyl)-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244618-66-4 CAPLUS
CN 2-Pyridinecarboximidamide, 4-[4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 244618-95-9 CAPLUS
CN Benzenecarboximidamide, 3-[4-[4-[(2R,6S)-2,6-dimethyl-1-piperidinyl]butyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244618-96-0 CAPLUS
CN Benzenecarboximidamide, 3-[4-[6-[(2R,6S)-2,6-dimethyl-1-piperidinyl]hexyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 244618-98-2 CAPLUS
CN 4H-1,4-Benzoxazine-4-propanamide, 2-[3-(aminoiminomethyl)phenyl]-N-[[(2R,6S)-2,6-dimethyl-1-piperidinyl]methyl]-2,3-dihydro-3-oxo-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244619-06-5 CAPLUS
CN Benzenecarboximidamide, 3-[3,4-dihydro-3-oxo-4-[5-(1-piperidinyl)pentyl]-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)



RN 244619-07-6 CAPLUS
CN Benzenecarboximidamide, 3-[3,4-dihydro-3-oxo-4-[5-(2,2,6,6-tetramethyl-1-piperidinyl)pentyl]-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)



L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 244619-08-7 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[5-[2-[3-(aminoiminomethyl)phenyl]-2,3-dihydro-3-oxo-4H-1,4-benzoxazin-4-yl]pentyl]- (9CI) (CA INDEX NAME)



RN 244619-09-8 CAPLUS
CN 3-Piperidinecarboxylic acid, 1-[5-[2-[3-(aminoiminomethyl)phenyl]-2,3-dihydro-3-oxo-4H-1,4-benzoxazin-4-yl]pentyl]- (9CI) (CA INDEX NAME)



RN 244619-10-1 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[5-[2-[3-(aminoiminomethyl)phenyl]-2,3-dihydro-3-oxo-4H-1,4-benzoxazin-4-yl]pentyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244619-11-2 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-(3,5-dimethyl-1-piperidinyl)pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)



RN 244619-12-3 CAPLUS
CN Benzenecarboximidamide, 3-[3,4-dihydro-4-[5-(4-hydroxy-1-piperidinyl)pentyl]-3-oxo-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244619-15-6 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-[2-[(dimethylamino)methyl]-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)



RN 244619-16-7 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-[4-(dimethylamino)-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244619-13-4 CAPLUS
CN Benzenecarboximidamide, 3-[3,4-dihydro-4-[5-(2-imino-1-piperidinyl)pentyl]-3-oxo-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)



RN 244619-14-5 CAPLUS
CN Benzenecarboximidamide, 3-[3,4-dihydro-3-oxo-4-[5-(4-oxo-1-piperidinyl)pentyl]-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244619-17-8 CAPLUS
CN 4-Piperidinesulfonic acid, 1-[5-[2-[3-(aminoiminomethyl)phenyl]-2,3-dihydro-3-oxo-4H-1,4-benzoxazin-4-yl]pentyl]- (9CI) (CA INDEX NAME)



RN 244619-18-9 CAPLUS
CN Benzenecarboximidamide, 3-[3,4-dihydro-3-oxo-4-[5-(2-phenyl-1-piperidinyl)pentyl]-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)



L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 244619-19-0 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-(2,5-dimethyl-1-pyrrolidinyl)pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)



RN 244619-20-3 CAPLUS
CN Benzenecarboximidamide, 3-[3,4-dihydro-3-oxo-4-[5-(1-pyrrolidinyl)pentyl]-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)



RN 244619-21-4 CAPLUS
CN Proline, 1-[5-[2-[3-(aminoiminomethyl)phenyl]-2,3-dihydro-3-oxo-4H-1,4-benzoxazin-4-yl]pentyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244619-22-5 CAPLUS
CN Acetamide, N-[1-[5-[2-[3-(aminoiminomethyl)phenyl]-2,3-dihydro-3-oxo-4H-1,4-benzoxazin-4-yl]pentyl]-3-pyrrolidinyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 244619-23-6 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-(3-amino-1-pyrrolidinyl)pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244619-24-7 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-[2,5-bis(methoxymethyl)-1-pyrrolidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)



RN 244619-25-8 CAPLUS
CN Benzenecarboximidamide, 3-[3,4-dihydro-4-[5-[2-(hydroxymethyl)-1-pyrrolidinyl]pentyl]-3-oxo-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)



RN 244619-26-9 CAPLUS
CN Benzenecarboximidamide, 3-[3,4-dihydro-4-[5-[2-(hydroxymethyl)-5-methyl-1-pyrrolidinyl]pentyl]-3-oxo-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244619-27-0 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-[bis(1-methylethyl)amino]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)



RN 244619-28-1 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-(diethylamino)pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)



RN 244619-29-2 CAPLUS
CN Benzenecarboximidamide, 3-[3,4-dihydro-4-[5-(methylamino)pentyl]-3-oxo-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244619-30-5 CAPLUS
CN Benzenecarboximidamide, 3-[3,4-dihydro-4-[5-(1-methyl-1H-imidazol-2-yl)pentyl]-3-oxo-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)



RN 244619-31-6 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-(2,5-dimethyl-1H-imidazol-1-yl)pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)



RN 244619-32-7 CAPLUS
CN Benzenecarboximidamide, 3-[3,4-dihydro-4-[5-(4-morpholinyl)pentyl]-3-oxo-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244619-35-0 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-(2,6-dimethyl-1-piperazinyl)pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)



RN 244619-36-1 CAPLUS
CN Benzenecarboximidamide, 3-[3,4-dihydro-3-oxo-4-[5-(1H-pyrazol-1-yl)pentyl]-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)



RN 244619-37-2 CAPLUS

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244619-33-8 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-(3,5-dimethyl-4-morpholinyl)pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)



RN 244619-34-9 CAPLUS
CN Benzenecarboximidamide, 3-[3,4-dihydro-3-oxo-4-[5-(1-piperazinyl)pentyl]-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN Benzenecarboximidamide, 3-[3,4-dihydro-3-oxo-4-[5-(1-pyrazolidinyl)pentyl]-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)



RN 244619-38-3 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-(2,5-dimethyl-1-pyrazolidinyl)pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)



RN 244619-39-4 CAPLUS
CN Benzenecarboximidamide, 3-[6-chloro-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244619-40-7 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-6-fluoro-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 244619-41-8 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-6-mercapto-3-oxo-2H-1,4-benzoxazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244619-44-1 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-6-methyl-3-oxo-2H-1,4-benzoxazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 244619-45-2 CAPLUS
CN 2H-1,4-Benzoxazine-6-carboxylic acid, 2-[3-(aminoiminomethyl)phenyl]-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244619-42-9 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-6-(methylthio)-3-oxo-2H-1,4-benzoxazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 244619-43-0 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-6-(trifluoromethyl)-2H-1,4-benzoxazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 244619-46-3 CAPLUS
CN 2H-1,4-Benzoxazine-6-carboxylic acid, 2-[3-(aminoiminomethyl)phenyl]-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 244619-47-4 CAPLUS
CN Benzenecarboximidamide, 3-[6-cyano-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 244619-48-5 CAPLUS
CN 2H-1,4-Benzoxazine-6-carboximidamide, 2-[3-(aminoiminomethyl)phenyl]-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244619-49-6 CAPLUS
CN 2H-1,4-Benzoxazine-6-carboximidamide, 2-[3-(aminoiminomethyl)phenyl]-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-N-hydroxy-3-oxo-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 244619-50-9 CAPLUS
CN 2H-1,4-Benzoxazine-6-carboximidic acid, 2-[3-(aminoiminomethyl)phenyl]-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-, hydrazide, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244619-53-2 CAPLUS
CN Benzenecarboximidamide, 3-[6-(aminomethyl)-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 244619-54-3 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-6-nitro-3-oxo-2H-1,4-benzoxazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244619-51-0 CAPLUS
CN 2H-1,4-Benzoxazine-6-carboxamide, 2-[3-(aminoiminomethyl)phenyl]-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 244619-52-1 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-6-(hydroxymethyl)-3-oxo-2H-1,4-benzoxazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 244619-55-4 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-6-hydroxy-3-oxo-2H-1,4-benzoxazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 244619-56-5 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-6-methoxy-3-oxo-2H-1,4-benzoxazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 244619-57-6 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-6-(phenylmethoxy)-2H-1,4-benzoxazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244619-58-7 CAPLUS
CN Acetic acid, [[2-[3-(aminoiminomethyl)phenyl]-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl]oxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 244619-59-8 CAPLUS
CN Propanoic acid, 3-[[2-[3-(aminoiminomethyl)phenyl]-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl]oxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244619-62-3 CAPLUS
CN β-Alanine, N-[2-[3-(aminoiminomethyl)phenyl]-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 244619-63-4 CAPLUS
CN Butanoic acid, 4-[[2-[3-(aminoiminomethyl)phenyl]-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244619-60-1 CAPLUS
CN Butanoic acid, 4-[[2-[3-(aminoiminomethyl)phenyl]-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl]oxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 244619-61-2 CAPLUS
CN Glycine, N-[2-[3-(aminoiminomethyl)phenyl]-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 244619-64-5 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-6-(2-hydroxyethoxy)-3-oxo-2H-1,4-benzoxazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 244619-65-6 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-6-(1H-tetrazol-5-ylmethoxy)-2H-1,4-benzoxazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 244619-66-7 CAPLUS
CN Benzenecarboximidamide, 3-[6-amino-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244619-67-8 CAPLUS
CN Benzenecarboximidamide, 3-[6-(butylamino)-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 244619-68-9 CAPLUS
CN Benzenecarboximidamide, 3-[6-(dimethylamino)-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244619-71-4 CAPLUS
CN Acetamide, N-[2-[3-(aminoiminomethyl)phenyl]-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 244619-72-5 CAPLUS
CN Cyclohexanecarboxamide, N-[2-[3-(aminoiminomethyl)phenyl]-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244619-69-0 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-6-(phenylamino)-2H-1,4-benzoxazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 244619-70-3 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-6-[(phenylmethyl)amino]-2H-1,4-benzoxazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 244619-73-6 CAPLUS
CN Cyclohexaneacetamide, N-[2-[3-(aminoiminomethyl)phenyl]-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 244619-74-7 CAPLUS
CN Benzamide, N-[2-[3-(aminoiminomethyl)phenyl]-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 244619-75-8 CAPLUS
CN Benzeneacetamide, N-[2-[3-(aminoiminomethyl)phenyl]-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244619-76-9 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-6-[(methylsulfonyl)amino]-3-oxo-2H-1,4-benzoxazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 244619-77-0 CAPLUS
CN Benzenecarboximidamide, 3-[6-[(cyclohexylsulfonyl)amino]-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244619-80-5 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-6-[[(phenylmethyl)sulfonyl]amino]-2H-1,4-benzoxazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 244619-81-6 CAPLUS
CN Benzenecarboximidamide, 3-[(2R)-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244619-78-1 CAPLUS
CN Benzenecarboximidamide, 3-[6-[[(cyclohexylmethyl)sulfonyl]amino]-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 244619-79-2 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-6-[(phenylsulfonyl)amino]-2H-1,4-benzoxazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 244619-82-7 CAPLUS
CN Benzenecarboximidamide, 3-[(2S)-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244619-83-8 CAPLUS
CN Benzenecarboximidamide, 3-[(2R)-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-4-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244619-84-9 CAPLUS
CN Benzenecarboximidamide, 3-[(2R)-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244619-85-0 CAPLUS
CN Benzenecarboximidamide, 3-[(2S)-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244619-86-1 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[5-(diethylamino)pentyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 244619-87-2 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 2-phenyl-4-[5-(1-pyrrolidinyl)pentyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244619-91-8 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 2-(2-chlorophenyl)-4-[5-(2,5-dimethyl-1-pyrrolidinyl)pentyl]- (9CI) (CA INDEX NAME)



RN 244619-92-9 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 2-(2-chlorophenyl)-4-[5-(2,6-dimethyl-1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)



RN 244619-93-0 CAPLUS
CN 4H-1,4-Benzoxazine-4-pentanimidamide, 2,3-dihydro-3-oxo-2-phenyl- (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244619-88-3 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[5-(2,3-dihydro-3-oxo-2-phenyl-4H-1,4-benzoxazin-4-yl)pentyl]- (9CI) (CA INDEX NAME)



RN 244619-89-4 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[5-(1H-imidazol-1-yl)pentyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 244619-90-7 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 2-(4-chlorophenyl)-4-[5-(2,6-dimethyl-1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244619-94-1 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 2-phenyl-4-[5-(1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)



RN 244619-95-2 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 2-(4-chlorophenyl)-4-[5-(2,5-dimethyl-1-pyrrolidinyl)pentyl]- (9CI) (CA INDEX NAME)



RN 244619-96-3 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 2-phenyl-4-[5-(1-pyrrolidinyl)pentyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 244619-87-2
CMF C23 H28 N2 O2

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 244619-98-5 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[6-(2,5-dimethyl-1-pyrrolidinyl)hexyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 244620-00-6 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 2-(2-naphthalenyl)-4-[5-(1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244620-01-7 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 4-(5-aminopentyl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 244620-02-8 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 6-methyl-2-phenyl-4-[5-(1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)



RN 244620-03-9 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 7-methoxy-2-phenyl-4-[5-(1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244620-04-0 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 8-chloro-2-phenyl-4-[5-(1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)



RN 244620-05-1 CAPLUS
CN 2H-1,4-Benzoxazine-6-carbonitrile, 3,4-dihydro-3-oxo-2-phenyl-4-[5-(1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)



RN 244620-07-3 CAPLUS
CN 2,6-Piperidinedione, 1-[5-(2,3-dihydro-3-oxo-2-phenyl-4H-1,4-benzoxazin-4-yl)pentyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244620-08-4 CAPLUS
CN 4H-1,4-Benzoxazine-4-propanenitrile, 2,3-dihydro-3-oxo-2-phenyl- (9CI) (CA INDEX NAME)



RN 244620-09-5 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanenitrile, 2,3-dihydro-3-oxo-2-phenyl- (9CI) (CA INDEX NAME)



RN 244620-10-8 CAPLUS
CN 4H-1,4-Benzoxazine-4-pentanenitrile, 2,3-dihydro-3-oxo-2-phenyl- (9CI) (CA INDEX NAME)



RN 244620-11-9 CAPLUS
CN Guanidine, [3-(2,3-dihydro-3-oxo-2-phenyl-4H-1,4-benzoxazin-4-yl)propyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244620-12-0 CAPLUS
CN Guanidine, [5-(2,3-dihydro-3-oxo-2-phenyl-4H-1,4-benzoxazin-4-yl)pentyl]- (9CI) (CA INDEX NAME)



RN 244620-13-1 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 2-(4-methoxyphenyl)-4-[5-(1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)



RN 244620-14-2 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 7-methyl-2-phenyl-4-[5-(1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244620-19-7 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 2-(4-methoxyphenyl)-4-[5-(1-piperazinyl)pentyl]- (9CI) (CA INDEX NAME)



RN 244620-20-0 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 2-(4-hydroxyphenyl)-4-[5-(1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)



RN 244620-21-1 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[5-(2,6-dimethyl-1-piperidinyl)pentyl]-2-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244620-15-3 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 5-methyl-2-phenyl-4-[5-(1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)



RN 244620-16-4 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 6-methoxy-2-phenyl-4-[5-(1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)



RN 244620-18-6 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 6-chloro-2-phenyl-4-[5-(1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244620-22-2 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 2-(4-methoxyphenyl)-4-[5-(4-methyl-1-piperazinyl)pentyl]- (9CI) (CA INDEX NAME)



RN 244620-23-3 CAPLUS
CN Benzonitrile, 4-[4-[5-(2,6-dimethyl-1-piperidinyl)pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)



RN 244620-24-4 CAPLUS
CN Benzenecarboximidamide, 4-[4-[5-(2,6-dimethyl-1-piperidinyl)pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244620-25-5 CAPLUS
CN Benzenecarbothioamide, 4-[4-[5-(2,6-dimethyl-1-piperidinyl)pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)



RN 244620-27-7 CAPLUS
CN Benzenecarboximidamide, 4-[4-[5-(2,6-dimethyl-1-piperidinyl)pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 244620-28-8 CAPLUS
CN Benzenecarboximidic acid, 4-[4-[5-(2,6-dimethyl-1-piperidinyl)pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-, hydrazide (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244620-34-6 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[5-(2,6-dimethyl-1-piperidinyl)pentyl]-2-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 244620-35-7 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 2-(3,4-dimethoxyphenyl)-4-[5-(2,6-dimethyl-1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)



RN 244620-36-8 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 2-(4-bromophenyl)-4-[5-(2,6-dimethyl-1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244620-29-9 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 6-amino-2-phenyl-4-[5-(1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)



RN 244620-30-2 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 4-(5-bromopentyl)-2-(3,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 244620-31-3 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 4-(5-bromopentyl)-2-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244620-37-9 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 8-methyl-2-phenyl-4-[5-(1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)



RN 244620-38-0 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[5-(2,6-dimethyl-1-piperidinyl)pentyl]-2-[4-[(phenylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 244620-39-1 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 2-(4-methoxyphenyl)-4-[5-(2,2,6,6-tetramethyl-1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244620-41-5 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 4-(5-bromopentyl)-2-(3,4-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 244620-43-7 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 2-(3,4-dichlorophenyl)-4-[5-(2,2,6,6-tetramethyl-1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)



RN 244620-47-1 CAPLUS
CN Piperidine, 1-[5-[2,3-dihydro-2-(4-methoxyphenyl)-3-oxo-4H-1,4-benzoxazin-4-yl]-1-oxopentyl]-2,2,6,6-tetramethyl- (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244620-50-6 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 2-[5-(aminomethyl)-2-hydroxyphenyl]-4-[5-(2,6-dimethyl-1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)



RN 244620-51-7 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 2-[3-(aminomethyl)phenyl]-4-[5-(2,6-dimethyl-1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)



RN 244620-52-8 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-(2,6-dimethyl-1-piperidinyl)pentyl]-3,4-dihydro-7-methyl-3-oxo-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)

RN 244620-53-9 CAPLUS

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244620-48-2 CAPLUS
CN Benzenecarboximidamide, 3-[4-[4-(2,6-dimethyl-1-piperidinyl)butyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)



RN 244620-49-3 CAPLUS
CN Benzenecarboximidamide, 3-[4-[6-(2,6-dimethyl-1-piperidinyl)hexyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)



L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN Benzenecarboximidamide, 3-[4-[5-(2,6-dimethyl-1-piperidinyl)pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 244620-54-0 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 2-[5-(aminomethyl)-2-methoxyphenyl]-4-[5-(2,6-dimethyl-1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)



RN 244620-55-1 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-(2,6-dimethyl-1-piperidinyl)pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-N-hydroxy-4-methoxy- (9CI) (CA INDEX NAME)



RN 244620-56-2 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-(2,6-dimethyl-1-piperidinyl)pentyl]-3,4-

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 244620-57-3 CAPLUS
CN Benzenecarboximidamide, 3-[7-chloro-4-[5-(2,6-dimethyl-1-piperidinyl)pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)



RN 244620-58-4 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 4-(5-bromopentyl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 244620-59-5 CAPLUS
CN Acetamide, N-[2-[3-(aminoiminomethyl)phenyl]-4-[5-(2,6-dimethyl-1-piperidinyl)pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl]- (9CI) (CA

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
INDEX NAME)



RN 244620-60-8 CAPLUS
CN Acetamide, N-[2-[5-(aminoiminomethyl)-2-hydroxyphenyl]-4-[5-(2,6-dimethyl-1-piperidinyl)pentyl]-3,4-dihydro-2-methyl-3-oxo-2H-1,4-benzoxazin-6-yl]- (9CI) (CA INDEX NAME)



RN 244620-63-1 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-(2,6-dimethyl-1-piperidinyl)pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-4-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244620-64-2 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-(2,6-dimethyl-1-piperidinyl)pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 244620-65-3 CAPLUS
CN 2H-1,4-Benzoxazine-6-acetic acid, 2-[3-(aminoiminomethyl)phenyl]-4-[5-(2,6-dimethyl-1-piperidinyl)pentyl]-3,4-dihydro-3-oxo- (9CI) (CA INDEX NAME)



RN 244620-68-6 CAPLUS
CN 2H-1,4-Benzoxazine-7-carboxylic acid, 2-[3-(aminoiminomethyl)phenyl]-4-[5-(2,6-dimethyl-1-piperidinyl)pentyl]-3,4-dihydro-3-oxo- (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244620-69-7 CAPLUS
CN Benzenecarboximidamide, 3-(3,4-dihydro-3-oxo-4-[4-(2-pyridinylamino)butyl]-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)



RN 244620-70-0 CAPLUS
CN 2H-1,4-Benzoxazine-7-carboxylic acid, 2-[3-(aminoiminomethyl)phenyl]-4-[5-(2,6-dimethyl-1-piperidinyl)pentyl]-3,4-dihydro-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 244620-71-1 CAPLUS
CN Benzenecarboximidamide, 3-[4-(5-(dihexylamino)pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)



RN 244620-72-2 CAPLUS
CN Benzenecarboximidamide, 3-[3,4-dihydro-4-[4-(methyl-2-pyridinylamino)butyl]-3-oxo-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)



RN 244620-73-3 CAPLUS
CN Morpholine, 4-[[3-[4-[5-(2,6-dimethyl-1-piperidinyl)pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]phenyl]iminomethyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244620-74-4 CAPLUS
CN Benzenecarboximidamide, 3-[3,4-dihydro-3-oxo-4-[4-(2-pyrimidinylamino)butyl]-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)



RN 244620-75-5 CAPLUS
CN Benzenecarboximidamide, 3-[4-[4-(cyclohexylamino)butyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)



L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 244620-76-6 CAPLUS
CN Pentitol, 5-[2-[3-(aminoiminomethyl)phenyl]-2,3-dihydro-3-oxo-4H-1,4-benzoxazin-4-yl]-1,2,5-trideoxy-1-(2,6-dimethyl-1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 244620-78-8 CAPLUS
CN 2H-1,4-Benzoxazine-6-carboxylic acid, 2-[3-(aminoiminomethyl)phenyl]-4-[5-(2,6-dimethyl-1-piperidinyl)pentyl]-3,4-dihydro-3-oxo- (9CI) (CA INDEX NAME)



RN 244620-81-3 CAPLUS
CN Benzenecarboximidamide, 3-[4-(5-aminopentyl)-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244620-82-4 CAPLUS
CN 2H-1,4-Benzoxazine-6-carboxylic acid, 2-[3-(aminoiminomethyl)phenyl]-4-[5-(2,6-dimethyl-1-piperidinyl)pentyl]-3,4-dihydro-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 244620-84-6 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-(2,6-dimethyl-1-piperidinyl)-3-pentenyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)



L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 244620-87-9 CAPLUS
CN 4-Thiazolecarboxylic acid, 3-acetyl-2,3-dihydro-2-(2-methoxyphenyl)-, 4-cyano-2-[4-[5-(2,6-dimethyl-1-piperidinyl)pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]phenyl ester (9CI) (CA INDEX NAME)



RN 244621-17-8 CAPLUS
CN 2H-1,4-Benzoxazine-6-carboximidamide, 3,4-dihydro-N-hydroxy-3-oxo-2-phenyl-4-[5-(1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)



RN 244621-18-9 CAPLUS
CN 2H-1,4-Benzoxazine-6-carboximidamide, 3,4-dihydro-3-oxo-2-phenyl-4-[5-(1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT **244621-32-7P 244621-33-8P 244621-34-9P**
244621-42-9P 244621-43-0P 244621-44-1P
244621-45-2P 244621-52-1P 244621-53-2P
244621-54-3P 244621-55-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzoxazinones and -thiazinones as serine protease inhibitors)

RN 244621-32-7 CAPLUS
CN Benzonitrile, 3-[4-(5-bromopentyl)-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)



RN 244621-33-8 CAPLUS
CN Benzonitrile, 3-[4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 244621-34-9 CAPLUS

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244621-19-0 CAPLUS
CN Benzenecarbothioamide, 3-[4-[5-(2,6-dimethyl-1-piperidinyl)pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)



RN 244621-20-3 CAPLUS
CN Benzenecarboximidamide, 3-[3,4-dihydro-3-oxo-4-[5-(tricyclo[3.3.1.13,7]dec-1-ylamino)pentyl]-2H-1,4-benzoxazin-2-yl]- (9CI) (CA INDEX NAME)



RN 244623-37-8 CAPLUS
CN 2H-1,4-Benzoxazine-6-carbonitrile, 3,4-dihydro-3-oxo-2-phenyl-2,4-bis[5-(1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN Benzenecarboximidamide, 3-[4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-N-[(trifluoroacetyl)oxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 244621-42-9 CAPLUS
CN Benzonitrile, 3-[4-(5-bromopentyl)-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-4-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 244621-43-0 CAPLUS
CN Benzonitrile, 3-[4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-4-(phenylmethoxy)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 244621-44-1 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-[(2R,6S)-2,6-dimethyl-1-

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-N-hydroxy-4-(phenylmethoxy)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 244621-45-2 CAPLUS
CN Benzenecarboximidamide, 3-[4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-4-(phenylmethoxy)-N-[(trifluoroacetyl)oxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 244621-52-1 CAPLUS
CN Benzonitrile, 3-[(2S)-4-(5-bromopentyl)-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-4-(phenylmethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-N-hydroxy-4-(phenylmethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 244621-53-2 CAPLUS
CN Benzonitrile, 3-[(2S)-3,4-dihydro-4-(5-iodopentyl)-3-oxo-2H-1,4-benzoxazin-2-yl]-4-(phenylmethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244621-54-3 CAPLUS
CN Benzonitrile, 3-[(2S)-4-[5-[(2R,6S)-2,6-dimethyl-1-piperidinyl]pentyl]-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]-4-(phenylmethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244621-55-4 CAPLUS
CN Benzenecarboximidamide, 3-[(2S)-4-[5-[(2R,6S)-2,6-dimethyl-1-

L7 ANSWER 14 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 22 Jul 1999
AB A study of the reaction of Ph magnesium bromide with various N-(cyanomethyl)oxazolidines showed that product formation (essentially 3-imidazolines and 2-aminomorpholines) is highly sensitive to the substitution pattern and stereochem., and appears to involve initial complexation of the Grignard reagent to ring-oxygen.

ACCESSION NUMBER: 1999:448446 CAPLUS
DOCUMENT NUMBER: 131:199648
TITLE: Substitution and stereochemical effects in the reactions of combined aminonitrile-oxazolidines with a Grignard reagent
AUTHOR(S): Le Bail, Marc; Perard, Joelle; Aitken, David J.; Husson, Henri-Philippe
CORPORATE SOURCE: Laboratoire de Chimie Therapeutique associe au CNRS, Faculte des Sciences Pharmaceutiques et biologiques, Universite Rene Descartes, Paris, 75270, Fr.
SOURCE: Tetrahedron Letters (1999), 40(29), 5309-5313
CODEN: TELEAY; ISSN: 0040-4039
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **241825-84-3P 241825-86-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(substitution and stereochem. effects in the reactions of N-(cyanomethyl)oxazolidines with a Grignard reagent)
RN 241825-84-3 CAPLUS
CN 2-Morpholinamine, 2,5-diphenyl-4-(1-phenylbutyl)-, (2S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 241825-86-5 CAPLUS
CN 2-Morpholinamine, 3-methyl-2,5-diphenyl-4-(1-phenylbutyl)-, (2S,3R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 15 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 29 Jun 1999
AB The synthesis, pharmacol. and toxicol. of derivs. of 1-(2-arylmorpholino)-3-phenyl-3-propanone oxime and related anilides are described. The structures of the new compds. were proved by IR, 1H NMR and occasionally with 13C NMR. The acute toxicity of the compds. in mice was determined. A comparative pharmacol. study of the in vivo effect on the central nervous system was realized by screening tests on pentobarbital-induced sleeping time, locomotor activity, and behavior despair test for antidepressive activity. The most active compound was 1-(2-phenylmorpholino)-3-phenyl-3-propanone oxime which showed low toxicity and antidepressive activity at a dose of 1/10 LD50.
ACCESSION NUMBER: 1999:400879 CAPLUS
DOCUMENT NUMBER: 131:111361
TITLE: Synthesis, toxicological and pharmacological assessment of morpholino oximes
AUTHOR(S): Avramova, Petya D.; Danchev, N. D.; Buyukliev, R. T.
CORPORATE SOURCE: Department Pharmaceutical Chemistry, Faculty Pharmacy, Sofia, 1000, Bulg.
SOURCE: Pharmazie (1999), 54(6), 409-411
CODEN: PHARAT; ISSN: 0031-7144
PUBLISHER: Govi-Verlag Pharmazeutischer Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **232613-47-7P**
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation, toxicity, and antidepressive activity of morpholinopropiophenone oximes)
RN 232613-47-7 CAPLUS
CN 1-Propanone, 3-[2-(4-chlorophenyl)-4-morpholinyl]-1-phenyl-, oxime (9CI) (CA INDEX NAME)



IT **232613-46-6P 232613-48-8P**
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation, toxicity, and antidepressive activity of morpholinopropiophenone oximes)
RN 232613-46-6 CAPLUS
CN 1-Propanone, 1-phenyl-3-(2-phenyl-4-morpholinyl)-, oxime (9CI) (CA INDEX NAME)

L7 ANSWER 15 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 232613-48-8 CAPLUS
CN 1-Propanone, 3-[2-(4-bromophenyl)-4-morpholinyl]-1-phenyl-, oxime (9CI) (CA INDEX NAME)



IT **220464-90-4 232613-51-3 232613-52-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation, toxicity, and antidepressive activity of morpholinopropiophenone oximes)
RN 220464-90-4 CAPLUS
CN 1-Propanone, 3-[2-(4-chlorophenyl)-4-morpholinyl]-1-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 232613-51-3 CAPLUS
CN 1-Propanone, 1-phenyl-3-(2-phenyl-4-morpholinyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

L7 ANSWER 15 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 232613-52-4 CAPLUS
CN 1-Propanone, 3-[2-(4-bromophenyl)-4-morpholinyl]-1-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

IT **232613-50-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, toxicity, and antidepressive activity of morpholinopropiophenone oximes)
RN 232613-50-2 CAPLUS
CN Morpholinium, 2-(4-chlorophenyl)-4-methyl-4-[3-oxo-3-(phenylamino)propyl]-, iodide (9CI) (CA INDEX NAME)



● I⁻

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 16 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 15 Apr 1999
AB A new pathway for the synthesis of 2-(1-hydroxyalkyl)- and 2-[1-(arylamino)alkyl]morpholines via α-hydroxy- or α-aminoalkylation of 3-morpholinones, followed by reduction with LiAlH4 of the intermediate compds. to the target substituted morpholines, is described.
ACCESSION NUMBER: 1999:232336 CAPLUS
DOCUMENT NUMBER: 131:5228
TITLE: A new synthesis of 2-(1-hydroxyalkyl)- and 2-(1-aminoalkyl)morpholines via 3-morpholinones
AUTHOR(S): Dobrev, Alexander; Nechev, Lubomir; Ivanov, Christo; Bon, Maryse
CORPORATE SOURCE: Faculty of Chemistry, University of Sofia, Sofia, 1126, Bulg.
SOURCE: Journal of Chemical Research, Synopses (1999), (3), 188-189, 1001-1047
CODEN: JRPSDC; ISSN: 0308-2342
PUBLISHER: Royal Society of Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 131:5228
IT **16187-72-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 2-(1-hydroxyalkyl)- and 2-(1-aminoalkyl)morpholines via 3-morpholinones)
RN 16187-72-7 CAPLUS
CN 3-Morpholinone, 4-butyl-6-phenyl- (8CI, 9CI) (CA INDEX NAME)



IT **225506-58-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of 2-(1-hydroxyalkyl)- and 2-(1-aminoalkyl)morpholines via 3-morpholinones)
RN 225506-58-1 CAPLUS
CN 3-Morpholinone, 4-butyl-2-(hydroxyphenylmethyl)-6-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 17 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 09 Apr 1999
AB The preparation of two new bisoxazolidines, two N-(2-hydroxyethyl)-N-alkylglycine derivs. and two morpholones is described. The structure of (5S,6R)-N-isopropyl-5-methyl-6-phenyl-1,4-oxazin-2-one was established by X-ray crystallog. anal.
ACCESSION NUMBER: 1999:220867 CAPLUS
DOCUMENT NUMBER: 130:338074
TITLE: Syntheses of bisoxazolidines and morpholones
AUTHOR(S): Santes, Victor; Ortiz, Aurelio; Santillan, Rosa; Gotierrez, Atilano; Farfan, Norberto
CORPORATE SOURCE: Departamento de Quimica, Centro de Investigacion y de Estudios Avanzados del IPN, Mexico D.F., 07000, Mex.
SOURCE: Synthetic Communications (1999), 29(8), 1277-1286
CODEN: SYNCAV; ISSN: 0039-7911
PUBLISHER: Marcel Dekker, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **224447-58-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of)
RN 224447-58-9 CAPLUS
CN 2-Morpholinone, 4-(2,2-dimethylpropyl)-5-methyl-6-phenyl-, (5S,6R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 18 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 03 Feb 1999
AB The synthesis of 2-aryl-4-(3-arylpropyl)morpholines, is described. Acute toxicity studies of the compds. were performed on mice. A comparative pharmacol. study of the in vivo effects on the central nervous system was undertaken using screening tests for hexobarbital induced sleeping time, locomotor activity, and behavior despair (for antidepressive activity). The most active compound, 4-(2-benzoylethyl)-2-phenyl-3-methylmorpholine, was studied for MAO-A and MAO-B inhibition in rat brain mitochondria prepns.
ACCESSION NUMBER: 1999:72677 CAPLUS
DOCUMENT NUMBER: 130:168308
TITLE: Synthesis, toxicological, and pharmacological assessment of derivatives of 2-aryl-4-(3-arylpropyl)morpholines
AUTHOR(S): Avramova, Petya; Danchev, Nicolai; Buyukliev, Rossen; Bogoslovova, Tatiana
CORPORATE SOURCE: Department Pharmaceutical Chemistry, Faculty Pharmacy, Sofia, 1000, Bulg.
SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1998), 331(11), 342-346
CODEN: ARPMAS; ISSN: 0365-6233
PUBLISHER: Wiley-VCH Verlag GmbH
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **155138-24-2P 220464-91-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aryl(arylpropyl)morpholines as MAO-inhibiting antidepressants)
RN 155138-24-2 CAPLUS
CN 1-Propanone, 1-(4-bromophenyl)-3-[2-(4-bromophenyl)-4-morpholinyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 220464-91-5 CAPLUS
CN 1-Propanone, 3-(3-methyl-2-phenyl-4-morpholinyl)-1-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

IT **155138-22-0P 155138-23-1P 220464-90-4P 220464-92-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of aryl(arylpropyl)morpholines as MAO-inhibiting antidepressants)
RN 155138-22-0 CAPLUS
CN 1-Propanone, 1-(4-bromophenyl)-3-(3-methyl-2-phenyl-4-morpholinyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 155138-23-1 CAPLUS
CN 1-Propanone, 1-(4-bromophenyl)-3-[2-(4-chlorophenyl)-4-morpholinyl]-, hydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 18 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 220464-90-4 CAPLUS
CN 1-Propanone, 3-[2-(4-chlorophenyl)-4-morpholinyl]-1-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 220464-92-6 CAPLUS
CN 4-Morpholinepropanol, α,2-bis(4-bromophenyl)- (9CI) (CA INDEX NAME)



IT **155138-20-8P 155138-21-9P 220464-93-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of aryl(arylpropyl)morpholines as MAO-inhibiting antidepressants)
RN 155138-20-8 CAPLUS
CN 1-Propanone, 1-(4-chlorophenyl)-3-(3-methyl-2-phenyl-4-morpholinyl)-, hydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 18 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 155138-21-9 CAPLUS
CN 1-Propanone, 1-(4-chlorophenyl)-3-[2-(4-chlorophenyl)-4-morpholinyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 220464-93-7 CAPLUS
CN 4-Morpholinepropanol, 3-methyl-α,2-diphenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 19 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 19 Nov 1998
AB We report herein an efficient and practical synthetic method for the preparation of enantiomerically pure 2-[(2R)-arylmorpholin-2-yl]ethanols, key intermediates of tachykinin receptor antagonist. Sharpless catalytic asym. dihydroxylation was employed to introduce the required absolute stereochem., and cyclization was accomplished by the Mitsunobu reaction.
ACCESSION NUMBER: 1998:733430 CAPLUS
DOCUMENT NUMBER: 130:66453
TITLE: An efficient synthesis of enantiomerically pure 2-[(2R)-arylmorpholin-2-yl]ethanols, key intermediates of tachykinin receptor antagonist
AUTHOR(S): Nishi, Takahide; Ishibashi, Koki; Nakajima, Katsuyoshi; Iio, Yukiko; Fukazawa, Tetsuya
CORPORATE SOURCE: Medicinal Chemistry Research Laboratories, Sankyo Co., Ltd., Tokyo, 140-8710, Japan
SOURCE: Tetrahedron: Asymmetry (1998), 9(18), 3251-3262
CODEN: TASYE3; ISSN: 0957-4166
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 130:66453
IT **218292-45-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of enantiomerically pure (arylmorpholinyl)ethanols)
RN 218292-45-6 CAPLUS
CN 2-Morpholineethanol, 2-(3,4-dichlorophenyl)-4-[(2R)-3,3,3-trifluoro-2-methoxy-1-oxo-2-phenylpropyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 20 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 21 Mar 1998
GI



AB Pyrido[3,2-b]oxazinones I (R = H, Ph; R1 = H, 4-F, 3-CF3; n = 2, 3, 4, 5) were prepared, pharmacol. evaluated, and compared with acetylsalicylic acid. The compound with the maximal combination of safety and analgesic efficacy was I (R = H, R1 = 4-F, n = 3) with ED50 values of 12.5 mg/kg po (mouse: phenylquinone writhing test) and 27.8 mg/kg po (rat: acetic acid writhing test). This compound proved to be more active than aspirin with a safety index of 5.1.
ACCESSION NUMBER: 1998:168432 CAPLUS
DOCUMENT NUMBER: 128:244026
TITLE: Substituted pyrido[3,2-b]oxazin-3(4H)-ones: synthesis and evaluation of antinociceptive activity
AUTHOR(S): Savelon, L.; Bizot-Espiard, J. G.; Caignard, D. H.; Pfeiffer, B.; Renard, P.; Viaud, M. C.; Guillaumet, G.
CORPORATE SOURCE: Institut de Chimie Organique et Analytique, associe au CNRS, Universite d'Orleans, Orleans, 45067, Fr.
SOURCE: Bioorganic & Medicinal Chemistry (1998), 6(2), 133-142
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **204916-57-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antinociceptive activity of)
RN 204916-57-4 CAPLUS
CN 2H-Pyrido[3,2-b]-1,4-oxazin-3(4H)-one, 2-phenyl-4-[4-(4-phenyl-1-piperazinyl)butyl]- (9CI) (CA INDEX NAME)



IT **204916-45-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

L7 ANSWER 20 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(Reactant or reagent)
(prepn. and antinociceptive activity of pyrido[3,2-b]oxazin-3(4H)-ones)
RN 204916-45-0 CAPLUS
CN 2H-Pyrido[3,2-b]-1,4-oxazin-3(4H)-one, 4-(4-bromobutyl)-2-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 21 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 19 Mar 1998
GI



I

AB The title compds. [I; R1 = C1-8 alkyl, C3-8 cycloalkyl, etc.; R2 = C1-4 alkyl; R3 = H, C1-5 alkyl, etc.; R4 = H, C1-6 alkyl, etc.; R5, R6 = H, (un)substituted C1-5 alkyl, etc.], optical isomers, pharmaceutically acceptable salts, hydrates, or solvates thereof, are prepared I have a potent phosphodiesterase (PDE) IV inhibitory activity, bronchodilatory and anti-inflammatory activities. Thus, 2-(2-chloroacetamido)-1-(3,4-dimethoxyphenyl)ethanol (preparation given) was treated with KOH in EtOH to give 51.4% I (R1 = R2 = Me, R3 = R4 = R5 = R6 = H), which showed IC50 of 3.7 X 10-5 M against PDE IV. Formulation containing I are also prepared

ACCESSION NUMBER: 1998:163576 CAPLUS
DOCUMENT NUMBER: 128:204892
TITLE: Preparation of 2-phenylmorpholin-5-one derivatives as phosphodiesterase IV inhibitors
INVENTOR(S): Ina, Shinji; Yamana, Kenjiro; Noda, Kyoji
PATENT ASSIGNEE(S): Nikken Chemicals Co., Ltd., Japan
SOURCE: PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9808828	A1	19980305	WO 1997-JP2970		19970826
W: CA, US					
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
EP 924204	A1	19990623	EP 1997-935890		19970826
R: CH, DE, FR, GB, IT, LI					
CA 2264685	C	20021015	CA 1997-2264685		19970826
CA 2264685	AA	19980305			
JP 10120665	A2	19980512	JP 1997-244834		19970827
US 6265402	B1	20010724	US 1999-242818		19990225
PRIORITY APPLN. INFO.:			JP 1996-242542	A	19960827
			WO 1997-JP2970	W	19970826

OTHER SOURCE(S): MARPAT 128:204892
IT **204014-88-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-phenylmorpholin-5-one derivs. as phosphodiesterase IV inhibitors)

L7 ANSWER 21 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 204014-88-0 CAPLUS
CN 3-Morpholinone, 4-butyl-6-[3-(cyclopentyloxy)-4-methoxyphenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 22 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 24 Oct 1997
AB Phenmetrazine is a central nervous system stimulant and is currently used as an anorectic agent. The drug is abused and reported to cause death from overdose. We describe a liquid-liquid extraction protocol for phenmetrazine from urine using 1-chlorobutane and subsequent derivatization using perfluorooctanoyl chloride for gas chromatog.-mass spectrometric confirmation. Quantitation of urinary phenmetrazine can be easily achieved by using N-propylamphetamine as an internal standard The perfluorooctanoyl derivative of phenmetrazine showed a weak mol. ion at m/z 573 and a characteristic strong peak at m/z 467 in the electron ionization mass spectrometry thus aiding unambiguous identification. The perfluorooctanoyl derivative of the internal standard did not show any mol. ion, but showed strong characteristic peaks at m/z 482 and 440. The within run and between run precisions of the assay were 1.7% and 3.2% at a urinary phenmetrazine concentration of 20 μg/mL. The within run and between run precisions were higher (9.4% and 10.8%) at a urinary phenmetrazine concentration of 1.0 μg/mL, which was very close to the detection limit of the assay. The assay was linear for urinary phenmetrazine concentration of 1 to 100 μg/mL with a detection limit of 0.5 μg/mL.

ACCESSION NUMBER: 1997:675131 CAPLUS
DOCUMENT NUMBER: 127:315616
TITLE: Determination of phenmetrazine in urine by gas chromatography-mass spectrometry after liquid-liquid extraction and derivatization with perfluorooctanoyl chloride
AUTHOR(S): Dasgupta, Amitava; Mahle, Christina E.
CORPORATE SOURCE: Clinical Chemistry and Toxicology Laboratories, Albuquerque, NM, USA
SOURCE: Journal of Forensic Sciences (1997), 42(5), 937-941
CODEN: JFSCAS; ISSN: 0022-1198
PUBLISHER: American Society for Testing and Materials
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **197714-82-2**
RL: PRP (Properties)
(phenmetrazine determination in urine by gas chromatog.-mass spectrometry after liquid-liquid extraction and derivatization with perfluorooctanoyl chloride)
RN 197714-82-2 CAPLUS
CN Morpholine, 3-methyl-4-(2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluoro-1-oxooctyl)-2-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 23 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 13 Sep 1997
GI



I



II

AB The title compds. (I; W = N-containing heterocyclyl; Y = single bond, lower alkylene, alkenylene, or alkynylene having CO optionally; Z = lower alkylene, alkenylene, or alkynylene having CO optionally; L = lower alkylene; R1, R2 = H, lower alkyl, etc.; R3, R4 = H, lower alkyl, alkenyl, alkynyl, aryl, etc.) are prepared I, possessing tumor necrosis factor inhibitory (NFkB) activity, are useful for prevention and treatment of inflammatory, virus, and autoimmunity diseases. Thus, 2-(4-chlorophenyl)-4-(3-piperazinopropyl)-2,3-dihydro-1,4-benzothiazin-3-one (preparation given) was reacted with 1,3-dimethyl-8-(3-bromopropyl)xanthin to give 73% the title compound (II). I were tested and showed inhibitory activity against luciferase.

ACCESSION NUMBER: 1997:587158 CAPLUS
DOCUMENT NUMBER: 127:190751
TITLE: Preparation of xanthin derivatives as necrosis factor inhibitors
INVENTOR(S): Sugiura, Masaki; Sugita, Naohisa; Sakurai, Hiroaki; Ozeki, Masakatsu; Kotado, Shinichi
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 17 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09227561	A2	19970902	JP 1996-33297	19960221

L7 ANSWER 23 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
PRIORITY APPLN. INFO.: JP 1996-33297 19960221
OTHER SOURCE(S): MARPAT 127:190751
IT **194426-43-2P 194426-45-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of xanthin derivs. as necrosis factor inhibitors)
RN 194426-43-2 CAPLUS
CN 1H-Purine-2,6-dione, 8-[3-[4-[3-[2-(4-chlorophenyl)-2,3-dihydro-3-oxo-4H-1,4-benzoxazin-4-yl]propyl]-1-piperazinyl]propyl]-3,7-dihydro-1,3-dimethyl-, (2E)-2-butenedioate (1:1), monohydrate (9CI) (CA INDEX NAME)

CM 1

CRN 194426-42-1
CMF C31 H36 Cl N7 O4



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 194426-45-4 CAPLUS
CN 1H-Purine-2,6-dione, 8-[3-[4-[3-[2-(4-chlorophenyl)-2,3-dihydro-3-oxo-4H-1,4-benzoxazin-4-yl]propyl]-1-piperazinyl]propyl]-3,7-dihydro-1-methyl-3-(2-methylpropyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 194426-44-3
CMF C34 H42 Cl N7 O4

L7 ANSWER 23 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



IT **194426-64-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of xanthin derivs. as necrosis factor inhibitors)
RN 194426-64-7 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 2-(4-chlorophenyl)-4-[3-(1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 24 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 17 Aug 1996
GI



I



II

AB This invention relates to a class of novel dicarboxy amide derivs. of lipophilic amines I wherein: A is O, S, NR, SO, SO2, or a bond; B is (CRR)1-2, O, S, NR, SO, SO2, RC:CR, C.tplbond.C, CO, or a bond; Y is, e.g., RNZ(CRR)dCRR, N-Z-piperidyl, where Z is COWCR7[(CR3R4)fCO2R][(CR5R6)gCO2R]; W is a bond, (CRR)h, or NR; R = H, alkyl; R1, R2 are independently H, alkyl, alkoxy, OH, halo, haloalkyl, Ph; R3-R6 are independently H, alkyl; R7 is H, NRR, or OH and when W is (CRR)h then R7 is OH; one of R3-R7 is OH; Ar1 and Ar2 are independently a mono- or diaryl or heteroaryl; p and q are independently 0-3; p + q is 0-4; d is 0-3; p + q + d is 1-3; f is 0-2; g is 0-2; h is 1-2; m and n are independently 0-2; which exhibit squalene synthase inhibition properties. Compds. of this invention reduce levels of serum cholesterol in the body without significantly reducing mevalonic metabolite synthesis. This invention relates also to pharmacol. compns. and method of treatment for lowering serum cholesterol levels using the compds. of this invention. Thus, e.g., coupling of prepared intermediates 3-hydroxy-3-(4-naphth-2-ylphenyl)piperidine with 3-hydroxy-3,4-bis(ethoxycarbonyl)butanoic acid afforded the diester intermediate which was hydrolyzed to the diaryl carbamoyl alkanedioic acid II which exhibited inhibition of squalene synthase with IC50 = 27 nM.
ACCESSION NUMBER: 1996:488751 CAPLUS
DOCUMENT NUMBER: 125:142750
TITLE: Polyarylcarbamoylaza- and -carbamoylalkanedioic acids as squalene synthase inhibitors
INVENTOR(S): Pauls, Henry W.; Choi, Yong-Mi; Studt, Robert W.; Maguire, Martin P.; Spada, Alfred P.; Cha, Don D.
PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Pharmaceuticals Inc., USA
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

L7 ANSWER 24 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

WO 9618615	A1	19960620	WO 1995-US15364	19951129
W: AL, AM, AT, AU, BB, BG, BR, BY, CA, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5556990	A	19960917	US 1994-357481	19941216
CA 2207429	AA	19960620	CA 1995-2207429	19951129
AU 9643698	A1	19960703	AU 1996-43698	19951129
AU 695852	B2	19980827		
EP 801644	A1	19971022	EP 1995-942489	19951129
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
JP 10511084	T2	19981027	JP 1995-518973	19951129

PRIORITY APPLN. INFO.: US 1994-357481 A 19941216
WO 1995-US15364 W 19951129

OTHER SOURCE(S): MARPAT 125:142750
IT **179821-70-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(polyarylcarbamoylaza- and -carbamoylalkanedioic acids as squalene synthase inhibitors)
RN 179821-70-6 CAPLUS
CN Butanedioic acid, 2-hydroxy-2-[2-[2-methyl-2-[4-(2-naphthalenyl)phenyl]-4-morpholinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 25 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 04 Nov 1995
GI For diagram(s), see printed CA Issue.
AB The photog. material comprises an ether compound I (Ar1, Ar2 = aryl, heterocyclic group; A = nonmetallic group forming 6-membered ring). The photog. material may further contain a hydroquinone derivative and/or tocopherol derivative It provides an image with improved light-stability and with good dye fading balance.
ACCESSION NUMBER: 1995:896729 CAPLUS
DOCUMENT NUMBER: 124:71465
TITLE: Silver halide color photographic material containing diaryloxane derivative to improve dye stability
INVENTOR(S): Morigaki, Masakazu; Negoro, Masayuki
PATENT ASSIGNEE(S): Fuji Photo Film Co Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 53 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07199430	A2	19950804	JP 1993-349813	19931228

PRIORITY APPLN. INFO.: JP 1993-349813 19931228
IT **171969-54-3**
RL: DEV (Device component use); MOA (Modifier or additive use); USES (Uses)
(Ag halide color photog. material containing diaryloxane derivative to improve dye stability)
RN 171969-54-3 CAPLUS
CN Morpholine, 2,6-bis(4-methylphenyl)-4-octyl- (9CI) (CA INDEX NAME)



L7 ANSWER 26 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 15 Sep 1995
GI



AB The title compds. [I; R1 - R5 = H, linear or branched C1-5 alkyl or alkoxy, halo, HO, CF3; R6 = H, linear or branched C1-5 alkyl; A = O, S; B = single bond, O, S; m = 1-5 integer; X = N, CH; Y = NH, O, S; Z = H, (CH2)nCO2R7; wherein R7 = H, linear or branched C1-5 alkyl; n = 1-5 integer], useful for the treatment and prevention of hyperlipidemia, hyperglycemia, obesity, hypertension, osteoporosis, thrombus, and complications of diabetes, are prepared Thus, 5-(4-hydroxybenzyl)-3-triphenylmethylthiazolidine-2,4-dione was condensed with 2-(3-chlorophenyl)-4-(2-hydroxy-1-methylethyl)morpholine by using PPh3 and di-Et azodicarboxylate in benzene at room temperature to give, after treatment with CF3CO2H, a title compound (II). II at 1 mg/kg body weight i.v. lowered by 39.6% the blood sugar of mice 120 min after s.c. injection of D-glucose (1.2 g/kg body weight).
ACCESSION NUMBER: 1995:792597 CAPLUS
DOCUMENT NUMBER: 123:198811
TITLE: Preparation of 2-phenylmorpholine and -thiomorpholine derivatives as hypolipidemias and hypoglycemias
INVENTOR(S): Yoshioka, Takao; Fujita, Takeshi; Aizawa, Juichi; Kanai, Tsutomu; Sano, Hiromi; Horikoshi, Hiroyoshi; Fujiwara, Toshihiko
PATENT ASSIGNEE(S): Sankyo Co, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 64 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07002848	A2	19950106	JP 1994-81217	19940420

L7 ANSWER 26 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
PRIORITY APPLN. INFO.: JP 1994-81217 A 19940420
JP 1993-98057 19930423
OTHER SOURCE(S): MARPAT 123:198811
IT **167848-19-3P 167848-20-6P 167848-21-7P**
167848-22-8P 167848-23-9P 167848-29-5P
167848-30-8P 167848-31-9P 167848-32-0P
167848-33-1P 167848-38-6P 167848-39-7P
167848-40-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate for preparation of phenylmorpholine and -thiomorpholine derivs. as inhibitors of aldose reductase and synthesis of thromboxane A2)
RN 167848-19-3 CAPLUS
CN 4-Morpholineacetic acid, 2-(3-chlorophenyl)-α-ethyl-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 167848-20-6 CAPLUS
CN 4-Morpholineethanol, 2-(3-chlorophenyl)-β-ethyl- (9CI) (CA INDEX NAME)



RN 167848-21-7 CAPLUS
CN 4-Morpholineethanol, β-ethyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 167848-22-8 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-[2-(3-chlorophenyl)-4-morpholinyl]butoxy]phenyl]methyl]-3-(triphenylmethyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 26 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 167848-23-9 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(2-phenyl-4-morpholinyl)butoxy]phenyl]methyl]-3-(triphenylmethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 167848-29-5 CAPLUS
CN 4-Morpholineacetic acid, 2-(3-chlorophenyl)-5-oxo-α-propyl-, ethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 26 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 167848-30-8 CAPLUS
CN 4-Morpholineethanol, 2-(3-chlorophenyl)-β-propyl- (9CI) (CA INDEX NAME)



RN 167848-31-9 CAPLUS
CN 4-Morpholineethanol, 2-phenyl-β-propyl- (9CI) (CA INDEX NAME)



RN 167848-32-0 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[[2-[2-(3-chlorophenyl)-4-morpholinyl]pentyl]oxy]phenyl]methyl]-3-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 167848-33-1 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[[2-(2-phenyl-4-morpholinyl)pentyl]oxy]phenyl]methyl]-3-(triphenylmethyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 26 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 167848-38-6 CAPLUS
CN 4-Morpholinepropanoic acid, 2-(3-chlorophenyl)-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 167848-39-7 CAPLUS
CN 4-Morpholinepropanol, 2-(3-chlorophenyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 26 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 167848-40-0 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[3-[2-(3-chlorophenyl)-4-morpholinyl]propoxy]phenyl]methyl]-3-(triphenylmethyl)- (9CI) (CA INDEX NAME)



IT **167847-89-4P 167847-90-7P 167847-93-0P**
167847-94-1P 167847-97-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylmorpholine and -thiomorpholine derivs. as inhibitors of aldose reductase and synthesis of thromboxane A2 for drugs)

RN 167847-89-4 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-[2-(3-chlorophenyl)-4-morpholinyl]butoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 167847-90-7 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(2-phenyl-4-morpholinyl)butoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 26 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 167847-93-0 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[[2-[2-(3-chlorophenyl)-4-morpholinyl]pentyl]oxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 167847-94-1 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[[2-(2-phenyl-4-morpholinyl)pentyl]oxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 26 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 167847-97-4 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[3-[2-(3-chlorophenyl)-4-morpholinyl]propoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 27 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 25 Jun 1994
GI



AB 2- And 2,3-disubstituted tetrahydrooxazine derivs. I.HCl (X = H, Cl, Br; R = H, Me; R1 = 4-ClC6H4, 4-BrC6H4) were prepared by Mannich reaction of tetrahydrooxazines with paraformaldehyde and R1COMe. I (X = H; R = Me; R1 = 4-ClC6H4) exerted an antireserpine effect stronger than that of imipramine. I failed to show an aphrodisiac effect.

ACCESSION NUMBER: 1994:323429 CAPLUS
DOCUMENT NUMBER: 120:323429
TITLE: Derivatives of 2- and 2,3-disubstituted tetrahydrooxazines
AUTHOR(S): Avramova, Petya; Yordanova, K.; Ilarionov, Y.
CORPORATE SOURCE: Dep. Pharm. Chem., Fac. Pharm., Sofia, 1000, Bulg.
SOURCE: Bulgarian Chemical Communications (1992), 25(3), 387-90
CODEN: BCHCE4; ISSN: 0324-1130
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **155138-20-8P 155138-21-9P 155138-22-0P 155138-23-1P 155138-24-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antireserpine and aphrodisiac effects of)
RN 155138-20-8 CAPLUS
CN 1-Propanone, 1-(4-chlorophenyl)-3-(3-methyl-2-phenyl-4-morpholinyl)-, hydrochloride (9CI) (CA INDEX NAME)



RN 155138-21-9 CAPLUS
CN 1-Propanone, 1-(4-chlorophenyl)-3-[2-(4-chlorophenyl)-4-morpholinyl]-, hydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 27 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 155138-22-0 CAPLUS
CN 1-Propanone, 1-(4-bromophenyl)-3-(3-methyl-2-phenyl-4-morpholinyl)-, hydrochloride (9CI) (CA INDEX NAME)



RN 155138-23-1 CAPLUS
CN 1-Propanone, 1-(4-bromophenyl)-3-[2-(4-chlorophenyl)-4-morpholinyl]-, hydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 27 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 155138-24-2 CAPLUS
CN 1-Propanone, 1-(4-bromophenyl)-3-[2-(4-bromophenyl)-4-morpholinyl]-, hydrochloride (9CI) (CA INDEX NAME)



L7 ANSWER 28 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 19 Mar 1994
AB A dynamic chiral stationary phase for the ligand exchange chiral liquid chromatog. was prepared by tentatively loading (1S,2R)-N,N-carboxymethyl dodecylnorephedrine monosodium salt prepared from (1S,2R)-norephedrine onto a com. reverse phase octadecyl-silica gel column and successfully used for the resolution of various amino acids without derivatization. The retention of the 2 enantiomers of amino acids on the column is significantly influenced by the organic modifier content, Cu(II) concentration and pH of the mobile phase. However, the enantioselectivity is significantly influenced mainly by the organic modifier content in the mobile phase. Based on the resolution trends of 2 enantiomers, a chiral recognition model concerning the enantioselective formation of ternary complex from the fixed ligand, amino acids and Cu(II) was proposed.
ACCESSION NUMBER: 1994:152651 CAPLUS
DOCUMENT NUMBER: 120:152651
TITLE: Optical resolution of racemic α-amino acids on a dynamic chiral stationary phase by ligand exchange chromatography
AUTHOR(S): Hyun, Myung Ho; Ryoo, Jae Jeong; Lim, Nam Eon
CORPORATE SOURCE: Dep. Chem., Pusan Natl. Univ., Pusan, 609-735, S. Korea
SOURCE: Journal of Liquid Chromatography (1993), 16(15), 3249-61
CODEN: JLCHD8; ISSN: 0148-3919
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **153083-84-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); ANST (Analytical study); PREP (Preparation); RACT (Reactant or reagent)
(preparation and ring cleavage of)
RN 153083-84-2 CAPLUS
CN 2-Morpholinone, 4-dodecyl-5-methyl-6-phenyl-, (5R-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 29 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 19 Mar 1994
GI



AB Title compds. I [R1, R2 = H, alkyl, cycloalkyl, (un)substituted Ph, (un)substituted phenylalkyl, etc.; A = alkylene; X = S, O; R3, R4 = H, alkyl, alkenyl, alkynyl, (un)substituted phenylalkyl, etc.] are prepared E.g., NaBH4 was added to a solution of 1-amino-2-naphthalenethiol in EtOH, the resulting mixture was stirred for 30 min, AcOH, NaOAc, and Me α-bromo-4-chlorophenylacetate were added, and the resulting mixture was stirred at room temperature overnight to give 3-(4-chlorophenyl)-1H-naphtho[2,1-b][1,4]thiazin-2-one, which was treated with 1-bromo-3-chloropropane in 96% KOH containing DMSO at room temperature overnight to
give 3-(4-chlorophenyl)-1-(3-chloropropyl)-1H-naphtho[2,1-b][1,4]thiazin-2(3H)-one, which was refluxed with Et2NH in acetone containing NaI and K2CO3 overnight to give I [R1 = 4-chlorophenyl, R2 = H, X = S, A = (CH2)3, R3 = R4 = Et]. In an in vitro study I [R1 = 4-chlorophenyl, R2 = H, X = S, A = (CH2)3, R3 = R4 = Et] oxalate (also prepared) allowed only 51.8% calcium to enter brain synaptosomes vs. 96% for the control.
ACCESSION NUMBER: 1994:134498 CAPLUS
DOCUMENT NUMBER: 120:134498
TITLE: Preparation of naphthothiazine analogs as calcium blockers
INVENTOR(S): Oozeki, Masakatsu; Kotado, Shinichi; Yasuda, Kosuke; Kudo, Koji; Maeda, Kayoko
PATENT ASSIGNEE(S): Tanabe Seiyaku Co, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 16 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05186441	A2	19930727	JP 1992-209841	19920806
PRIORITY APPLN. INFO.:			JP 1991-285410 A1	19910806

OTHER SOURCE(S): MARPAT 120:134498
IT **152799-99-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as calcium blocker)
RN 152799-99-0 CAPLUS
CN 1H-Naphth[2,1-b][1,4]oxazin-2(3H)-one, 3-(4-chlorophenyl)-1-[3-(dimethylamino)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 29 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

L7 ANSWER 30 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 05 Mar 1994
GI



I

AB Title compds. [I; R1 = (Ph-substituted) dialkylamino, (substituted) pyrrolidino, piperidino, hexamethylenimino, etc.; R2 = H, alkyl; R3 = (substituted) Ph, naphthyl, indanyl, quinolyl, 1,2,3,4-tetrahydroquinolyl, isoquinolyl, carbazotyl, dibenzofuryl, etc.], were prepared Thus, 4-nitrophenylalanine was converted in several steps to 4-amino-3-nitrophenylalanyl 4-methylpiperidineamide. This in CH2Cl2 containing ET3N was condensed with 4-amino-3,5-dichlorobenzenesulfonyl chloride and the product was hydrogenated in HCO2H over Pd/C to give 4-amino-N-[1-(1H-benzimidazol-5-ylmethyl)-2-(4-methylpiperidin-1-yl)-2-oxoethyl]-3,5-dichlorobenzenesulfonamide. I showed ED200 of 1.7 ~ 9.2 μM in a test of thrombin-induced blood coagulation.
ACCESSION NUMBER: 1994:107744 CAPLUS
DOCUMENT NUMBER: 120:107744
TITLE: Preparation of benzimidazolylalaninamides as antithrombotics
INVENTOR(S): Heckel, Armin; Sauter, Robert; Psiorz, Manfred; Binder, Klaus; Mueller, Thomas; Zimmermann, Rainer
PATENT ASSIGNEE(S): Dr. Karl Thomae GmbH, Germany
SOURCE: Eur. Pat. Appl., 37 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 555824	A1	19930818	EP 1993-102052	19930210
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
DE 4204270	A1	19931104	DE 1992-4204270	19920213
US 5391556	A	19950221	US 1993-14598	19930208
AU 9332968	A1	19930819	AU 1993-32968	19930211
AU 663556	B2	19951012		
CA 2089466	AA	19930814	CA 1993-2089466	19930212
NO 9300517	A	19930816	NO 1993-517	19930212
HU 63624	A2	19930928	HU 1993-385	19930212
JP 06016648	A2	19940125	JP 1993-24205	19930212
ZA 9300975	A	19940812	ZA 1993-975	19930212
IL 104703	A1	19970713	IL 1993-104703	19930212
PRIORITY APPLN. INFO.:			DE 1992-4204270 A	19920213

OTHER SOURCE(S): MARPAT 120:107744
IT **152134-83-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of, as antithrombotic)
RN 152134-83-3 CAPLUS
CN Morpholine, 4-[2-[[(4-amino-3,5-dichlorophenyl)sulfonyl]amino]-3-(1H-benzimidazol-5-yl)-1-oxopropyl]-2-phenyl- (9CI) (CA INDEX NAME)

L7 ANSWER 30 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L7 ANSWER 31 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 25 Dec 1993
GI



I

AB The title compds. I [R1, R2 = H, (un)substituted lower alkyl, cycloalkyl, (un)substituted Ph, etc; A = alkylene group; X = S, O; R3, R4= H, (un)substituted lower alkyl, alkenyl, etc] as Ca antagonists are prepared and salts thereof are effective for the prevention and treatment of cerebral ischemia, symptoms due to cerebral nerve damage, convulsion, and/or epilepsy. For example, 3-(4-chlorophenyl)-1-(diethylaminoacetyl)-2,3-dihydro-1H-naphtho[2,1-b][1,4]thiazine was prepared and its antiepileptic activity was tested with mice.

ACCESSION NUMBER: 1993:662529 CAPLUS
DOCUMENT NUMBER: 119:262529
TITLE: Naphthoxazines and naphthothiazines as calcium antagonists
INVENTOR(S): Oozeki, Masakatsu; Kotado, Shinichi; Yasuda, Kosuke; Kudo, Koji; Maeda, Kayoko
PATENT ASSIGNEE(S): Tanabe Seiyaku Co, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 21 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05194235	A2	19930803	JP 1992-226344	19920709
PRIORITY APPLN. INFO.:			JP 1991-276092	A1 19910725

OTHER SOURCE(S): MARPAT 119:262529
IT **151259-24-4P 151518-92-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as calcium antagonist)
RN 151259-24-4 CAPLUS
CN 1H-Naphth[2,1-b][1,4]oxazine, 3-(4-chlorophenyl)-1-[3-(dimethylamino)-1-oxopropyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

L7 ANSWER 31 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 151518-92-2 CAPLUS
CN 1H-Naphth[2,1-b][1,4]oxazine, 3-(4-chlorophenyl)-1-[3-(dimethylamino)-1-oxopropyl]-2,3-dihydro-, ethanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 151259-24-4
CMF C23 H23 Cl N2 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4

L7 ANSWER 32 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 24 Jan 1993
AB The influence of the hydroxazine derivative PS1 on blood serum levels of sex and gonadotropic hormones were studied in male rabbits. One hour after i.v. administration, serum levels of testosterone and prolactin were increased, but returned to normal during the second hour. PS1 did not influence estradiol, progesterone, FSH, and LH levels. The aphrodisiac activity of PS1 is discussed.

ACCESSION NUMBER: 1993:16129 CAPLUS
DOCUMENT NUMBER: 118:16129
TITLE: Effects of a hydroxazine derivative on serum levels of sex and gonadotropic hormones in male rabbits
AUTHOR(S): Ilarionov, I.; Milanov, S.; Danchev, N.
CORPORATE SOURCE: NIFF, MA, Sofia, Bulg.
SOURCE: Farmatsiya (Sofia, Bulgaria) (1991), 41(4), 46-8
CODEN: FMTYA2; ISSN: 0428-0296
DOCUMENT TYPE: Journal
LANGUAGE: Bulgarian
IT **117278-53-2**
RL: BIOL (Biological study)
(blood serum hormones responses to, as male aphrodisiac)
RN 117278-53-2 CAPLUS
CN 1-Propanone, 2-methyl-3-(2-methyl-2,3-diphenyl-4-morpholinyl)-1-phenyl- (9CI) (CA INDEX NAME)



L7 ANSWER 33 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 05 Sep 1992
GI

AB Some substituted 3-phenylmorpholines I (Ar = 2-, 3-MeOC6H4, 2-, 3-ClC6H4, 3-O2NC6H4, 2-, 3-HOC6H4) and 3-thienylmorpholines I (Ar = 2-, 3-thienyl), isosteres of 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP), were prepared and submitted to binding assays on D-2 dopaminergic and 5-HT1 and 5-HT2 serotonergic receptors, in comparison with 3-PPP and its analog 1-propyl-3-(2-hydroxy/methoxyphenyl)piperidine. Thus, ArCOMe (Ar = 3-O2NC6H4, 2-, 3-thienyl) were brominated to BrCH2COAr which cyclized with HO(CH2)2NH(CH2)2Me to give I. The results show the loss of D-2 affinity for all morpholines, while a certain activity was still observable for piperidine derivs. Regarding the serotonergic affinity, only I (Ar = 2-, 3-MeOC6H4, 2-, 3-ClC6H4) were moderately active on the 5-HT1A receptor, either when the substituent was in the C-2 or C-3 position, whereas no tested compds. showed affinity toward the 5-HT2 receptor.

ACCESSION NUMBER: 1992:490221 CAPLUS
DOCUMENT NUMBER: 117:90221
TITLE: Oxygen isosteric derivatives of 3-(3-hydroxyphenyl)-N-n-propylpiperidine
AUTHOR(S): Perrone, Roberto; Berardi, Francesco; Leopoldo, Marcello; Tortorella, Vincenzo; Lograno, Marcello D.; Daniele, Eugenia; Govoni, Stefano
CORPORATE SOURCE: Dip. Farmaco-chim., Univ. Bari, Bari, 70126, Italy
SOURCE: Journal of Medicinal Chemistry (1992), 35(16), 3045-9
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English

IT **142363-78-8P 142363-79-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrogenation of)

RN 142363-78-8 CAPLUS
CN Morpholine, 2-[2-(phenylmethoxy)phenyl]-4-propyl- (9CI) (CA INDEX NAME)



RN 142363-79-9 CAPLUS
CN Morpholine, 2-[3-(phenylmethoxy)phenyl]-4-propyl- (9CI) (CA INDEX NAME)

L7 ANSWER 33 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 142363-70-0 CAPLUS
CN 3-Morpholinone, 6-(3-chlorophenyl)-4-propyl- (9CI) (CA INDEX NAME)



IT **142363-71-1P 142363-72-2P 142363-73-3P**
142363-74-4P 142363-82-4P 142363-83-5P
142363-84-6P 142363-85-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and serotoninergic receptor affinity of)

RN 142363-71-1 CAPLUS
CN Morpholine, 2-(2-methoxyphenyl)-4-propyl- (9CI) (CA INDEX NAME)



RN 142363-72-2 CAPLUS
CN Morpholine, 2-(3-methoxyphenyl)-4-propyl- (9CI) (CA INDEX NAME)



RN 142363-73-3 CAPLUS
CN Morpholine, 2-(2-chlorophenyl)-4-propyl- (9CI) (CA INDEX NAME)



RN 142363-74-4 CAPLUS
CN Morpholine, 2-(3-chlorophenyl)-4-propyl- (9CI) (CA INDEX NAME)

L7 ANSWER 33 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT **142363-67-5P 142363-68-6P 142363-69-7P**
142363-70-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)

RN 142363-67-5 CAPLUS
CN 3-Morpholinone, 6-(2-methoxyphenyl)-4-propyl- (9CI) (CA INDEX NAME)



RN 142363-68-6 CAPLUS
CN 3-Morpholinone, 6-(3-methoxyphenyl)-4-propyl- (9CI) (CA INDEX NAME)



RN 142363-69-7 CAPLUS
CN 3-Morpholinone, 6-(2-chlorophenyl)-4-propyl- (9CI) (CA INDEX NAME)



L7 ANSWER 33 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 142363-82-4 CAPLUS
CN Morpholine, 2-(2-methoxyphenyl)-4-propyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 142363-83-5 CAPLUS
CN Morpholine, 2-(3-methoxyphenyl)-4-propyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 142363-84-6 CAPLUS
CN Morpholine, 2-(2-chlorophenyl)-4-propyl-, hydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 33 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 142363-85-7 CAPLUS
CN Morpholine, 2-(3-chlorophenyl)-4-propyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

IT **142363-75-5P 142363-80-2P 142363-81-3P**
142363-86-8P 142363-89-1P 142363-90-4P
142363-91-5P 142363-92-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 142363-75-5 CAPLUS
CN Morpholine, 2-(3-nitrophenyl)-4-propyl- (9CI) (CA INDEX NAME)



RN 142363-80-2 CAPLUS
CN Phenol, 2-(4-propyl-2-morpholinyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 33 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 142363-81-3 CAPLUS
CN Phenol, 3-(4-propyl-2-morpholinyl)- (9CI) (CA INDEX NAME)



RN 142363-86-8 CAPLUS
CN Morpholine, 2-(3-nitrophenyl)-4-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 142363-89-1 CAPLUS
CN Morpholine, 2-[2-(phenylmethoxy)phenyl]-4-propyl-, hydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 33 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 142363-90-4 CAPLUS
CN Morpholine, 2-[3-(phenylmethoxy)phenyl]-4-propyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 142363-91-5 CAPLUS
CN Phenol, 2-(4-propyl-2-morpholinyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 142363-92-6 CAPLUS
CN Phenol, 3-(4-propyl-2-morpholinyl)-, hydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 33 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

L7 ANSWER 34 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 31 May 1992
GI



I II III

AB Morpholine derivs. I [R = alkyl, cycloalkyl, (substituted) aralkyl, heterocyclylalkyl, etc.; R1 = (substituted) pyridyl, tetrazolopyridyl, etc.] are prepared Cyclization of 5.6 g amino alc. II with ClCH2COCl in CH2Cl2 gave 2.16 g oxomorpholine derivative III (X = O), which (2.09 g) was reduced with BH3-Me2S in THF under N to give 1.99 g morpholine derivative III (X = 2 H) (IV). Reduction of 1.66 g IV with SnCl2.2H2O-HCl in MeOH gave 1.39 g I (R = Me3C, R1 = 6-amino-3-pyridyl), which was converted to its citrate salt. The daily doses of I were 0.01-1.0 mg/kg as animal growth promoters, 2-150 mg as bronchodilators, 200-1000 mg as antidepressants and antiobesity agents.

ACCESSION NUMBER: 1992:214513 CAPLUS
DOCUMENT NUMBER: 116:214513
TITLE: Preparation of morpholine derivatives as animal growth promoters, bronchodilators, antidepressants, and antiobesity agents
INVENTOR(S): Fisher, Michael H.; Wyvratt, Matthew J.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: U.S., 10 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5077290	A	19911231	US 1990-597976	19901011
US 5124328	A	19920623	US 1991-767285	19910926
PRIORITY APPLN. INFO.:			US 1990-597976	A3 19901011

OTHER SOURCE(S): MARPAT 116:214513
IT **140690-68-2P 140690-69-3P 140690-70-6P 140690-71-7P 140690-72-8P 140690-73-9P 141137-41-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)

L7 ANSWER 34 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(prepn. of, as drug and animal growth promoter)
RN 140690-68-2 CAPLUS
CN 2-Pyridinamine, 5-[4-(1-methyl-3-phenylpropyl)-2-morpholinyl]- (9CI) (CA INDEX NAME)



RN 140690-69-3 CAPLUS
CN 2-Pyridinamine, 5-[4-(1,1-dimethyl-3-phenylpropyl)-2-morpholinyl]- (9CI) (CA INDEX NAME)



RN 140690-70-6 CAPLUS
CN 2-Pyridinamine, 5-[4-[3-(3-methoxyphenyl)-1,1-dimethylpropyl]-2-morpholinyl]- (9CI) (CA INDEX NAME)



RN 140690-71-7 CAPLUS
CN Phenol, 4-[3-[2-(6-amino-3-pyridinyl)-4-morpholinyl]-3-methylbutyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 34 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 140690-72-8 CAPLUS
CN Phenol, 3-[3-[2-(6-amino-3-pyridinyl)-4-morpholinyl]-3-methylbutyl]- (9CI) (CA INDEX NAME)



RN 140690-73-9 CAPLUS
CN Phenol, 4-[3-[2-(6-amino-3-pyridinyl)-4-morpholinyl]butyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 34 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 141137-41-9 CAPLUS
CN 2-Pyridinamine, 5-[4-(1,1-dimethylpropyl)-2-morpholinyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 35 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 28 Jun 1991
GI



II III

AB AYNR1R2 [I; A = (substituted) N-heterocycle; Y = (substituted) C2-4 alkylene; R1, R2 = C2-6 alkyl; NR1R2 = (substituted) 5-7-membered heterocycle containing optional O atom] were prepared A solution of 2.05 g phthalimide derivative II in Et2O was added dropwise to a suspension of LiAlH4 in THF with cooling under N, and the mixture was refluxed 4 h to give 1.58 g isoindoline derivative III which showed 80% inhibition of glutamic acid at 2 + 10-4 M. Also prepared were 17 addnl. I and many salts.

ACCESSION NUMBER: 1991:247137 CAPLUS
DOCUMENT NUMBER: 114:247137
TITLE: Preparation of nitrogen heterocyclic alkylamines as glutamate antagonists
INVENTOR(S): Mazaki, Mitsuo; Morifuji, Naoya; Hashimoto, Koichi; Shinozaki, Atsuhiko
PATENT ASSIGNEE(S): Nippon Chemiphar Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 16 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03014562	A2	19910123	JP 1988-88611	19880411
PRIORITY APPLN. INFO.:			JP 1988-88611	19880411

OTHER SOURCE(S): MARPAT 114:247137
IT **134144-94-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as glutamate antagonist)
RN 134144-94-8 CAPLUS
CN Morpholine, 3-(3-methylbutyl)-2-phenyl-4-[3-(1-piperidinyl)propyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L7 ANSWER 35 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L7 ANSWER 36 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 19 Apr 1991
AB A series 37 previously synthesized arylpropanolamine carbonates and carbamates was tested for anti-reserpine effects (inhibition of reserpine-induced hypothermia and ptosis) and aphrodisiac effects in mice and rats given the agents i.p. at 0.1 LD50 doses. Relationship between antidepressant, anxiolytic, and aphrodisiac activities were revealed and may serve for indirect estns. of either activity.

ACCESSION NUMBER: 1991:135923 CAPLUS
DOCUMENT NUMBER: 114:135923
TITLE: Relationship between antireserpine and aphrodisiac effects. Pharmacologic aspects
AUTHOR(S): Ilarionov, I.; Avramova, P.
CORPORATE SOURCE: MA, Sofia, Bulg.
SOURCE: Farmatsiya (Sofia, Bulgaria) (1990), 40(3), 32-8
CODEN: FMTYA2; ISSN: 0428-0296
DOCUMENT TYPE: Journal
LANGUAGE: Bulgarian
IT **66064-00-4 66064-01-5**
RL: PRP (Properties)
(aphrodisiac and anti-reserpine effects of)
RN 66064-00-4 CAPLUS
CN Carbonic acid, 2-methyl-3-(3-methyl-2-phenyl-4-morpholinyl)-1-phenylpropyl phenyl ester (9CI) (CA INDEX NAME)



RN 66064-01-5 CAPLUS
CN 4-Morpholinepropanol, β,3-dimethyl-α,2-diphenyl-, carbamate (ester) (9CI) (CA INDEX NAME)



L7 ANSWER 37 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 06 Apr 1991
AB The neuropharmacol. effects of PS-1 (2,3-dimethyl-3-phenyl-trans-hydroxazinopropiophenone-HCl) were studied in mice and rats. PS-1 had stimulating properties of the amphetamine type. Unlike amphetamine, PS-1 did not induce drug dependence and withdrawal syndrome after a prolonged treatment.

ACCESSION NUMBER: 1991:114959 CAPLUS
DOCUMENT NUMBER: 114:114959
TITLE: Neuropharmacological study on a hydroxasinic derivative
AUTHOR(S): Ilarionov, I.; Bantutova, I.; Yakimova, K.
CORPORATE SOURCE: MA, Sofia, Bulg.
SOURCE: Eksperimentalna Meditsina i Morfologiya (1990), 29(2), 28-33
CODEN: EKMMA8; ISSN: 0367-0643
DOCUMENT TYPE: Journal
LANGUAGE: Bulgarian
IT **132412-71-6**
RL: BIOL (Biological study)
(neuropharmacol. of)
RN 132412-71-6 CAPLUS
CN 1-Propanone, 2-methyl-3-(3-methyl-2-phenyl-4-morpholinyl)-1-phenyl- (9CI) (CA INDEX NAME)



L7 ANSWER 38 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 06 Jul 1990
GI



AB Cyclocondensation reaction of 3,4-(MeO)2C6H3COCH2Br with HOCH2CH2NHR (R = Me, Et, Bu, CHMe2, cyclohexyl) in 99.7% HCO2H in 1:2:2 ratio at 180° for 15 h gave 25-62% title compds., I (same R), in yields which increased in the stated order of R.

ACCESSION NUMBER: 1990:406254 CAPLUS
DOCUMENT NUMBER: 113:6254
TITLE: Synthesis of 4-alkyl-2-(3,4-dimethoxyphenyl)morpholines
AUTHOR(S): Iordanova, K.; Danchev, D.
CORPORATE SOURCE: BMA, Sofia, Bulg.
SOURCE: Farmatsiya (Sofia, Bulgaria) (1989), 39(4), 1-3
CODEN: FMTYA2; ISSN: 0428-0296
DOCUMENT TYPE: Journal
LANGUAGE: Bulgarian
OTHER SOURCE(S): CASREACT 113:6254
IT **127578-75-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, by cyclocondensation reaction of dimethoxyphenacyl bromide with ethanolamine derivative)
RN 127578-75-0 CAPLUS
CN Morpholine, 4-butyl-2-(3,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 39 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 26 May 1990
GI



AB The title compds. I [R1 = H, alkyl; R2 = Me, Bu; R2R3 = (CH2)4; R3, R4 = H; R3R4 = (CH2)4] were prepared by reaction of R4CH(OH)CHR3NHR2 with BrCH2COPh, followed by O-alkylation of the obtained hydroxymorpholines with excess alcs. I [R1 = Bu, R2 = Me, R3 = R4 = H) and I [R1 = Pr, R2R3 = (CH2)4, R4 = H] showed significant antinociceptive activity. I could be classified into 2 subgroups, according to their lipophilicity. Within the subgroups, RM values from reversed phase thin-layer chromatog. were a reliable index of the lipophilic characteristics.

ACCESSION NUMBER: 1990:198268 CAPLUS
DOCUMENT NUMBER: 112:198268
TITLE: Lipophilicity of some substituted morpholine derivatives synthesized as potential antinociceptive agents
AUTHOR(S): Rekka, Eleni; Retsas, Stavros; Demopoulos, Vassilis J.; Kourounakis, Panos N.
CORPORATE SOURCE: Sch. Pharm., Univ. Thessaloniki, Thessaloniki, 540 06, Greece
SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1990), 323(1), 53-6
CODEN: ARPMAS; ISSN: 0365-6233
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 112:198268
IT **126806-69-7P 126806-70-0P 126806-71-1P**
126806-72-2P 126806-92-6P 126806-93-7P
126806-94-8P 126806-95-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antinociceptive activity of)
RN 126806-69-7 CAPLUS
CN 2-Morpholinol, 4-butyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 126806-70-0 CAPLUS
CN Morpholine, 4-butyl-2-ethoxy-2-phenyl- (9CI) (CA INDEX NAME)

L7 ANSWER 39 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 126806-71-1 CAPLUS
CN Morpholine, 4-butyl-2-phenyl-2-propoxy- (9CI) (CA INDEX NAME)



RN 126806-72-2 CAPLUS
CN Morpholine, 2-butoxy-4-butyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 126806-92-6 CAPLUS
CN 2-Morpholinol, 4-butyl-2-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126806-93-7 CAPLUS
CN Morpholine, 4-butyl-2-ethoxy-2-phenyl-, hydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 39 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 126806-94-8 CAPLUS
CN Morpholine, 4-butyl-2-phenyl-2-propoxy-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126806-95-9 CAPLUS
CN Morpholine, 2-butoxy-4-butyl-2-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

L7 ANSWER 40 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 20 Aug 1989
GI



AB The psychotropic effects of the title derivative (I; 18 and 30 mg/kg), a possible antidepressant, were studied in rats with learned helplessness (passivity) in avoidance tests with conditioned (sound, light) and unconditioned (electroshock) stimuli. The effects of I were compared with those of imipramine. The percentage of escape reactions occurring during 30 daily tests was increased by both agents. The latency period between stimuli and escape reactions also decreased after single oral doses or repeated treatment for 15 days. The effect was more pronounced with the conditioned stimuli. I also had an aphrodisiac effect in mice in reversing learned conditioned reflex impotence.

ACCESSION NUMBER: 1989:450296 CAPLUS
DOCUMENT NUMBER: 111:50296
TITLE: Influence of a tetrahydroxazine derivative on conditioned and unconditioned reflex activity in experimental animals
AUTHOR(S): Ilarionov, I.; Danchev, N.
CORPORATE SOURCE: BMA, Sofia, Bulg.
SOURCE: Eksperimentalna Meditsina i Morfologiya (1989), 28(1), 5-9
CODEN: EKMMA8; ISSN: 0367-0643
DOCUMENT TYPE: Journal
LANGUAGE: Bulgarian

IT **117278-53-2**
RL: PRP (Properties)
(psychotropic effects of, in conditioned and unconditioned reflex behavior)
RN 117278-53-2 CAPLUS
CN 1-Propanone, 2-methyl-3-(2-methyl-2,3-diphenyl-4-morpholinyl)-1-phenyl- (9CI) (CA INDEX NAME)



L7 ANSWER 41 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 21 Jan 1989
GI



AB The title compds. [I; A = CO, CH(OR) where in R = H, acyl, aroyl; R1 = alkyl, alkenyl, alkynyl, etc.; R2 = H, alkyl, aryl, aralkyl; R3 = H, alkyl; R4 = alkyl; X = H, halo, alkyl], useful as herbicides, are prepared Refluxing a mixture of 2.27 g amine derivative II with 1.7 g 2,3-dimethylmaleic anhydride in HOAc gave 1.7 g maleimide derivative I (R1 = Et, R2 = R3 = H, R4 = Me, A = CO), which showed >95% control of barnyard grass, etc., at 0.5 kg/ha with <10% damage to rice plants, vs. 50-90% damage with a reference compound

ACCESSION NUMBER: 1989:23902 CAPLUS
DOCUMENT NUMBER: 110:23902
TITLE: Preparation of (dialkylmaleimido) benzoxazine derivatives as herbicides
INVENTOR(S): Kume, Toyohiko; Goshima, Toshio; Kaji, Shuzo; Yamaguchi, Naoko; Yanagi, Akihiko; Hayakawa, Hidenori; Yagi, Shigeki
PATENT ASSIGNEE(S): Nihon Tokushu Noyaku Seizo K. K., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 19 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 63014782	A2	19880121	JP 1986-157890	19860707
US 4729784	A	19880308	US 1987-65443	19870623
EP 255601	A2	19880210	EP 1987-109174	19870626
EP 255601	A3	19890308		
EP 255601	B1	19910911		
R: BE, CH, DE, FR, GB, IT, LI, NL				
BR 8703423	A	19880322	BR 1987-3423	19870706
PRIORITY APPLN. INFO.:			JP 1986-157890 A	19860707

OTHER SOURCE(S): CASREACT 110:23902; MARPAT 110:23902

IT **118124-37-1P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as herbicide)
RN 118124-37-1 CAPLUS
CN 1H-Pyrrole-2,5-dione, 1-(3,4-dihydro-3-oxo-2-phenyl-4-propyl-2H-1,4-benzoxazin-6-yl)-3,4-dimethyl- (9CI) (CA INDEX NAME)

L7 ANSWER 41 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L7 ANSWER 42 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 24 Dec 1988
GI



AB The title compds. [I; R = H, Rl = halo; R = R1 = H, OH, C1-3 alkoxy, PhCH2O; RR1 = OCH2O; R2 = 1,3-dioxolanyl, R3; R3 = H, (un)substituted Ph; R4 = H1 C1-6 alkyl, C3-6 alkenyl, PhCH2 HO(CH2)3, 4-MeOC6H4, substituted alkyl moieties Q-Q2; R5 = C1-3 alkyl; n = 2,3; when R1 = halo, R4 H] and their oxalate and dioxalate salts were prepared as cytoprotective agents, useful in reducing gastric acid secretion and in the prevention and treatment of ulcers. 3-F3CC6H4NH2 and Me2CHCH2CH2ONO (II) were stirred 24 h at room temperature in furan to give 2-[3-(trifluoromethyl)phenyl]furan which was refluxed with II in THF while 2-H2NC6H4CO2H was added dropwise to give 1,4-epoxynaphthalene III. The latter was cleaved with O3, reduced to a diol with LiAlH4, esterified with MeSO2Cl, and cyclocondensed with PhhcH2NH2 to give I (R-R2 = H, R3 = 3-F3CC6H4, R4 = PhCH2). This was debenzylated by hydrogenation over Pd/C to give I (R-R2 = R4 = H, R3 = 3-F3CC6H4), converted to its monooxalate salt (IV). In rats 25 mg IV/kg orally reduced EtOH-induced stomach mucosal and submucosal lesions 56%. At the same dose IV reduced gastric secretion in rats 71%.

ACCESSION NUMBER: 1988:631042 CAPLUS
DOCUMENT NUMBER: 109:231042
TITLE: Preparation of 1,5-epoxy-2,3,4,5-tetrahydro-1H-3-benzazepines and their use in treatment of ulcers
INVENTOR(S): Wachter, Michael P.; Karanewsky, Donald S.
PATENT ASSIGNEE(S): Ortho Pharmaceutical Corp., USA
SOURCE: U.S., 22 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

L7 ANSWER 42 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

US 4761413	A	19880802	US 1986-945273		19861222
US 4855426	A	19890808	US 1988-181619		19880414
US 4910198	A	19900320	US 1989-358036		19890526
PRIORITY APPLN. INFO.:			US 1986-945273	A3	19861222
			US 1988-181619	A3	19880414

OTHER SOURCE(S): CASREACT 109:231042; MARPAT 109:231042

IT **117572-83-5P 117572-84-6P 117572-85-7P**
117572-86-8P 117572-94-8P 117572-95-9P
117572-98-2P 117572-99-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn of, as ulcer inhibitor)

RN 117572-83-5 CAPLUS
CN 1,5-Epoxy-1H-3-benzazepine, 2,3,4,5-tetrahydro-3-[3-(4-morpholinyl)propyl]-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 117572-84-6 CAPLUS
CN 1,5-Epoxy-1H-3-benzazepine, 2,3,4,5-tetrahydro-3-[3-(4-morpholinyl)propyl]-1-[3-(trifluoromethyl)phenyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 117572-83-5
CMF C24 H27 F3 N2 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4

L7 ANSWER 42 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 1,5-Epoxy-1H-3-benzazepine, 2,3,4,5-tetrahydro-3-[3-(1-piperidinylmethyl)phenoxy]propyl]- (9CI) (CA INDEX NAME)



RN 117572-95-9 CAPLUS
CN 1,5-Epoxy-1H-3-benzazepine, 2,3,4,5-tetrahydro-1-phenyl-3-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 117572-94-8
CMF C31 H36 N2 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 117572-98-2 CAPLUS
CN 1,5-Epoxy-1H-3-benzazepine, 2,3,4,5-tetrahydro-3-[3-(4-morpholinyl)propyl]-1,5-diphenyl- (9CI) (CA INDEX NAME)



RN 117572-99-3 CAPLUS
CN 1,5-Epoxy-1H-3-benzazepine, 2,3,4,5-tetrahydro-3-[3-(4-morpholinyl)propyl]-1,5-diphenyl-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

L7 ANSWER 42 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 117572-85-7 CAPLUS
CN 1,5-Epoxy-1H-3-benzazepine, 2,3,4,5-tetrahydro-3-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 117572-86-8 CAPLUS
CN 1,5-Epoxy-1H-3-benzazepine, 2,3,4,5-tetrahydro-3-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-1-[3-(trifluoromethyl)phenyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 117572-85-7
CMF C32 H35 F3 N2 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 117572-94-8 CAPLUS

L7 ANSWER 42 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CM 1

CRN 117572-98-2
CMF C29 H32 N2 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4

L7 ANSWER 43 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 25 Nov 1988
AB The compound 2-methyl-2,3-phenyl-3-methyltetrahydroxazine propiophenone hydrochloride was evaluated by by the following pharmacol. effects: antireserpine and antihaloperidol effects in the jumping test, anorexic effects, and local anesthetic action. ED50's and LD50's as well as therapeutic indexes of this compound were determined in comparison with d-amphetamine, imipramine, and phendimetrazine. The local anesthetic effect of the compound was comparable to that of cocaine. The newly investigated compound was most similar to the preparation of d-amphetamine.
ACCESSION NUMBER: 1988:583400 CAPLUS
DOCUMENT NUMBER: 109:183400
TITLE: Pharmacological studies on a tetrahydroxazinic derivative
AUTHOR(S): Ilarionov, I.
CORPORATE SOURCE: MA, Sofia, Bulg.
SOURCE: Eksperimentalna Meditsina i Morfologiya (1988), 27(3), 17-22
CODEN: EKMMA8; ISSN: 0367-0643
DOCUMENT TYPE: Journal
LANGUAGE: Bulgarian
IT **117278-53-2**
RL: PRP (Properties)
(neuropharmacol. and stimulant effect of)
RN 117278-53-2 CAPLUS
CN 1-Propanone, 2-methyl-3-(2-methyl-2,3-diphenyl-4-morpholinyl)-1-phenyl- (9CI) (CA INDEX NAME)



L7 ANSWER 44 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 16 Nov 1985
GI



AB Indazole derivs. (I; R = H, Cl, Me, MeO, H2N; R1-4 = H, alkyl, halo, Ph; X = O, S; Z = alkylene) and their physiol. compatible salts were prepared I were effective antiinflammatants and antiulcers at 100 mg/kg oral in rats. Thus, stirring a mixture of 9.43 g II and 11 g III in MeOH at 80° gave 71% I (R-R3 = H, R4 = 3-Me, X = O, Z = CH2CH2CO), which (1.05 g) was reduced with 0.44 g LiAlH4 in dioxane at 80° to give 81% I (R-R3 = H, R4 = 3-Me, X = O, Z = CH2CH2CH2).
ACCESSION NUMBER: 1985:560501 CAPLUS
DOCUMENT NUMBER: 103:160501
TITLE: Aminoindazole derivatives
PATENT ASSIGNEE(S): Asahi Chemical Industry Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 60061569	A2	19850409	JP 1983-169214	19830916

PRIORITY APPLN. INFO.: JP 1983-169214 19830916
IT **97842-95-0P 97843-14-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, antiinflammatory and antiulcer activity of)
RN 97842-95-0 CAPLUS
CN 1H-Indazol-3-amine, N-[3-(2-phenyl-4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 44 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 97843-14-6 CAPLUS
CN 1H-Indazol-3-amine, N-[3-(2-phenyl-4-morpholinyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L7 ANSWER 45 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 04 Oct 1985
GI



AB Indazole derivs. (I; R = H, Cl, Me, MeO, H2N; R1, R2, R3, R4 = H, alkyl, halo, Ph; X = O, S,; Z = alkylene) and their physiol. compatible salts were prepared I were effective antiinflammatants and antiulcers at 100 mg/kg oral in rats. Thus, stirring a mixture of 10.8 g II (R5 = R6 = R7 = H) and 14.45 g phthalic anhydride in dioxane at 120° gave 87% II (R5 = H, R6R7N = phthalimido), which was treated with 11 g III in dioxane at 80° to give 59% IV. Hydrolysis of 3.59 g IV with 2.5 g N2H4.H2O in EtOH gave 71% I (R-R3=H, R4 = 3-Me, X = O, Z = CH2CH2CO), which (1.05 g) was reduced with LiAlH4 in dioxane to give 70% I (R-R3 = H, R4 = 1-Me, X = O, Z = CH2CH2CH2).
ACCESSION NUMBER: 1985:504962 CAPLUS
DOCUMENT NUMBER: 103:104962
TITLE: 1-Substituted indazole derivatives
PATENT ASSIGNEE(S): Asahi Chemical Industry Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 60061568	A2	19850409	JP 1983-169213	19830916

PRIORITY APPLN. INFO.: JP 1983-169213 19830916
IT **97843-32-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, antiinflammatant and antiulcer activity of)
RN 97843-32-8 CAPLUS
CN 1H-Indazol-3-amine, 1-[3-(2-phenyl-4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 45 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT **97843-49-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, antiinflammatory, and antiulcer activity of)
RN 97843-49-7 CAPLUS
CN 1H-Indazol-3-amine, 1-[3-(2-phenyl-4-morpholinyl)propyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

L7 ANSWER 46 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L7 ANSWER 46 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 29 Sep 1984
GI



AB Thirty-seven title compds. I (R = H, Me; R1 = H, Me, Et, Me2CH, Ph; R2 = H, HO; R3 = H, Me, Et, R32 = piperidino, morpholino; n = 0, 1), effective analgesics at 20-200 mg/kg, were prepared Thus, 0.42 mol NaH in oil was added to 0.4 mol pyridine derivative II in DMF at 7-13°, 0.4 mol MeCHBrCO2Et was added, and the mixture stirred at 23-30° to give 84.4% III, which (0.1 mol) was treated with 0.1 mol NaH in oil in xylene at 83°, 0.238 mol Et2NCH2CH2Br was added, and the mixture refluxed to give 74.8% I (R = R2 = H, R1 = Me, R3 = Et, n = 0).
ACCESSION NUMBER: 1984:510931 CAPLUS
DOCUMENT NUMBER: 101:110931
TITLE: 2 H-Pyrido[3,2-b]-1,4-oxazine derivatives as analgesic compositions
PATENT ASSIGNEE(S): Nippon Redarii K. K., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 20 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 59048489	A2	19840319	JP 1982-159886	19820914

PRIORITY APPLN. INFO.: JP 1982-159886 19820914
IT **86267-28-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 86267-28-9 CAPLUS
CN 2H-Pyrido[3,2-b]-1,4-oxazin-3(4H)-one, 4-[3-(diethylamino)-2-hydroxypropyl]-2-phenyl- (9CI) (CA INDEX NAME)

L7 ANSWER 47 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 18 Aug 1984
GI



AB Bromination of PhCH:CH2 in the presence of ethylene oxide by Br2-CCl4 gave a mixture containing 85% BrCH2CH2OCHPhCH2Br (I) and 15% BrCH2CH2OCH2CHPhBr which were aminated by Bu2NH to give II (R = Bu). Analogous amination by Et2NH, piperidine, or morpholine gave 60-72% II [R = Et, R2 = (CH2)5, CH2CH2OCH2CH2]. Similarly, chlorination of PhCH:CH2 and ethylene oxide gave only ClCH2CH2OCHPhCH2Cl which was aminated by R2NH (R = Bu, Et, R2 = (CH2)5, CH2CH2OCH2CH2] to give 59-76% R2NCH2CH2OCHPhCH2Cl.
ACCESSION NUMBER: 1984:455012 CAPLUS
DOCUMENT NUMBER: 101:55012
TITLE: Cohalogenation of styrene with oxirane with subsequent reaction of the synthesized ethers with secondary amines
AUTHOR(S): Egeonu, Ch. Kh.; Gurbanov, P. A.; Movsumzade, M. M.; Agaeva, A. E.
CORPORATE SOURCE: Azerb. Inst. Nefti Khim., Baku, USSR
SOURCE: Doklady - Akademiya Nauk Azerbaidzhanskoi SSR (1983), 39(9), 56-60
CODEN: DAZRA7; ISSN: 0002-3078
DOCUMENT TYPE: Journal
LANGUAGE: Russian
OTHER SOURCE(S): CASREACT 101:55012
IT **91045-43-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 91045-43-1 CAPLUS
CN Morpholinium, 4,4-dibutyl-2-phenyl-, bromide (9CI) (CA INDEX NAME)



● Br⁻

L7 ANSWER 48 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 08 Jun 1984
GI



AB Acylation of pyridooxazines I (R = H, Me, Et, Ph; R1 = H, Me) with R2COCl (R2 = Me, Et, Ph, PhCH2) gave 36-76% the title compds. II. II showed little local anesthetic activity, however the analgesic activity of II was approx. equal to that of aspirin.

ACCESSION NUMBER: 1984:191807 CAPLUS
DOCUMENT NUMBER: 100:191807
TITLE: Studies on pyridinol derivatives. X. Synthesis and pharmacological activity of 4-acyl-3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazine derivatives
AUTHOR(S): Takeda, Hideo; Hisamichi, Kanehiko
CORPORATE SOURCE: Tohoku Coll. Pharm., Sendai, 983, Japan
SOURCE: Yakugaku Zasshi (1983), 103(12), 1247-56
CODEN: YKKZAJ; ISSN: 0031-6903
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
IT **89970-32-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, local anesthetic, and analgesic activity of)
RN 89970-32-1 CAPLUS
CN 2H-Pyrido[3,2-b]-1,4-oxazine, 3,4-dihydro-4-(1-oxopropyl)-2-phenyl- (9CI) (CA INDEX NAME)



L7 ANSWER 49 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 12 May 1984
GI



AB N-Substituted 4-(2-morpholinyl)indoles I (R = Me, Et, Pr) were prepared from 4-acetylindole (II) which was itself prepared from 4-cyanoindole. Bromination of ketone II followed by reaction with amines and subsequent NaBH4 reduction, gave amino alcs. These were converted to α-chloro amides that were cyclized to lactams. LiAlH4 reduction served both to remove the protecting group and to reduce the lactams to the 4-(2-morpholinyl)indoles.

ACCESSION NUMBER: 1984:6427 CAPLUS
DOCUMENT NUMBER: 100:6427
TITLE: Synthesis of 4-(4-alkyl-2-morpholinyl)indoles
AUTHOR(S): Clark, Robin D.
CORPORATE SOURCE: Inst. Org. Chem., Syntex Res., Palo Alto, CA, 94304, USA
SOURCE: Journal of Heterocyclic Chemistry (1983), 20(5), 1393-5
CODEN: JHTCAD; ISSN: 0022-152X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 100:6427
IT **88059-35-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)
RN 88059-35-2 CAPLUS
CN 1H-Indole-1-carboxylic acid, 4-(5-oxo-4-propyl-2-morpholinyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 49 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT **88059-37-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 88059-37-4 CAPLUS
CN 1H-Indole, 4-(4-propyl-2-morpholinyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 88059-36-3
CMF C15 H20 N2 O



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



L7 ANSWER 50 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 12 May 1984
GI



AB Twenty-five pyridooxazin-3-one derivs. (I; R = H, Me, Et, Ph; R1 = H, Me) were synthesized by three different methods, and obtained as hydrochlorides. The local anesthetic activity of I was inferior to that of cocaine or lidocaine and their analgesic activity was approx. equivalent to or slightly weaker than that of pyrabital.

ACCESSION NUMBER: 1983:422402 CAPLUS
DOCUMENT NUMBER: 99:22402
TITLE: Studies on pyridinol derivatives. III. Synthesis and pharmacological activity of 2H-pyrido[3,2-b]-1,4-oxazin-3-one derivatives 2
AUTHOR(S): Takeda, Hideo; Hisamichi, Kanehiko
CORPORATE SOURCE: Tohoku Coll. Pharm., Sendai, 983, Japan
SOURCE: Yakugaku Zasshi (1983), 103(2), 153-64
CODEN: YKKZAJ; ISSN: 0031-6903
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
OTHER SOURCE(S): CASREACT 99:22402
IT **86267-28-9P 86267-29-0P 86267-30-3P**
86267-31-4P 86267-32-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, local anesthetic and analgesic activity of)
RN 86267-28-9 CAPLUS
CN 2H-Pyrido[3,2-b]-1,4-oxazin-3(4H)-one, 4-[3-(diethylamino)-2-hydroxypropyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 86267-29-0 CAPLUS
CN 2H-Pyrido[3,2-b]-1,4-oxazin-3(4H)-one, 4-[3-(dipropylamino)-2-hydroxypropyl]-2-phenyl- (9CI) (CA INDEX NAME)

L7 ANSWER 50 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 86267-30-3 CAPLUS
CN 2H-Pyrido[3,2-b]-1,4-oxazin-3(4H)-one, 4-[2-hydroxy-3-(1-pyrrolidinyl)propyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 86267-31-4 CAPLUS
CN 2H-Pyrido[3,2-b]-1,4-oxazin-3(4H)-one, 4-[2-hydroxy-3-(1-piperidinyl)propyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 86267-32-5 CAPLUS

L7 ANSWER 50 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 2H-Pyrido[3,2-b]-1,4-oxazin-3(4H)-one, 4-[2-hydroxy-3-(4-morpholinyl)propyl]-2-phenyl- (9CI) (CA INDEX NAME)



L7 ANSWER 51 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 12 May 1984
GI



I

AB The title compds. I [X = O, S, (CH2)n (where n = 0, 1, 2), CO, imino; R = H, (substituted) alkyl, aryl; R1 = H, Me] were prepared Thus, stirring a mixture of 3.1 g trans-Me(CH2)5COCH:CHCO(CH2)7CO2H (II), 40 mL CHCl3, 1.1 g Et3N, 1.5 g ClCO2CH2CHMe2, and 1.3 g 1-benzylpiperazine at room temperature overnight gave 3.90 g trans-I (X = benzylimino, R = R1 = H). I had higher anti-tumor and blood platelet aggregation-inhibiting activities than II.

ACCESSION NUMBER: 1983:179423 CAPLUS
DOCUMENT NUMBER: 98:179423
TITLE: Octadecenoic acid amides
PATENT ASSIGNEE(S): Nippon Shinyaku Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 58008062	A2	19830118	JP 1981-104629	19810703
PRIORITY APPLN. INFO.:			JP 1981-104629	19810703

OTHER SOURCE(S): CASREACT 98:179423
IT **85462-39-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and pharmacol. activities of)
RN 85462-39-1 CAPLUS
CN Morpholine, 2-phenyl-4-(1,9,12-trioxo-10-octadecenyl)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L7 ANSWER 51 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L7 ANSWER 52 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 12 May 1984
GI



AB Reductive amination of 4-R1C6H4COCH2OAc (R1 = H, Br, Cl, MeO) with HOCH2CH2NHR (R = Me, Et, Pr, CHMe2, Bu, CH2Ph) and HCO2H according to the Leuckart-Wallach reaction gave morpholines I. The intermediates of the reaction were discussed. 4-R1C6H4COCH2X (X = halo) reacted analogously.

ACCESSION NUMBER: 1982:544826 CAPLUS
DOCUMENT NUMBER: 97:144826
TITLE: New method for the synthesis of 2,4-disubstituted morpholines
AUTHOR(S): Yordanova, K.; Shvedov, V.; Dantchev, D.
CORPORATE SOURCE: Pharm. Fak., Med. Akad., Sofia, 1000, Bulg.
SOURCE: Chemische Berichte (1982), 115(7), 2635-42
CODEN: CHBEAM; ISSN: 0009-2940
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 97:144826
IT **21532-11-6P 21532-12-7P 23972-47-6P**
23972-48-7P 23980-51-0P 23980-57-6P
83081-11-2P 83081-12-3P 83081-13-4P
83081-24-7P 83081-25-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, by Leuckart-Wallach alkylation of (alkylamino)ethanol with acetoxyacetophenone)
RN 21532-11-6 CAPLUS
CN Morpholine, 2-phenyl-4-propyl- (8CI, 9CI) (CA INDEX NAME)



RN 21532-12-7 CAPLUS
CN Morpholine, 4-butyl-2-phenyl- (8CI, 9CI) (CA INDEX NAME)

L7 ANSWER 52 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN Morpholine, 4-butyl-2-phenyl-, hydrochloride (8CI, 9CI) (CA INDEX NAME)



● HCl

RN 83081-11-2 CAPLUS
CN Morpholine, 2-(4-bromophenyl)-4-butyl- (9CI) (CA INDEX NAME)



RN 83081-12-3 CAPLUS
CN Morpholine, 2-(4-bromophenyl)-4-butyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 83081-13-4 CAPLUS
CN Morpholine, 2-(4-bromophenyl)-4-butyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 83081-11-2
CMF C14 H20 Br N O

L7 ANSWER 52 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 23972-47-6 CAPLUS
CN Morpholine, 4-butyl-2-(4-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 23972-48-7 CAPLUS
CN Morpholine, 4-butyl-2-(4-chlorophenyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 23980-51-0 CAPLUS
CN Morpholine, 2-phenyl-4-propyl-, hydrochloride (8CI, 9CI) (CA INDEX NAME)

● HCl

RN 23980-57-6 CAPLUS

L7 ANSWER 52 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 83081-24-7 CAPLUS
CN Morpholine, 4-butyl-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 83081-25-8 CAPLUS
CN Morpholine, 4-butyl-2-(4-methoxyphenyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

L7 ANSWER 53 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 12 May 1984
AB erythro- And threo-PhCR(OH)CHMeCH2NR1R2 [I, R = H, Et; R1 = H, R2 = CO2Ph, CONH2, Ac, Me; R1 = Et, R2 = CO2Ph, CONH2; R1 = R2 = Me; R1R2 = (CH2)5, CH2CH2OCHMeCH2Ph] were separated by fractional crystallization and chromatog. on silica or alumina. Derivs. PhCR(OR3)CHMeCH2NR1R2 (R3 = CO2Ph, CONH2, Ac, Me) were also prepared NMR showed that I favored the erythro-axial conformation and their O-substituted derivs. retain the preference for conformations with gauche H-atoms.
ACCESSION NUMBER: 1982:199199 CAPLUS
DOCUMENT NUMBER: 96:199199
TITLE: Stereochemistry of diastereomeric 3-(dialkylamino)propanols and O-substituted derivatives
AUTHOR(S): Spasov, S.; Avramova, P.; Palamareva, M.
CORPORATE SOURCE: Inst. Org. Chem., Sofia, Bulg.
SOURCE: Journal fuer Praktische Chemie (Leipzig) (1981), 323(5), 793-800
CODEN: JPCEAO; ISSN: 0021-8383
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 96:199199
IT **66064-06-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, derivatization, and conformation of)
RN 66064-06-0 CAPLUS
CN 4-Morpholinepropanol, β,3-dimethyl-α,2-diphenyl- (9CI) (CA INDEX NAME)



L7 ANSWER 54 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 12 May 1984
GI



I



II

AB Pharmacol. expts. in cats, mice, and rats indicated that 2-methyl-3-(2-phenyl-3-methyltetrahydrooxazino)propiophenone-HCl (I) [**66063-96-5**] and 1-(phenoxycarboxy)-1-phenyl-2-methyl-3-(2-phenyl-3-methyltetrahydrooxazino)propane-HCl (II) [**74686-85-4**] have analeptic, analgetic, hypertensive, and convulsant activities.
ACCESSION NUMBER: 1980:507096 CAPLUS
DOCUMENT NUMBER: 93:107096
TITLE: Pharmacological studies of the compounds 2-methyl-3-(2-phenyl-3-methyltetrahydrooxazino)propiophenol hydrochloride and 1-(phenoxycarboxy)-1-phenyl-2-methyl-3-(2-phenyl-3-methyltetrahydrooxazino)propane hydrochloride
AUTHOR(S): Ilarionov, I.; Todorova, P.
CORPORATE SOURCE: Med. Akad., Sofia, Bulg.
SOURCE: Eksperimentalna Meditsina i Morfologiya (1980), 19(1), 41-6
CODEN: EKMMA8; ISSN: 0367-0643
DOCUMENT TYPE: Journal
LANGUAGE: Bulgarian
IT **66063-96-5 74686-85-4**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacol. of)
RN 66063-96-5 CAPLUS
CN 1-Propanone, 2-methyl-3-(3-methyl-2-phenyl-4-morpholinyl)-1-phenyl-, hydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 54 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 74686-85-4 CAPLUS
CN Carbonic acid, 2-methyl-3-(3-methyl-2-phenyl-4-morpholinyl)-1-phenylpropyl phenyl ester, hydrochloride (9CI) (CA INDEX NAME)



● HCl

L7 ANSWER 55 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 12 May 1984
GI



I, RR1= O, HCl
II, R=H, R1= O2COPh
III, R=H, R1=O2CNH2

AB Several synthetic carbonic and carbamic acid esters showed potent antidepressant activity in antireserpine test in mice. These compds. also showed central nervous system stimulatory activities. PS-1 (I) [**66063-96-5**], P-8 (II) [**66064-00-4**], and P-8-Y (III) [**66064-01-5**] reversed the reserpine-induced hypothermia, whereas I, PS-4 [**66064-06-0**], and II effectively antagonized reserpine-induced ptosis in mice. The antireserpine activity of these esters was, in some cases, stronger than imipramine. The esters were administered i.p., at doses 200-400 mg/kg body weight Toxicities included tetanic convulsions and death within 4-18 min after injection of a LD.
ACCESSION NUMBER: 1978:164048 CAPLUS
DOCUMENT NUMBER: 88:164048
TITLE: Synthesis, pharmacologic and toxicologic study of carbonic and carbamic acid esters. Part 1
AUTHOR(S): Avramova, P.; Dryanovska, L.; Ilarionov, Y.
CORPORATE SOURCE: Chair Pharm. Org. Chem., Sofia, Bulg.
SOURCE: Pharmazie (1977), 32(10), 575-7
CODEN: PHARAT; ISSN: 0031-7144
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **66063-96-5 66064-00-4 66064-01-5 66064-06-0**
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(antidepressant activity and toxicity of)
RN 66063-96-5 CAPLUS
CN 1-Propanone, 2-methyl-3-(3-methyl-2-phenyl-4-morpholinyl)-1-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 66064-00-4 CAPLUS
CN Carbonic acid, 2-methyl-3-(3-methyl-2-phenyl-4-morpholinyl)-1-phenylpropyl phenyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 55 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 66064-01-5 CAPLUS
CN 4-Morpholinepropanol, β,3-dimethyl-α,2-diphenyl-, carbamate (ester) (9CI) (CA INDEX NAME)



RN 66064-06-0 CAPLUS
CN 4-Morpholinepropanol, β,3-dimethyl-α,2-diphenyl- (9CI) (CA INDEX NAME)



L7 ANSWER 56 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 12 May 1984
GI For diagram(s), see printed CA Issue.
AB 4-Substituted-2,3-Dihydro-1,4-benzoxazine-3-ones (I) with an aminoalkyl or hydroxyalkyl group on the N were prepared and tested for analgesic activity in mice. I with a propanediol group had analgesic activity, while those with an aminoalkyl group on the N had little or no activity. The most interesting compound tested was I, R = CH2CHHCOH2OH, R1 = Me, R2 = R3 = H, R4 = Cl [52042-24-7].
ACCESSION NUMBER: 1976:12313 CAPLUS
DOCUMENT NUMBER: 84:12313
TITLE: Synthesis and pharmacological activity of 4-substituted-2,3-dihydro-1,4-benzoxazin-3-ones
AUTHOR(S): Thuillier, Germaine; Laforest, Jacqueline; Bessin, Pierre; Bonnet, Jacqueline; Thuillier, Jean
CORPORATE SOURCE: Cent. Rech. Pharmacol. Albert Roland, Chilly-Mazarin, Fr.
SOURCE: European Journal of Medicinal Chemistry (1975), 10(1), 37-42
CODEN: EJMCA5; ISSN: 0223-5234
DOCUMENT TYPE: Journal
LANGUAGE: French
OTHER SOURCE(S): CASREACT 84:12313
IT **57462-98-3**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(analgesic activity of)
RN 57462-98-3 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 6-chloro-4-(2,3-dihydroxypropyl)-2-phenyl- (9CI) (CA INDEX NAME)



L7 ANSWER 57 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 12 May 1984
GI For diagram(s), see printed CA Issue.
AB Morpholinones I (R = Cl-4 alkyl, Ph, CH2Ph, cyclohexyl; R1 = Me, Et, Ph) were prepared by cyclizing R1CH(OH)CH2NHR with ClCH2CO2Et. R1CH(OH)CH2NHR were prepared by treating the epoxides II with RNH2. The insecticidal activity of I was low.
ACCESSION NUMBER: 1975:72896 CAPLUS
DOCUMENT NUMBER: 82:72896
TITLE: Preparation of 2-morpholinones and their biological activities
AUTHOR(S): Tawaa, Shinkichi; Eto, Morifusa; Maekawa, Kazuyuki
CORPORATE SOURCE: Fac. Agric., Kyushu Univ., Fukuoka, Japan
SOURCE: Journal of the Faculty of Agriculture, Kyushu University (1974), 18(4), 253-68
CODEN: JFAKAU; ISSN: 0023-6152
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **55475-08-6P 55475-10-0P 55475-11-1P 55475-12-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and insecticidal activity of)
RN 55475-08-6 CAPLUS
CN 2-Morpholinone, 6-phenyl-4-propyl- (9CI) (CA INDEX NAME)



RN 55475-10-0 CAPLUS
CN 2-Morpholinone, 4-butyl-6-phenyl- (9CI) (CA INDEX NAME)



RN 55475-11-1 CAPLUS
CN 2-Morpholinone, 4-(2-methylpropyl)-6-phenyl- (9CI) (CA INDEX NAME)



L7 ANSWER 57 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 55475-12-2 CAPLUS
CN 2-Morpholinone, 4-(1-methylpropyl)-6-phenyl- (9CI) (CA INDEX NAME)



IT **55475-35-9P 55475-37-1P 55492-84-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 55475-35-9 CAPLUS
CN 2-Morpholinone, 6-phenyl-4-propyl-, compd. with 2,4,6-trinitrophenol (9CI) (CA INDEX NAME)

CM 1

CRN 55475-08-6
CMF C13 H17 N O2



CM 2

CRN 88-89-1
CMF C6 H3 N3 O7



RN 55475-37-1 CAPLUS
CN 2-Morpholinone, 4-(2-methylpropyl)-6-phenyl-, compd. with 2,4,6-trinitrophenol (9CI) (CA INDEX NAME)

CM 1

CRN 55475-11-1
CMF C14 H19 N O2

L7 ANSWER 57 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CM 2

CRN 88-89-1
CMF C6 H3 N3 O7



RN 55492-84-7 CAPLUS
CN 2-Morpholinone, 4-(1-methylpropyl)-6-phenyl-, compd. with 2,4,6-trinitrophenol (9CI) (CA INDEX NAME)

CM 1

CRN 55475-12-2
CMF C14 H19 N O2



CM 2

CRN 88-89-1
CMF C6 H3 N3 O7

L7 ANSWER 57 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L7 ANSWER 58 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 12 May 1984
AB DL-2-Amino-1-phenylpropanol reacted with N-benzyloxy-carbonyl-L-aspartic acid α-p-nitrophenyl β-benzyl ester in DMF at room temperature to give benzyl 3-benzyloxycarbonylamino-N-DL-(1-methyl-2-hydroxyphenethyl)-L-succinamate, which was hydrogenated in MeOH containing Pd to yield 3-amino-N-dL-(1-methyl-2-hydroxyphenethyl)-L-succinamic acid. Similarly, .apprx.48 addnl. compds. were prepared with sweetening and antiinflammatory activity.

ACCESSION NUMBER: 1974:146537 CAPLUS
DOCUMENT NUMBER: 80:146537
TITLE: 3-Amino-N-substituted succinamic acids and intermediates
INVENTOR(S): Mazur, Robert H.; Schlatter, James M.; Goldkamp, Arthur H.
PATENT ASSIGNEE(S): G.D. Searle and Co.
SOURCE: U.S., 8 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3803223	A	19740409	US 1970-56753	19700720
US 442431	A1	19760323	US 1974-442431	19740214
US 4011260	A	19770308		
US 4025551	A	19770524	US 1975-642890	19751222
PRIORITY APPLN. INFO.:			US 1968-704229 A2	19680209
			US 1970-56753 A2	19700720
			US 1974-442431 A2	19740214

IT **25353-93-9P 27842-06-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 25353-93-9 CAPLUS
CN 4-Morpholinebutanoic acid, 3-methyl-γ-oxo-2-phenyl-β-[[(phenylmethoxy)carbonyl]amino]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 27842-06-4 CAPLUS
CN 4-Morpholinebutanoic acid, β-amino-3-methyl-γ-oxo-2-phenyl- (9CI) (CA INDEX NAME)

L7 ANSWER 58 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L7 ANSWER 59 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 12 May 1984
GI For diagram(s), see printed CA Issue.
AB Morpholine derivs. I (R = 3-pyridyl, 5-thiazolyl, p-ClC6H4OCMe2) were prepared by treating 3-methyl-2-phenylmorpholine with RCOCl. I are hypocholesteremics and appetite depressants.
ACCESSION NUMBER: 1974:48010 CAPLUS
DOCUMENT NUMBER: 80:48010
TITLE: Morpholine derivatives
PATENT ASSIGNEE(S): Dynachim S.a r.l.
SOURCE: Fr. Demande, 16 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2168139	A1	19730831	FR 1972-1441	19720117
PRIORITY APPLN. INFO.:			FR 1972-1441 A	19720117

IT **37435-07-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 37435-07-7 CAPLUS
CN Morpholine, 4-[2-(4-chlorophenoxy)-2-methyl-1-oxopropyl]-3-methyl-2-phenyl- (9CI) (CA INDEX NAME)



L7 ANSWER 60 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 12 May 1984
GI For diagram(s), see printed CA Issue.
AB Eight oxazines (I, R = H, Bu, or CH2Ph; R1 = CO2Et, CO2Me, CO2H, or CH2OH) and (or) their hydrochlorides were prepared from PhCH:CHCO2R2 (R2 = Me or Et) by treatment with HOCH2CH2Cl and Me3COBr to give R2O2CCHBrCHPhOCH2CH2Cl and reaction of these with RNH2 (R = Bu or CH2Ph), optionally followed by hydrogenolytic cleavage of the benzyl group, hydrolysis of I (R1 = CO2R2) to give the acids, and reduction of these to give I (R1 = CH2OH).
ACCESSION NUMBER: 1974:27266 CAPLUS
DOCUMENT NUMBER: 80:27266
TITLE: Tetrahydro-2-phenyl-1,4-oxazines
INVENTOR(S): Mauvernay, Roland Y.; Bush, Norbert; Simond, Jacques; Monteil, Andre; Moleyre, Jacques
PATENT ASSIGNEE(S): Centre Europeen de Recherches Mauvernay
SOURCE: Ger. Offen., 14 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2318024	A1	19731031	DE 1973-2318024	19730410
FR 2179578	A1	19731123	FR 1972-12892	19720413
GB 1411666	A	19751029	GB 1973-17718	19730412
PRIORITY APPLN. INFO.:			FR 1972-12892 A	19720413

IT **50784-43-5P 50784-50-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 50784-43-5 CAPLUS
CN 3-Morpholinecarboxylic acid, 4-butyl-2-phenyl-, methyl ester (9CI) (CA INDEX NAME)



RN 50784-50-4 CAPLUS
CN 3-Morpholinecarboxylic acid, 4-butyl-2-phenyl-, methyl ester, hydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 60 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

L7 ANSWER 61 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 12 May 1984
GI For diagram(s), see printed CA Issue.
AB the title compds. (I), antidepressants, were prepared by oxidizing the corresponding alcs. E.g., 4-[4-(p-fluorophenyl)-4-hydroxybutyl]morpholine in C6H6 was stirred with MnO2 to give I (R = F, X = H). Among 7 more I similarly prepared were the following (R and X given): Cl, H; OMe, H; H, 3-Me; H, 2,6-Me2; H, 2,6-Ph2.
ACCESSION NUMBER: 1973:16196 CAPLUS
DOCUMENT NUMBER: 78:16196
TITLE: Morpholine derivatives
INVENTOR(S): Yamamoto, Hisao; Nakao, Masaru; Sasajima, Kikuo; Maruyama, Isamu; Katayama, Shigenari
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Jpn. Tokkyo Koho, 3 pp.
CODEN: JAXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 47040062	B4	19721009	JP 1969-100295	19691212

IT **5170-26-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 5170-26-3 CAPLUS
CN 1-Butanone, 4-(2,6-diphenyl-4-morpholinyl)-1-phenyl- (9CI) (CA INDEX NAME)



L7 ANSWER 62 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 12 May 1984
GI For diagram(s), see printed CA Issue.
AB The morpholide (I) was prepared by treating 3-methyl-2-phenylmorpholine with p-ClC6H4OCMe2COCl and Et3N.
ACCESSION NUMBER: 1972:501634 CAPLUS
DOCUMENT NUMBER: 77:101634
TITLE: Phenoxyalkanoyl morpholides
INVENTOR(S): Aries, Robert
SOURCE: Fr., 13 pp.
CODEN: FRXXAK
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2094499		19720310	FR 1970-23209	19700623

IT **37435-07-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 37435-07-7 CAPLUS
CN Morpholine, 4-[2-(4-chlorophenoxy)-2-methyl-1-oxopropyl]-3-methyl-2-phenyl- (9CI) (CA INDEX NAME)



L7 ANSWER 63 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 12 May 1984
GI For diagram(s), see printed CA Issue.
AB The title compds. (I, R = allyl, Bu, iso-Bu, isopentyl, C7H15, cyclohexyl, or PhCH2) were prepared (Fr. P.V. 142,274) and pharmacol. activity tested on mice and rats. They were effective in daily doese of 2-50 mg. preferably 10 mg for adults, and can be administered orally in the usual solid pharmaceutical compns.
ACCESSION NUMBER: 1972:144845 CAPLUS
DOCUMENT NUMBER: 76:144845
TITLE: Tranquilizing, analgesic, and antiinflammatory 4-substituted 2-[(3-trifluoromethyl)phenyl]tetrahydro-1,4,-oxazines
INVENTOR(S): Mauvernay, Roland Y.; Busch, Norbert; Moleyre, Jacques; Simond, Jacques
PATENT ASSIGNEE(S): Centre Europeen de Recherches Mauvernay
SOURCE: Fr. M., 11 pp.
CODEN: FMXXAJ
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 7745		19700309	FR 1968-173894	19681115

IT **26629-95-8 36163-28-7 36163-29-8 36163-30-1**
RL: BIOL (Biological study)
(pharmaceutical)
RN 26629-95-8 CAPLUS
CN Morpholine, 4-butyl-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 36163-28-7 CAPLUS
CN Morpholine, 4-(2-methylpropyl)-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 63 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 36163-29-8 CAPLUS
CN Morpholine, 4-heptyl-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 36163-30-1 CAPLUS
CN Morpholine, 4-(3-methylbutyl)-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 64 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 12 May 1984
AB Dihydropyrido[3,2-b]-1,4-oxazines were prepared Reactions of these compds. with alkylating agents, LiAlH4, Br, CuCN, and phosphorus sulfide were investigated.
ACCESSION NUMBER: 1972:34186 CAPLUS
DOCUMENT NUMBER: 76:34186
TITLE: Reactions of 3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazines
AUTHOR(S): Clauson-Kaas, Niels; Lei, Joergen; Heide, Henning
CORPORATE SOURCE: Farum, Den.
SOURCE: Acta Chemica Scandinavica (1947-1973) (1971), 25(8), 3135-43
CODEN: ACSAA4; ISSN: 0001-5393
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **34950-60-2P 34950-68-0P 34950-69-1P 34950-77-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 34950-60-2 CAPLUS
CN 4H-Pyrido[3,2-b]-1,4-oxazine-4-propanamine, 2,3-dihydro-N,N-dimethyl-2,2-diphenyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 34950-68-0 CAPLUS
CN 2H-Pyrido[3,2-b]-1,4-oxazin-3(4H)-one, 4-[3-(dimethylamino)propyl]-2,2-diphenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 34950-69-1 CAPLUS
CN 2H-Pyrido[3,2-b]-1,4-oxazin-3(4H)-one, 4-[3-(dimethylamino)propyl]-2,2-diphenyl- (9CI) (CA INDEX NAME)

L7 ANSWER 64 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 34950-77-1 CAPLUS
CN 2H-Pyrido[3,2-b]-1,4-oxazin-3-ol, 4-[3-(dimethylamino)propyl]-3,4-dihydro-2,2-diphenyl- (9CI) (CA INDEX NAME)



L7 ANSWER 65 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 12 May 1984
GI For diagram(s), see printed CA Issue.
AB I (R = H, Me, 4-ClC6H4, or Ph; R1 = Me2NCH2CH2, 2-piperidinoethyl, or a similar aminoalkyl group; R2 = H or Cl), useful as antispasmodics, antiphlogistics, antipyretics, and analgesics, are prepared Thus, 2,3-dihydro-1,4-benzoxazin-3-one, NaNH2, Me2NCH2CH2Cl, and xylene are refluxed to prepare I (R = R2 = H, R1 = Me2NCH2CH2).
ACCESSION NUMBER: 1972:14553 CAPLUS
DOCUMENT NUMBER: 76:14553
TITLE: Basically substituted 2,3-dihydro-1,4-benzoxazin-3-ones
INVENTOR(S): Zschiedrich, Johannes; Thomas, Eckhard
SOURCE: Ger. (East), 3 pp.
CODEN: GEXXA8
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DD 79293		19710120	DD	19700204

IT **34867-33-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 34867-33-9 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 6-chloro-4-[3-(dimethylamino)propyl]-2-phenyl- (9CI) (CA INDEX NAME)



L7 ANSWER 66 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 12 May 1984
GI For diagram(s), see printed CA Issue.
AB Title compds. (I) with antiphlogistic, antipyretic, and analgesic activity, were prepared by alkylation of I (R1 = H) with R1Cl in the presence of Na or Na compds. Thus, I (R = R1 = R2 = H), NaNH2, and ClCH2CH2NMe2 was refluxed in xylene 3 hr to give I (R = R2 = H, R1 = CH2CH2NMe2). Similarly prepared were I (R-R2 given): Me, β-piperidinoethyl, H; p-ClC6H4, CH2CH2NMe2, H; Ph, (CH2)3NMe2, Cl.
ACCESSION NUMBER: 1971:529818 CAPLUS
DOCUMENT NUMBER: 75:129818
TITLE: 4-(Aminoalkyl)-2,3-dihydro-4H-1,4-benzoxazin-3-ones
INVENTOR(S): Zschiedrich, Johannes; Thomas, Eckhard
PATENT ASSIGNEE(S): VEB Deutsches Hydrierwerk
SOURCE: Ger. Offen., 8 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2044530	A	19710819	DE 1970-2044530	19700909
SU 430553	D	19740530	SU 1970-1482213	19701007
SU 437300	D	19740725	SU 1970-1754059	19701007
FR 2079223	A5	19711112	FR 1970-40233	19701109
CH 555356	A	19741031	CH 1970-17904	19701203
PRIORITY APPLN. INFO.:			DD 1970-145276 A	19700204

IT **33980-29-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 33980-29-9 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[3-(dimethylamino)propyl]-2-phenyl- (8CI) (CA INDEX NAME)



L7 ANSWER 67 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 12 May 1984
GI For diagram(s), see printed CA Issue.
AB The title compds. (I) were prepared by reaction of a primary amine (RNH2) with 2-[3-(trifluoromethyl)-phenyl]-2-(2-chloroethoxy)-1-bromoethane (II). Thus, n-hexylamine reacted with II to give 2-[3-(trifluoromethyl)phenyl]-4-hexyltetrahydro-1,4-oxazine. Similarly were prepared I (R = pentyl, Pr, and phenethyl). The results of pharmacodynamic tests are given.
ACCESSION NUMBER: 1971:488619 CAPLUS
DOCUMENT NUMBER: 75:88619
TITLE: Tranquillizing, antiinflammatory, and analgesic 2-[(3-trifluoromethyl)phenyl]-4-alkyltetrahydro-1,4-oxazines
INVENTOR(S): Mauvernay, Roland Y.; Busch, Norbert; Moleyre, Jacques; Simond, Jacques
PATENT ASSIGNEE(S): Centre Europeen de Recherches Mauvernay
SOURCE: Fr. Demande, 10 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2035753		19710122	FR	19690219

IT **33743-97-4P 33743-98-5P 33743-99-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 33743-97-4 CAPLUS
CN Morpholine, 4-hexyl-2-(α,α,α-trifluoro-m-tolyl)- (8CI) (CA INDEX NAME)



RN 33743-98-5 CAPLUS
CN Morpholine, 4-pentyl-2-(α,α,α-trifluoro-m-tolyl)- (8CI) (CA INDEX NAME)



L7 ANSWER 67 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 33743-99-6 CAPLUS
CN Morpholine, 4-propyl-2-(α,α,α-trifluoro-m-tolyl)- (8CI) (CA INDEX NAME)



L7 ANSWER 68 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 12 May 1984
GI For diagram(s), see printed CA Issue.
AB The muscle relaxant reactivity of 3-morpholinones I (R = O) is observed in rats and mice. 3-Morpholinones, I (R = O), and 3-morpholinethiones, I (R = S) (Ar = Ph or a substituted phenyl group; Ar1 = H, Ph) are prepared according to known methods, including hydrogenation of 6-aryl-4H-1,4-oxazin-3(2H)-ones (II).
ACCESSION NUMBER: 1971:100071 CAPLUS
DOCUMENT NUMBER: 74:100071
TITLE: 3-Morpholinone and 3-morpholinethione derivatives as muscular relaxants and tranquilizers
PATENT ASSIGNEE(S): McNeil Laboratories, Inc.
SOURCE: Fr. M., 16 pp.
CODEN: FMXXAJ
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 6206		19680902	FR	19660606

IT **16187-69-2P 16187-71-6P 16187-72-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 16187-69-2 CAPLUS
CN 3-Morpholinone, 4-isobutyryl-5-methyl-6-phenyl- (8CI) (CA INDEX NAME)



RN 16187-71-6 CAPLUS
CN 3-Morpholinone, 4-butyl-5-methyl-6-phenyl- (8CI) (CA INDEX NAME)



RN 16187-72-7 CAPLUS
CN 3-Morpholinone, 4-butyl-6-phenyl- (8CI, 9CI) (CA INDEX NAME)

L7 ANSWER 68 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L7 ANSWER 69 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 12 May 1984
GI For diagram(s), see printed CA Issue.
AB The tranquilizing title salts (I) were prepared Thus, refluxing II and 2-(p-fluorophenyl)-2-(3-chloropropyl)-1,3-dioxolane 16 hr in BuOH containing K2CO3 and treating the product with oxalic acid hydrate gave 28 I (R = F, n = 3). I (R = H, n = 2) was similarly prepared
ACCESSION NUMBER: 1971:88004 CAPLUS
DOCUMENT NUMBER: 74:88004
TITLE: 4-[1-(ω-Benzoylalkyl)-3-pyrrolidinyl]-2H-1,4-benzoxazin-3(4H)-one oxalates
INVENTOR(S): Helsley, Grover C.
PATENT ASSIGNEE(S): A. H. Robins Co., Inc.
SOURCE: Ger. Offen., 12 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2033641	A	19710114	DE 1970-2033641	19700707
US 3699105	A	19721017	US 1969-839705	19690707
GB 1307590	A	19730221	GB 1970-32427	19700703
ES 381458	A1	19721116	ES 1970-381458	19700704
ZA 7004609	A	19710331	ZA 1970-4609	19700706
FR 2059486	A5	19710604	FR 1970-25006	19700706
FR 2059486	B1	19741011		
CH 527214	A	19720831	CH 1970-527214	19700706
CA 954860	A1	19740917	CA 1970-87561	19700707
JP 49046317	B4	19741209	JP 1970-58806	19700707
PRIORITY APPLN. INFO.:			US 1969-839705 A	19690707

IT **30914-96-6P**, 2H-1,4-Benzoxazin-3(4H)-one, 4-[3-(2,5-dimethyl-1-pyrrolidinyl)propyl]-2-phenyl- **30914-98-8P**, 2H-1,4-Benzoxazin-3(4H)-one, 4-[5-(2,5-dimethyl-1-pyrrolidinyl)pentyl]-2-phenyl-
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 30914-96-6 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[3-(2,5-dimethyl-1-pyrrolidinyl)propyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 30914-98-8 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 4-[5-(2,5-dimethyl-1-pyrrolidinyl)pentyl]-2-phenyl- (9CI) (CA INDEX NAME)

L7 ANSWER 69 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L7 ANSWER 70 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 12 May 1984

GI For diagram(s), see printed CA Issue.

AB The title compds. (I) are prepared Thus, 1040 ml CHCl3 containing 426 g ClCH2CH2OCH:CH2 at - 10° treated dropwise with stirring with 640 g Br gave 65% ClCH2CH2OCHBrCH2Br (II), b13 102°, n23D 1.5305. Anhydrous Et2O (1500 ml) containing m-F3CC6H4MgBr (from 48.6 g Mg and 455.7 g m-F3CC6H4Br) refluxed gently with stirring and treated dropwise with 550 g II 300 ml anhydrous Et2O and the mixture refluxed 2 hr gave 54% ClCH2CH2OCH(C6H4CF3-m)CH2Br (III),b0.1 98°, n20D 1.4970, 95% pure material. PhMe (100 ml) containing 33.15 g III and 20 g iso-PrNH2 autoclaved at 100° gave 50% I R = iso-Pr), b3 99°, n24D 1.4751; HCl salt m. 164°. Similarly were produced the corresponding 4-allyl, 4-cyclohexyl, 4-benzyl, and 4-butyl derivs. characterized by their HCl salts.

ACCESSION NUMBER: 1970:79065 CAPLUS
DOCUMENT NUMBER: 72:79065
TITLE: 2-(m-Trifluoromethylphenyl)-4-substituted tetrahydro-1,4-oxazines
INVENTOR(S): Mauvernay, Roland Y.; Busch, Norbert; Moleyre, Jacques; Simond, Jacques
PATENT ASSIGNEE(S): Centre Europeen de Recherches Mauvernay
SOURCE: Fr., 5 pp.
CODEN: FRXXAK
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 1564792		19690425	FR	19680304
DE 1910477			DE	
GB 1221734			GB	
US 3637680		19720000	US	

IT **26629-94-7P 26629-95-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 26629-94-7 CAPLUS

CN Morpholine, 4-butyl-2-(α,α,α-trifluoro-m-tolyl)-, hydrochloride (8CI) (CA INDEX NAME)



● HCl

L7 ANSWER 70 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 26629-95-8 CAPLUS

CN Morpholine, 4-butyl-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 71 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 12 May 1984

GI For diagram(s), see printed CA Issue.

AB Derivs. of amphetamine and phenmetrazine (I) were prepared for anal. by gas chromatog. with electron capture (EC) detection. N-Trichloroacetyl derivs. had favorable properties in terms of high EC- response, narrow and sym. peak shape, and facile formation. Mass spectra of derivs. of amphetamine, methamphetamine, p-hydroxyamphetamine, I, Me phenidate, chlorphentermine, and diethylpropion were record ed with a combined gas chromatograph mass spectrometer (GC-MS). The preparation of derivs. was of advantage since the free amines show tailing peaks on the phases which can be used with GC-MS. Also, the mass spectrum of the derivative frequently assumed a more complex character giving more structural information and facilitating pos. identification.

ACCESSION NUMBER: 1970:66075 CAPLUS
DOCUMENT NUMBER: 72:66075
TITLE: Derivatives of sympathomimetic amines for gas chromatography with electron capture detection and mass spectrometry
AUTHOR(S): Anggard, Erik; Hankey, Alexander
CORPORATE SOURCE: Dep. Pharmacol., Karolinska Inst., Stockholm, Swed.
SOURCE: Acta Chemica Scandinavica (1947-1973) (1969), 23(9), 3110-19
CODEN: ACSAA4; ISSN: 0001-5393
DOCUMENT TYPE: Journal
LANGUAGE: English

IT **27765-83-9**
RL: PRP (Properties)
(mass spectrum of)

RN 27765-83-9 CAPLUS

CN Morpholine, 3-methyl-2-phenyl-4-propionyl- (8CI) (CA INDEX NAME)



L7 ANSWER 72 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 12 May 1984
AB The title compds. RR1NCOCH(NH2)CH2CO2H (I) are used as sweetening and as antiinflammatory agents. To a solution of 17.85 parts N-benzyloxycarbonyl-l-asparaginic acid β-benzyl ester and 5.9 volume parts N-methylmorpholine in 76.5 parts anhydrous tetrahydrofuran at -20° 7 volume parts iso-BuO2CCl was added dropwise, the mixture stirred 5 min, cooled to -30°, 8.25 volume parts dl-1,4-dimethylpentylamine added dropwise at -10 to -15°, and the mixture kept 16 hr at 5° and worked up to give 3-benzyloxycarbonylamino-N-dl-1',4'-dimethylpentyl-l-succinamic acid benzyl ester, m. 90-103°, [α] -7° (MeOH). A solution of 4.53 parts dl-2-amino-1-phenylpropanol in 22.5 parts HCONMe2 was stirred a few min with 15.06 parts N-benzyloxycarbonyl-l-asparaginic acid α-p-nitrophenyl β-benzyl diester and the mixture left 16 hr at room temperature and worked up to give 3-benzyloxycarbonylamino-N-(dl-1-methyl-2-hydroxyphenethyl)-l-succinamic acid benzyl ester, m. 72-84° [α] -9° (MeOH). A mixture of 4.9 parts 3-benzyloxycarbonylamino-N-(dl-1-methyl-2-hydroxyphenethyl)-l-succinamic acid benzyl ester, 0.5 parts Pd black and 120 parts MeOH at room temperature was shaken with H at 4 atm pressure until 2 mole equivs. H was absorbed to give I (R = H, R1 = dl-PhCH(OH)CHMe, m. 188-90°, [α] = 10° (H2O). Many other compds. were cited, together with their physical properties; >90 other examples of prepns. were given.
ACCESSION NUMBER: 1970:44128 CAPLUS
DOCUMENT NUMBER: 72:44128
TITLE: N3- and N4-Substituted 3-aminosuccinamic acid derivatives
INVENTOR(S): Mazur, Robert H.; Goldkamp, Arthur H.; Schlatter, James M.
PATENT ASSIGNEE(S): G.D. Searle and Co.
SOURCE: Ger. Offen., 54 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1906048	A	19690828	DE 1969-1906048	19690207
FR 2001650	A5	19690926	FR 1969-2910	19690207
FR 2001650	B1	19730713		
GB 1228271	A	19710415	GB 1969-1228271	19690207
GB 1228272	A	19710415	GB 1969-1228272	19690207
JP 48024378	B4	19730720	JP 1969-9660	19690208
FR 2065653	A5	19710806	FR 1970-21149	19700609

PRIORITY APPLN. INFO.: US 1968-704229 A 19680209
IT **25353-93-9P 27842-06-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 25353-93-9 CAPLUS
CN 4-Morpholinebutanoic acid, 3-methyl-γ-oxo-2-phenyl-β-[[(phenylmethoxy)carbonyl]amino]-, phenylmethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 72 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 27842-06-4 CAPLUS
CN 4-Morpholinebutanoic acid, β-amino-3-methyl-γ-oxo-2-phenyl- (9CI) (CA INDEX NAME)



L7 ANSWER 73 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 12 May 1984
GI For diagram(s), see printed CA Issue.
AB Mixts. of olefins RR1C:CH2 and HOCH2CH2Cl are treated with tert-BuOBr to give ethers RR1C(OCH2CH2,Cl)CH2Br (I); and the I are treated with amines R2NH2 to give II. Thus, tert-Bu-OBr is slowly added to a mixture of 104 g. styrene, 160 g. HOCH2CH2Cl, and 150 ml. CCl4 at -10° to give 115 g. PhCH(OCH2CH2Cl)CH2Br (III), b1·5 116-18°, n1D9·8 1.5510. Similarly prepared are the following I (R, R1, b.p./mm., and nD given): H, p-ClC6H4, 125-6°/0.5, 1.5640 (18°); H, Me, 79°/11, 1.475 (19°); Me, Me, 63-5°/4, 1.4765 (22°); H, p-FC6H4CH2, 140°/2, 1.5280 (19.6°). A mixture of 39.52 g. III, 44 g. cyclohexylamine, and 150 ml. PhMe is refluxed 12 hrs. to give 26 g. 2-phenyl-4-cyclohexyltetrahydro-1,4-oxazine, b13 197°, n21D 1.5370; HCl salt m. 162°. Similarly prepared are the following II (R = Ph, R1 = H) (R2, b.p./mm., nD, and m.p. HCl salt given): Pr, 105°/1, 1.5174 (20.2°), 158°; iso-Pr, 98°/1, 1.5519 (19.4°), 156°; allyl, 92°/1, 1.5300, 149°; Bu, 160°/13, 1.5120 (23°), 165°; iso-Bu, 97°/1, 1.5100 (19°), 155°; amyl, 167°/12, 1.508 (23°), 145°; isoamyl, 103°/1, 1.5089 (20.5°), 142°; hexyl, 132°/1, 1.5080 (19.2°), 140°; n-heptyl, 189°/12, 1.5025 (23°), 140°; n-octyl, 147°/2, 1.5010 (19°), 135°; PhCH2CHMe, 171°/1, 1.5648 (22°), 167°; PhCH2CH2, 165°/1, 1.5670 (18°), 160°; PhCH2, 154°/1, 1.5701 (21°), 166°; p-ClC6H4CH2CH2, (m. 59°), -, 160°; CH2CH2OH, 128°/1, 1.5469 (18.2°), 124°; iso-PrO(CH2)3, 150°/3, 1.5042 (20.2°), 148°; EtO(CH2)3, 146°/3, 1.5100 (20.4°), 143°; BuO(CH2)3, 173°/3, 1.5040 (20.2°), 145°; the following II (R = p-ClC6H4, R1 = H) (R2, b.p./mm., nD, and m.p. HCl salt given): iso-Pr, 122°/1, 1.5218 (19.6°), 165°; isoamyl, 141°/1, 1.5219 (19.8°), 170°; Bu, 123°/1, 1.5268 (19.8°), 155°; cyclohexyl, 166°/1, 1.5475 (21.6°), 178°; iso-PrO(CH2)3, 175°/1, 1.5143 (20.2°), 172°; EtO(CH2)3, 165°/2, 1.5211 (21°), 168°; BuO(CH2)3, 183°/2, 1.5135 (21°), 168°; PhCH2, 167°/1, 1.5755 (21.8°), 162°; the following II (R = p-FC6H4CH2, R1 = H) (R2, b.p./mm., nD, and m.p. HCl salt given): Pr, 111°/2, 1.5022 (19.4°), 140°; isoamyl, 141°/1.5, 1.4950 (21.9°), 149°; iso-PrO-(CH2)3, 157°/1, 1.4905 (21.8°), 135°; Bu, 127°/2, 1.4988 (19.4°), 152°; hexyl, 151°/2, 1.4972 (22°), 145°; cyclohexyl, 164°/2, -, 175°; and the following II (R, R1, R2, b.p./mm., nD, and m.p. HCl salt given): Me, Me, iso-Pr, 65°/14, 1.4415 (22°), 166°; Me, Me, isoamyl, 89.5°/13, 1.4478 (21.4°), 172°; Me, Me, Ph-CH2CH2, 108°/2, 1.5092 (21.2°), 173°; Me, Me, PhCH2CHMe, 126°/3, 1.5098 (21.4°), 165°; Me, H, PhCH2CH2, 141°/11, 1.5182 (19.6°), 166°; Me, H, PhCH2CHMe, 148.5°/11, 1.5180 (19.6°), 164°; Me, H, p-ClC6H4CH2, 151°/11, 1.5335 (19.4°), 163°; Me, H, pyridylmethyl, 115°/2, 1.5210 (22°), di-HCl salt m. 165°; Me, H, 3,4-(MeO)2C6H3CH2, 132°/2, 1.5332 (21.4°), 172°. II (R = Ph, R1 = H, R2 = PhCH2) (102 g.) is hydrogenated over 11 g. 5% Pd/C 12 hrs. to give 51.5 g. II (R = Ph, R1 = R2 = H)(IV), b2 97°, n21·6D 1.5482, HCl salt m. 148°. A mixture of 24 g. IV, 35 g. HCO2H, and 19 g. 30% H2CO is heated 6 hrs. to give 20.2 g. II (R = Ph, R1 = H, R2 = Me), b5 95°, n23D 1.5260; HCl salt m. 145°.
ACCESSION NUMBER: 1969:501868 CAPLUS

L7 ANSWER 73 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
DOCUMENT NUMBER: 71:101868
TITLE: 2,4- and 2,2,4-Substituted tetrahydro-1,4-oxazines
INVENTOR(S): Busch, Norbert; Moleyre, Jacques; Mauvernay, Roland Y.
PATENT ASSIGNEE(S): Centre Europeen de Recherches Mauvernay
SOURCE: Fr., 9 pp.
CODEN: FRXXAK
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 1535615		19680809	FR	19670626
DE 1643857			DE	
GB 1184023			GB	

IT **21532-11-6P 21532-12-7P 21532-13-8P**
21532-14-9P 21563-81-5P 21563-82-6P
23222-65-3P 23972-38-5P 23972-39-6P
23972-40-9P 23972-45-4P 23972-46-5P
23972-47-6P 23972-48-7P 23972-51-2P
23972-52-3P 23972-53-4P 23972-54-5P
23972-55-6P 23980-51-0P 23980-57-6P
23980-58-7P 23980-59-8P 23980-60-1P
23980-62-3P 23980-67-8P 23980-68-9P
23980-70-3P 23980-80-5P 23980-81-6P
25455-50-9P 25455-51-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 21532-11-6 CAPLUS
CN Morpholine, 2-phenyl-4-propyl- (8CI, 9CI) (CA INDEX NAME)



RN 21532-12-7 CAPLUS
CN Morpholine, 4-butyl-2-phenyl- (8CI, 9CI) (CA INDEX NAME)



RN 21532-13-8 CAPLUS
CN Morpholine, 4-pentyl-2-phenyl- (8CI) (CA INDEX NAME)

L7 ANSWER 73 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 21532-14-9 CAPLUS
CN Morpholine, 4-hexyl-2-phenyl- (8CI) (CA INDEX NAME)

RN 21563-81-5 CAPLUS
CN Morpholine, 4-heptyl-2-phenyl- (8CI) (CA INDEX NAME)



RN 21563-82-6 CAPLUS
CN Morpholine, 4-octyl-2-phenyl- (8CI) (CA INDEX NAME)



RN 23222-65-3 CAPLUS
CN Morpholine, 4-isopentyl-2-phenyl- (8CI) (CA INDEX NAME)

L7 ANSWER 73 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 23972-38-5 CAPLUS
CN Morpholine, 4-(3-ethoxypropyl)-2-phenyl- (8CI) (CA INDEX NAME)



RN 23972-39-6 CAPLUS
CN Morpholine, 4-(3-ethoxypropyl)-2-phenyl-, hydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 23972-40-9 CAPLUS
CN Morpholine, 4-(3-butoxypropyl)-2-phenyl- (8CI) (CA INDEX NAME)



RN 23972-45-4 CAPLUS
CN Morpholine, 2-(p-chlorophenyl)-4-isopentyl- (8CI) (CA INDEX NAME)

L7 ANSWER 73 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 23972-46-5 CAPLUS
CN Morpholine, 2-(p-chlorophenyl)-4-isopentyl-, hydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 23972-47-6 CAPLUS
CN Morpholine, 4-butyl-2-(4-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 23972-48-7 CAPLUS
CN Morpholine, 4-butyl-2-(4-chlorophenyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 23972-51-2 CAPLUS
CN Morpholine, 2-(p-chlorophenyl)-4-(3-isopropoxypropyl)- (8CI) (CA INDEX NAME)

L7 ANSWER 73 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 23972-52-3 CAPLUS
CN Morpholine, 2-(p-chlorophenyl)-4-(3-ethoxypropyl)- (8CI) (CA INDEX NAME)



RN 23972-53-4 CAPLUS
CN Morpholine, 2-(p-chlorophenyl)-4-(3-ethoxypropyl)-, hydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 23972-54-5 CAPLUS
CN Morpholine, 4-(3-butoxypropyl)-2-(p-chlorophenyl)- (8CI) (CA INDEX NAME)



RN 23972-55-6 CAPLUS
CN Morpholine, 4-(3-butoxypropyl)-2-(p-chlorophenyl)-, hydrochloride (8CI) (CA INDEX NAME)

L7 ANSWER 73 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 23980-51-0 CAPLUS
CN Morpholine, 2-phenyl-4-propyl-, hydrochloride (8CI, 9CI) (CA INDEX NAME)



● HCl

RN 23980-57-6 CAPLUS
CN Morpholine, 4-butyl-2-phenyl-, hydrochloride (8CI, 9CI) (CA INDEX NAME)

● HCl

RN 23980-58-7 CAPLUS
CN Morpholine, 4-isobutyl-2-phenyl- (8CI) (CA INDEX NAME)

L7 ANSWER 73 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 23980-59-8 CAPLUS
CN Morpholine, 4-isobutyl-2-phenyl-, hydrochloride (8CI) (CA INDEX NAME)

● HCl

RN 23980-60-1 CAPLUS
CN Morpholine, 4-pentyl-2-phenyl-, hydrochloride (8CI) (CA INDEX NAME)

● HCl

RN 23980-62-3 CAPLUS
CN Morpholine, 4-isopentyl-2-phenyl-, hydrochloride (8CI) (CA INDEX NAME)

L7 ANSWER 73 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 23980-67-8 CAPLUS
CN Morpholine, 4-hexyl-2-phenyl-, hydrochloride (8CI) (CA INDEX NAME)

● HCl

RN 23980-68-9 CAPLUS
CN Morpholine, 4-heptyl-2-phenyl-, hydrochloride (8CI) (CA INDEX NAME)

● HCl

RN 23980-70-3 CAPLUS
CN Morpholine, 4-octyl-2-phenyl-, hydrochloride (8CI) (CA INDEX NAME)

L7 ANSWER 73 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

● HCl

RN 23980-80-5 CAPLUS
CN Morpholine, 4-(3-isopropoxypropyl)-2-phenyl- (8CI) (CA INDEX NAME)



RN 23980-81-6 CAPLUS
CN Morpholine, 4-(3-isopropoxypropyl)-2-phenyl-, hydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 25455-50-9 CAPLUS
CN Morpholine, 4-(3-butoxypropyl)-2-phenyl-, hydrochloride (8CI) (CA INDEX NAME)



● HCl

L7 ANSWER 73 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 25455-51-0 CAPLUS
CN Morpholine, 2-(p-chlorophenyl)-4-(3-isopropoxypropyl)-, hydrochloride (8CI) (CA INDEX NAME)



● HCl

L7 ANSWER 74 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 12 May 1984
AB The pharmacodynamic properties of Pr2CHCO2H amides and esters were examined The following Pr2CHCONR1R2 were prepared (R1, R2, % yield, and m.p. or b.p./mm. given): Me, H, 81, 108.7°; Et, H, 75, 96°; iso-Bu, H, 40, 80.2°; heptyl, H, 52, 39.1°; allyl, H, 85, 71.5°; cyclopropyl, H, 59, 111.1°; cyclopentyl, H, 62, 108.6°; m-ClC6H4CHCMe2 (sic), H, 80, 100.7°; PhCH2, H, 53, 90.5°; Me, Me, 77, 75° /2; Et, Et, 38, 92°/2; iso-Pr, iso-Pr, 66, 160°/20; Bu, Bu, 48, 124°/2; allyl, allyl, 79, 108°/2; NH2, H, 25, 126.1°; 1-naphthyl, H, 55, 148.4°; 2-naphthyl, H, 81, 153°; 3-pyridyl, H, 24, 100.1°; 2-pyrimidinyl, H, 60, 101.3°; 4-NCC6H4, H, 54, 167.4°; 3-acetylphenyl, H, 62, 95.4°; 4-acetylphenyl, H, 45, 147.3°; 4-propiophenyl, H, 72, 129.1°. The following Pr2CHCOR were prepared (R, % yield, b.p./mm., and n2D0 given): propylenimino, 70, 130°/2, 1.4481; pyrrolidinyl, 53, 130°/2, 1.4620; 2-methylpiperidino, 52, 170°/5, 1.4680; 3-methylpiperidino, 59, 170°/5, 1.4677; 4-methylpiperidino, 35, 200°/5, 1.4674; 2,6-dimethylpiperidino, 53, 210°/5, 1.4662; 3,6-dimethyl-2-phenylmorpholino, 88, 215°/51, 1.5128; piperazino, 72, 238°, 1.4813; 4-methyl-1-piperazinyl, 54, 140°/2, 1.4939; 4-(hydroxyethyl)-1-piperazinyl, 42, 180°/2, 1.4741. The following (Pr2CHCONH)2R were prepared (R, % yield, and m.p. given): CH2CH2, 58, 206.3°; 1,2-phenylene, 52, 118.8°; 1,4-phenylene, 63, 390°; 3-chloro-1,2-phenylene, 37, 126.3°; 4,4'-diphenylene, 61, 325°; piperazine, 88, 53.5°. The following Pr2CHCO2R were prepared (R, % yield, b.p./mm., and n2D0 given): Me, 80, 171°, 1.4152; dodecyl, 11, 125°/2, 1.4414; docosanyl, 85, 160°/2, 1.5022; allyl, 40, 170°/2, 1.4274; oleyl, 45, 148°/2, 1.4550; 2-chloroethyl, 78, 107°/2, 1.4363; 2,2,2-trichloroethyl, 90, 126°/2, 1.4542; 2,2,2-tribromoethyl, 76, 166°/2, 1.5048; Ph, 35, 126°/2, 1.4790; 1-naphthyl, 50, 185°/ 20, 1.5478; 2-naphthyl, 76, 180°/20, 1.5540; 2-(trifluoromethyl)phenyl, 22, 185°/20, 1.4486. The following Pr2CHCONH(CH2)nNR2 were prepared (n, R, % yield base, % yield salt, m.p. or b.p./mm. for the base, and salt given): 2, Me, 62, 33, 39.5°, 98° (HCl); 2, Et, 60, 41, 170°/2, 106° (HCl); 2, iso-Pr, 62, 81, 52°, 120°; 3, Me, 16, -,220-30°/15°, -; 3, Et, 78, 51, 35.2, 79.8° (oxalate); 3, Bu, 58, 70, 110°, 107.3° (oxalate). The following Pr2CHCO2(CH2)nNR2 were prepared (n, R, % yield and m.p. or b.p. given): 2, Me, 58, 97°/2 (oxalate m. 140°); 2, Et, 80, 118°/2. The following Pr2CHCONH(CH2)2N+Et2R X- were prepared (R, X, % yield, and m.p. given): Me, I, 48, 42°; Et, I, 52, 98.1°; PhCH2, Cl, 81, 107.8°. The following PrCHCO2CH2CH2N+R2R1 X- were prepared (R, R1, X, % yield, and m.p. given): Me, Et, I, 50, 58-5°; Et, Et, I, 67, 169°; Me, PhCh2, Cl, 52, 94°. None of the derivs. had the anticonvulsant properties of Pr2CHCO2H. The hypnotic and tranquilizing properties of these derivs. were discussed.
ACCESSION NUMBER: 1969:86985 CAPLUS
DOCUMENT NUMBER: 70:86985
TITLE: Dipropylacetic acid derivatives. III. Amides and esters
AUTHOR(S): Benoit-Guyod, Jean L.; et al.
CORPORATE SOURCE: Fac. Mixte Med. Pharm., Grenoble, Fr.
SOURCE: Chimica Therapeutica (1968), 3(5), 336-42
CODEN: CHTPBA; ISSN: 0009-4374
DOCUMENT TYPE: Journal

L7 ANSWER 74 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
LANGUAGE: French
IT **22632-50-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 22632-50-4 CAPLUS
CN Morpholine, 3,6-dimethyl-2-phenyl-4-(2-propylvaleryl)- (8CI) (CA INDEX NAME)



L7 ANSWER 75 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 12 May 1984
AB Studies made by B. and B. (1968) of the gas-liquid chromatographic retention indexes of 2-phenyl-4-alkyl-tetrahydro-1,4-oxazine homologs were extended to the isomers in which the alkyl substituent (R) is iso-Pr, Pr, iso-Bu, Bu, isopentyl, pentyl, or allyl. Retention indexes are presented for the isomers on Chromosorb W columns coated with 8% Apiezon L + 2% KOH and with 10% UCON Polar 50 HB 2000 + 10% KOH and on a silicone oil XF 1150/ Chromosorb G (acid-washed) column, at 175, 200, or 225°. The retention indexes are related linearly to the b.p. at normal pressure for the compds. with unbranched R groups. An average value for the difference between the retention indexes of a pair of isomers can be determined
ACCESSION NUMBER: 1969:43891 CAPLUS
DOCUMENT NUMBER: 70:43891
TITLE: Establishment and study of retention indexes of members of a homologous series, 2-phenyl-4-alkyltetrahydro-1,4-oxazines. III. Behavior of several isomers
AUTHOR(S): Bondivenne, R.; Busch, Norbert
CORPORATE SOURCE: Serv. Chim. Organ., C.E.R.M., Riom, Fr.
SOURCE: Journal of Gas Chromatography (1968), 6(11), 548-50
CODEN: JGCRAY; ISSN: 0096-2686
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **21532-12-7 21532-13-8 23222-65-3 23980-58-7**
RL: ANT (Analyte); ANST (Analytical study)
(chromatog. of)
RN 21532-12-7 CAPLUS
CN Morpholine, 4-butyl-2-phenyl- (8CI, 9CI) (CA INDEX NAME)

RN 21532-13-8 CAPLUS
CN Morpholine, 4-pentyl-2-phenyl- (8CI) (CA INDEX NAME)

RN 23222-65-3 CAPLUS
CN Morpholine, 4-isopentyl-2-phenyl- (8CI) (CA INDEX NAME)

L7 ANSWER 75 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 23980-58-7 CAPLUS
CN Morpholine, 4-isobutyl-2-phenyl- (8CI) (CA INDEX NAME)

IT **21532-11-6P**
RL: ANST (Analytical study); PREP (Preparation)
(preparation of)
RN 21532-11-6 CAPLUS
CN Morpholine, 2-phenyl-4-propyl- (8CI, 9CI) (CA INDEX NAME)

L7 ANSWER 76 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 12 May 1984
AB Retention indexes were calculated for compds. belonging to a homologous series and examined by chromatog. on a polar liquid phase. A math. relation was established between these retention indexes and b.p. at normal pressure for the 3 studied column temps. (175, 200, 225°). This relation allows extrapolation of the 1st results to other compds. of the same series. There is an increase in the index of 100 units for each addnl. CH2 group.
ACCESSION NUMBER: 1968:489896 CAPLUS
DOCUMENT NUMBER: 69:89896
TITLE: Establishment and study of retention indexes of members of a homologous series: 2-phenyl-4-alkyl-tetrahydro-1,4-oxazines. II. Third liquid phase
AUTHOR(S): Bondivenne, R.; Busch, N.
CORPORATE SOURCE: Serv. Chim. Org., Riom, Fr.
SOURCE: Journal of Gas Chromatography (1968), 6(8), 455-7
CODEN: JGCRAY; ISSN: 0096-2686
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **21532-11-6 21532-12-7 21532-13-8**
21532-14-9 21563-81-5 21563-82-6
RL: PRP (Properties)
(chromatographic retention indexes of, boiling point in relation to)
RN 21532-11-6 CAPLUS
CN Morpholine, 2-phenyl-4-propyl- (8CI, 9CI) (CA INDEX NAME)

RN 21532-12-7 CAPLUS
CN Morpholine, 4-butyl-2-phenyl- (8CI, 9CI) (CA INDEX NAME)

RN 21532-13-8 CAPLUS
CN Morpholine, 4-pentyl-2-phenyl- (8CI) (CA INDEX NAME)

L7 ANSWER 76 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 21532-14-9 CAPLUS
CN Morpholine, 4-hexyl-2-phenyl- (8CI) (CA INDEX NAME)

RN 21563-81-5 CAPLUS
CN Morpholine, 4-heptyl-2-phenyl- (8CI) (CA INDEX NAME)

RN 21563-82-6 CAPLUS
CN Morpholine, 4-octyl-2-phenyl- (8CI) (CA INDEX NAME)

L7 ANSWER 77 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 12 May 1984
GI For diagram(s), see printed CA Issue.
AB Kovats retention indexes were calculated for I, where R was Me and straight-chain C3-8 on polar and nonpolar gas chromatographic columns. The 8% Apiezon L-2% KOH/Chromosorb W and 10% silicone oil XF 1150/Chromosorb G (acid-washed) columns were standardized with normal alkanes. N carrier gas and a H flame ionization detector were used. The retention indexes are tabulated at 175, 200, and 225°. The differences in the indexes between the nonpolar and polar phases permitted the verification of the structure of addnl. I homologs having retention times different from those obtained for the I studied. For the Apiezon L-KOH column, a math. relation was established between the retention index (IR) and the b.p. (Tb) at normal pressure: IR = 8.29 Tb-758.9, so that retention indexes can be approximated for I homologs from b.p. data.
ACCESSION NUMBER: 1968:483187 CAPLUS
DOCUMENT NUMBER: 69:83187
TITLE: Retention indexes of substances of a homologous series, 2-phenyl-4-alkyltetrahydro-1,4-oxazines
AUTHOR(S): Bondivenne, R.; Busch, N.
CORPORATE SOURCE: Serv. Chem. Org., C.E.R.M., Riom, Fr.
SOURCE: Journal of Gas Chromatography (1968), 6(4), 198-202
CODEN: JGCRAY; ISSN: 0096-2686
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **21532-11-6 21532-12-7 21532-13-8**
21532-14-9 21563-81-5 21563-82-6
RL: ANT (Analyte); ANST (Analytical study)
(chromatog. of)
RN 21532-11-6 CAPLUS
CN Morpholine, 2-phenyl-4-propyl- (8CI, 9CI) (CA INDEX NAME)



RN 21532-12-7 CAPLUS
CN Morpholine, 4-butyl-2-phenyl- (8CI, 9CI) (CA INDEX NAME)



RN 21532-13-8 CAPLUS
CN Morpholine, 4-pentyl-2-phenyl- (8CI) (CA INDEX NAME)

L7 ANSWER 77 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 21532-14-9 CAPLUS
CN Morpholine, 4-hexyl-2-phenyl- (8CI) (CA INDEX NAME)

RN 21563-81-5 CAPLUS
CN Morpholine, 4-heptyl-2-phenyl- (8CI) (CA INDEX NAME)



RN 21563-82-6 CAPLUS
CN Morpholine, 4-octyl-2-phenyl- (8CI) (CA INDEX NAME)



L7 ANSWER 78 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 12 May 1984
AB The title compds. are tranquilizers. To a suspension of 50 g. α-(1-aminoethyl)benzyl alc. (dl-norephedrine) in 500 ml. of C6H6 was added 24 g. 50% NaH dispersion in portions, and the mixture stirred for 1 hr. Then a solution containing 43 g. freshly distilled Et chloroacetate in 50 ml. C6H6 was added over 15 min. and the mixture stirred for 1 hr. The suspension was treated with enough H2O to dissolve the solid and the mixture was extracted with 5% aqueous HCl. The acid solution was extracted with Et2O and the Et2O and C6H6 portions were combined, dried, and concentrated The oily solid was washed with a small amount of H2O and recrystd. from AcOEt to give cis-5-methyl-6-phenyl-3-morpholinone, m. 138-40.5°. Similarly prepared were: trans-5-methyl-6-phenyl-3-morpholinone, m. 168-71°; 6-phenyl-3-morpholinone, m. 108-9.5°; 4,5-dimethyl-6-phenyl-3-morpholinone, b0.1 117-20°, n23D 1.5428; 6-(p-methoxyphenyl)-3-morpholinone, m. 151.8-2.8°; N-(β-hydroxy-α-methylphenethyl)-2-phenyl-2-chloroacetamide, m. 150-2°; 2,6-diphenyl-5-methyl-3-morpholinone, m. 177-82°; N-(β-hydroxy-α-methyl-β-phenylphenethyl)-2-chloroacetamide, m. 181-1.5°; 5-methyl-6,6-diphenyl-3-morpholinone, m. 265-6°; N-(β-hydroxy-α-phenylphenethyl)-2-chloroacetamide, m. 187-9°; 5,6-diphenyl-3-morpholinone, m. 182-3°; N-(p-chloro-β-hydroxy-α-methylphenethyl)-2-chloroacetamide, m. 92-4°; 6-(p-chlorophenyl)-5-methyl-3-morpholinone, 146-8.5°; N-(β-hydroxy-α-methylphenethyl)-N-methyl-2-chloro-2-phenylacetamide; 4,5-dimethyl-2,6-diphenyl-3-morpholinone, b0.05 172-6°; 4-diethylaminoethyl-5-methyl-6-phenyl-3-morpholinone-HCl, m. 224-5.5°; 6-(p-chlorophenyl)-3-morpholinone, m. 148.5-50°; N-(β-hydroxy-3,4,5-trimethoxyphenethyl)-2-chloroacetamide, m. 111-12°; 6-((3,4,5-trimethoxyphenyl)-3-morpholinone, m. 161.5-1.8°; 4-acetyl-5-methyl-6-phenyl-3-morpholinone, b0.06-0.08 108-9°; 4-isobutyryl-5-methyl-6-phenyl-3-morpholinone, b0.06 126-8°; 4-benzoyl-5-methyl-6-phenyl-3-morpholinone, m. 119.5-24.5°; 4-butyl-5-methyl-6-phenyl-3-morpholinone, b0.03 115°; 4-butyl-6-phenyl-3-morpholinone, b0.075 123-5°; N - (β - hydroxy - p - trifluoromethylphenethyl) - 2-chloroacetamide, m. 92.5-95°; 6 - (α,α,α - trifluoro - p - tolyl)-3-morpholinone, m. 115.5-16.5°; 3'-trifluoromethylpropiophenone, b0.05 58-60°; 2 - hydroxymino - 3' - trifluoromethylpropiophenone, m. 115-16°; α - (1-aminoethyl) - m - trifluoromethylbenzyl alc. hydrochloride, m. 204°; N - (β-hydroxy- α - methyl - m - trifluoromethylphenethyl) - 2 - chloroacetamide, m. 65.5-8.5°; 5 - methyl - 6 - (α,α,α - trifluoro - m - tolyl)- 3 - morpholinone, m. 110-1.5°; 5-methyl-6-phenyl-4-(α,α,α-trifluoro-p-toluoyl)-3-morpholinone, m. 119.5-20.5°; 4-(p-chlorobenzoyl)-5-methyl-6-phenyl-3-morpholinone, m. 113-14°; 4'-trifluoromethylpropiophenone; 2 - hydroxyimino - 4' - trifluoromethylpropiophenone, m. 134-7°; 2-amino-4'-trifluoromethylpropiophenone-HCl, m. 253-6°; α-(1-aminoethyl)-p-trifluoromethylbenzyl alc. hydrochloride, m. 240-50°; N-(β-hydroxy-α-methyl-p-trifluoromethylphenethyl)-2-chloroacetamide, m. 93-5°; 5-methyl-6-(α,α,α-trifluoro-p-tolyl)-3-morpholinone, m. 127.5-29°; 2-chloroacetamido-4'-chloropropiophenone, m. 104.5-5.5°; 6-(p-chlorophenyl)-5-methyl-4H-1,4-oxazin-3(2H)-one, m. 205-7°; 4-benzoyl-6-(α,α,α-trifluoro-p-tolyl)-3-morpholinone, m.

L7 ANSWER 78 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
156-7°; N-(β-hydroxy-α-methylphenthyl)-2,2-dichloroacetamide, m. 96-7°; 2-morpholino-5-methyl-6-phenyl-3-morpholinone, m. 212-15°; 2-hydroxy-5-methyl-6-phenyl-3-morpholinonone, m. 197-8.5°; 2-chloroacetamidopropiophenone, m. 87-8°; 5-methyl-6-phenyl-4H-1,4-oxazin-3(2H)-one, m. 227-9°; α-hydroxylimino-4'-benzyloxypropiophenone, m. 138-9°; α-(1-aminoethyl)-p-benzyloxybenzyl alc., m. 114-21.5°; the HCl salt m. 195-200°; N-(p-benzyloxy - β - hydroxy-α - methylphenethyl) - 2 - chloroacetamide, m. 123-4.5°; 6-(p-benzyloxyphenyl)-5-methyl-3-morpholinone, m. 181.5-2.5°; 6-(p-hydroxyphenyl-5-methyl-3-morpholinone, m. 240.5-2.5°; cis-5-methyl-6-phenyl-morpholine-3-thione m. 160-1°; 2'-trifluoromethylpropionone, b0.5 55-8°; 2-hydroxy-amino-2'-trifluoromethylpropiophenone, m. 96-7°; 2-amino-2'-trifluoromethylpropiophenone-HCl, m. 223.5-24°; α-(1-aminoethyl)-o-trifluoromethylbenzyl alc. hydrochloride, m. 247-50°; N-(β-hydroxy-α-methyl- o - trifluoromethylphenethyl) - 2 - chloroacetamide; 5-methyl-6-(α,α,α-trifluoro-o-tolyl)-3-morpholinone, m. 142.5-4.5°; 5-methyl-6-phenyl-3-morpholinone.

ACCESSION NUMBER:	1967:432693 CAPLUS
DOCUMENT NUMBER:	67:32693
TITLE:	3-Morpholines, thiones, and 5,6oxazines
INVENTOR(S):	Gannon, Walter F.; Poos, George I.
PATENT ASSIGNEE(S):	McNeil Laboratories, Inc.
SOURCE:	U.S., 9 pp. CODEN: USXXAM
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3308121		19670307	US	19611113
GB 1116736			GB	

IT **16187-69-2P 16187-71-6P 16187-72-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 16187-69-2 CAPLUS
CN 3-Morpholinone, 4-isobutyryl-5-methyl-6-phenyl- (8CI) (CA INDEX NAME)



RN 16187-71-6 CAPLUS
CN 3-Morpholinone, 4-butyl-5-methyl-6-phenyl- (8CI) (CA INDEX NAME)

L7 ANSWER 78 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 16187-72-7 CAPLUS
CN 3-Morpholinone, 4-butyl-6-phenyl- (8CI, 9CI) (CA INDEX NAME)



L7 ANSWER 79 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 22 Apr 2001
GI For diagram(s), see printed CA Issue.
AB Compds. of the general formula I are prepared and can be used as antidepressants. Thus, a mixture of 4.35 g. morpholine, 12.9 g. p-ClC6H4CO(CH2)3Cl, 5 g. NaHCO3, 0.1 g. NaI, and 100 ml. PhMe is refluxed 5 days to give 4'-chloro-4-morpholinobutyrophenone-HCl, m. 179° (EtOH-ether). Similarly prepared are the following I (X, R, R1, R2, b.p./mm., m.p. and m.p. of salt given): MeO, H, H, H, --, --, HCl 202-3° (EtOH-ether); F, Me, H, Me, --, --, HCl 201-2° (EtOH-ether); Cl, Me, H, Me, --, --, HCl.2H2O 192°; MeO, Me, H, Me, --, --, HCl.H2O 186-7°; H, Me, H, Me, --, --, HCl 203-4°; F, Ph, Me, H, --, --, HCl 228-30°; H, H, Me, H, --, --, HCl 144-5° (EtOH-ether); F, Me, H, H, 130-3/0.05 (n22D 1.5175), --, --; H, Ph, H, Ph, --, 116° (MeOH), HCl 195° (EtOH); H, p-ClC6H4, H, H, --, --, HCl 194° (MeOH-ether); H, Me, H, H, --, --, HCl 177° (EtOH); Me, H, H, H, --, --, --, I (X = R = R1 = R2 = H) (5.8 g.) is treated with 0.5 g. LiAlH4 in 70 ml. ether to give α-(3-morpholinopropyl)benzyl alc. (II), m. 69° (petroleum ether). A mixture of 9.1 g. II, 50 ml. Ac2O, and H2SO4 is refluxed 2 hrs. to give α-(3-morpholinopropyl)benzyl acetate, b002 140-2°, n23D 1.5160.
ACCESSION NUMBER: 1966:52088 CAPLUS
DOCUMENT NUMBER: 64:52088
ORIGINAL REFERENCE NO.: 64:9738e-g
TITLE: γ-Morpholinobutyrophenones
INVENTOR(S): Jack, David; Harper, Norman J.; Ritchie, Alexander C.; Hayes, Norman F.
PATENT ASSIGNEE(S): Allen & Hanburys Ltd.
SOURCE: 15 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BE 653093		19641231	BE	
			GB	19630917

PRIORITY APPLN. INFO.:
IT **5170-55-8**, Butyrophenone, 4'-fluoro-4-(3-methyl-2-phenylmorpholino)-, hydrochloride
(manufacture and use as antidepressive drug)
RN 5170-55-8 CAPLUS
CN Butyrophenone, 4'-fluoro-4-(3-methyl-2-phenylmorpholino)-, hydrochloride (7CI, 8CI) (CA INDEX NAME)



● HCl

L7 ANSWER 79 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 5170-58-1 CAPLUS
CN Butyrophenone, 4-(3-methyl-2-phenylmorpholino)-, hydrochloride (7CI, 8CI) (CA INDEX NAME)



● HCl

RN 5170-59-2 CAPLUS
CN Butyrophenone, 4-(3-methyl-2-phenylmorpholino)- (7CI, 8CI) (CA INDEX NAME)



RN 5170-61-6 CAPLUS
CN Butyrophenone, 4-[2-(p-chlorophenyl)morpholino]- (7CI, 8CI) (CA INDEX NAME)

L7 ANSWER 79 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
IT **5170-26-3**, Butyrophenone, 4-(2,6-diphenylmorpholino)-
5170-27-4, Butyrophenone, 4-(2,6-diphenylmorpholino)-, hydrochloride **5170-28-5**, Butyrophenone, 4-[2-(p-chlorophenyl]morpholino)-, hydrochloride **5170-58-1**, Butyrophenone, 4-(3-methyl-2-phenylmorpholino)-
5170-59-2, Butyrophenone, 4-(3-methyl-2-phenylmorpholino)-
5170-61-6, Butyrophenone, 4-[2-(p-chlorophenyl]morpholino]-
5487-29-6, Butyrophenone, 4'-fluoro-4-(3-methyl-2-phenylmorpholino)-
(preparation of)
RN 5170-26-3 CAPLUS
CN 1-Butanone, 4-(2,6-diphenyl-4-morpholinyl)-1-phenyl- (9CI) (CA INDEX NAME)



RN 5170-27-4 CAPLUS
CN Butyrophenone, 4-(2,6-diphenylmorpholino)-, hydrochloride (7CI, 8CI) (CA INDEX NAME)



● HCl

RN 5170-28-5 CAPLUS
CN Butyrophenone, 4-[2-(p-chlorophenyl)morpholino]-, hydrochloride (7CI, 8CI) (CA INDEX NAME)

L7 ANSWER 79 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 5487-29-6 CAPLUS
CN Butyrophenone, 4'-fluoro-4-(3-methyl-2-phenylmorpholino)- (7CI, 8CI) (CA INDEX NAME)



L7 ANSWER 80 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 22 Apr 2001
GI For diagram(s), see printed CA Issue.
AB 7-Dipropylamino-2-butylamino-3-imino-3H-phenoxazine (50 g.) in 1 l. Me2CO and 200 cc. H3PO4 (d. 1.7) refluxed 0.5 hr., diluted with dilute aqueous KOH, and extracted with Et2O, and the residue from the extract chromatographed on Al2O3 gave oily I which treated with alc. HCl and diluted with iso-Pr2O yielded I.HCl. The crude I hydrogenated in EtOH over PtO2 and reoxidized with air yielded the red, crystalline I, m. 83-4° (80% aqueous Me2CO), green in H2O turning blood-red upon the addition of excess HCl. I exhibits a tuberculostatic activity.
ACCESSION NUMBER: 1966:52087 CAPLUS
DOCUMENT NUMBER: 64:52087
ORIGINAL REFERENCE NO.: 64:9738c-e
TITLE: Phenoxazine derivative
PATENT ASSIGNEE(S): Roussel-UCLAF
SOURCE: 4 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
NL 302969		19651025	NL	19631231

IT **5170-58-1**, Butyrophenone, 4-(3-methyl-2-phenylmorpholino)-, hydrochloride **5170-59-2**, Butyrophenone, 4-(3-methyl-2-phenylmorpholino)- (preparation of)
RN 5170-58-1 CAPLUS
CN Butyrophenone, 4-(3-methyl-2-phenylmorpholino)-, hydrochloride (7CI, 8CI) (CA INDEX NAME)



● HCl

RN 5170-59-2 CAPLUS
CN Butyrophenone, 4-(3-methyl-2-phenylmorpholino)- (7CI, 8CI) (CA INDEX NAME)

L7 ANSWER 80 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L7 ANSWER 81 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 22 Apr 2001
GI For diagram(s), see printed CA Issue.
AB The title compds. (I) are prepared by treating an oxirane with a hydroxyamine followed by cyclization of the resulting diol with acidic reagents. Thus, 48 parts styrene oxide (II), 35.6 parts 1,2-dimethylethanolamine (III), and 2 parts H2O was heated 3 hrs. at 40-50° and then 15 hrs. at 80-90° to give N-(3-hydroxy-2-butyl)-N-(2-hydroxy-2-phenylethyl)amine (IV), b0.0002 106°. IV (40 parts) in 200 parts concentrated H2SO4 was stirred at room temperature with occasional cooling and kept 24 hrs. afforded I (Ar = Ph, R1 = R3 = H, R2 = R4 = Me), b0.0007 68°. Similarly, 9.8 parts cyclohexene oxide, 16.5 parts l-ephedrine, and 0.5 part H2O was heated 3 hrs., the mixture cooled and dissolved in 200 parts ether, a solution of 9.8 parts concentrated H2SO4 in 100 parts Et2O added at 0°, Et2O distilled, and the residue mixed with 100 parts concentrated H2SO4 and kept 14 hrs. at room temperature afforded I [Ar = Ph, R1 = R3 = Me, (R2R4 =)(CH2)4], b0.02 91-3° The following I were similarly prepared (Ar, R1, R2, R3, R4, and b.p. given): Ph, H, Me, Bu, Me, b0.001 81-2°; Ph, H, Me, Me, Me, b0.0007 56-7°; Ph, Me, (R2R4 =)(CH2)4, H, b0.005 93-5°; Ph, H, (R2R4 =)(CH2)2, H, b0.1 130-40°; p-HOC6H4, H, (R2R4 =)(CH2)4, Me, - (m. 228-9°); p-MeOC6H4, H, Me, H, Me, b0.0001 95-6°. These substances are hypotensive agents and stimulate the central nervous system
ACCESSION NUMBER: 1964:45763 CAPLUS
DOCUMENT NUMBER: 60:45763
ORIGINAL REFERENCE NO.: 60:8040c-f
TITLE: 2-Phenyl-5,6-dimethylmorpholines and 2-phenyl-5,6-tetra-methylenemorpholines
INVENTOR(S): Zimmermann, Markus; Haefliger, Franz
PATENT ASSIGNEE(S): Geigy Chemical Corp.
SOURCE: 3 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3112311		19631126	US	
PRIORITY APPLN. INFO.:			CH	19570405

IT **93145-27-8**, Morpholine, 4-butyl-2,3-dimethyl-6-phenyl- (preparation of)
RN 93145-27-8 CAPLUS
CN Morpholine, 4-butyl-2,3-dimethyl-6-phenyl- (7CI) (CA INDEX NAME)



L7 ANSWER 82 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 22 Apr 2001
GI For diagram(s), see printed CA Issue.
AB Substituted morpholines (I) (R = alkyl with 1-5 C atoms; R1 = small alkyl group) are prepared by cyclizing diethanolamines: HOCH2CH2NRCHR1CHPhOH or by alkylating 2-phenyl-3-alkylmorpholines. Thus, 10 g. 1-phenyl[N-(β-hydroxyethyl)-N-methylamino]propan-1-ol, HCl salt and 20 g. p-MeC6H4SO3H is stirred 20 hrs. at 140°, the mixture cooled, diluted with H2O, made alkaline with 35% aqueous NaOH, extracted with ether, and the extract dried and distilled to give 84% 2-phenyl-3,4-dimethylmorpholine, b12 145°; HCl salt m. 165-6°, L.D.50 450 mg./kg. mouse subcutaneously. Similarly prepared is 2-phenyl-3-methyl-4-amylmorpholine (87%), b0.5; 115-19°; HCl salt m. 238°, L.D.50 1.48 g./kg. mouse subcutaneously. Also prepared is 2-phenyl-3-methyl-4-ethylmorpholine, b4 132°.
ACCESSION NUMBER: 1963:14911 CAPLUS
DOCUMENT NUMBER: 58:14911
ORIGINAL REFERENCE NO.: 58:2458d-f
TITLE: Substituted morpholines
INVENTOR(S): Kurzen, Fritz; Siemer, Harm; Doppstadt, Adolf
PATENT ASSIGNEE(S): Ravensberg G.m.b.H. Chemische Fabrik
SOURCE: 4 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1137439		19621004	DE	19540710

IT **93145-28-9**, Morpholine, 3-methyl-4-pentyl-2-phenyl-, hydrochloride **93145-29-0**, Morpholine, 3-methyl-4-pentyl-2-phenyl- (preparation of)
RN 93145-28-9 CAPLUS
CN Morpholine, 3-methyl-4-pentyl-2-phenyl-, hydrochloride (7CI) (CA INDEX NAME)



● HCl

RN 93145-29-0 CAPLUS
CN Morpholine, 3-methyl-4-pentyl-2-phenyl- (7CI) (CA INDEX NAME)



L7 ANSWER 82 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L7 ANSWER 83 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 22 Apr 2001
AB cf. CA 55, 20616d. Absorption spectra, 230-300 mu, for R2NCH2CH2CPh2CONR'R'', R2NCH2CHMeCPh2CONR'R'', and R2NCHMeCH2CPh2CONR'R'' were analyzed, where R' and R'' are H, Et, Me, pyrrolidinyl, and piperidinyl; and R2N is Me2N, Pr2N, iso-Pr2N, pyrrolidinyl, piperidinyl, morpholinyl, and hexahydroazepinyl. The form of the curve is different for the 3 types of compound, and can be used for structure determination
ACCESSION NUMBER: 1962:460312 CAPLUS
DOCUMENT NUMBER: 57:60312
ORIGINAL REFERENCE NO.: 57:11973c-d
TITLE: Ultraviolet absorption of substituted α,α-diphenylbutyramides
AUTHOR(S): Loomans, Jos; Demoen, Paul
CORPORATE SOURCE: Res. Lab. Dr. C. Janssen, Beerse, Belg.
SOURCE: Mededel. Vlaam. Chem. Ver. (1962), 24, 54-64
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
IT **95129-52-5**, 4-Morpholinebutyramide, N,N-dimethyl-2,2-diphenyl- (spectrum of)
RN 95129-52-5 CAPLUS
CN 4-Morpholinebutyramide, N,N-dimethyl-2,2-diphenyl- (7CI) (CA INDEX NAME)



L7 ANSWER 84 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 22 Apr 2001
GI For diagram(s), see printed CA Issue.
AB The title compds. (I) wherein Z is alkylene and R is imido, are capable of inhibition of the appetite. They can be made by heating 3-methyl-2-phenylmorpholine (II) with an imide in the presence of formalin, using an alc. reaction medium; or preferably by heating II with a haloalkylimide, XZR, in the presence of anhydrous base. For example, to a solution of succinimide (9 parts by weight) in absolute EtOH (80) is added II (8) and 36% formalin (18). The mixture is heated at 90° 1 hr. and enough H2O is added to produce turbidity. Crystallization occurs on cooling and standing. The product is filtered and recrystd. (cyclohexane) to give 3-methyl-2-phenyl-4-succinimidomethylmorpholine, m. 127-30°. The 4-phthalimido derivative m. 142-4°, can be made from phthalimide, II, and formalin in absolute EtOH. The 4-(2-succinimidoethyl)-HCl derivative, m. 287-9°, may be made from II, and -N-(2-bromoethyl)succinimide. The 4-(2-phthalimidoethyl)-HCl, m. 247-51°, was made from N-(2-bromoethyl)phthalimide and II. The 4-(5-succinimidopentyl)-HCl derivative, m. 167.5-73°, was made from II and N-(5-bromopentyl)succinimide, d-3-Methyl-2-phenyl-4-succinimidomethylmorpholine, m. 125-34° and a sp. rotation of 8.79°, was made from succinimide, d-3-methyl-2-phenylmorpholine and formalin with EtOH solvent.
ACCESSION NUMBER: 1962:442881 CAPLUS
DOCUMENT NUMBER: 57:42881
ORIGINAL REFERENCE NO.: 57:8586h-i,8587a-b
TITLE: 4-Imidoalkyl-3-methyl-2-phenylmorpholines
INVENTOR(S): Kalm, Max J.; Rorig, Kurt J.
PATENT ASSIGNEE(S): G.D. Searle and Co.
SOURCE: 3 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3025293		19620313	US	19580407

IT **100028-29-3**, Succinimide, N-[5-(3-methyl-2-phenylmorpholino)pentyl]-, hydrochloride (preparation of)
RN 100028-29-3 CAPLUS
CN Succinimide, N-[5-(3-methyl-2-phenylmorpholino)pentyl]-, hydrochloride (6CI, 7CI) (CA INDEX NAME)



● HCl

L7 ANSWER 84 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L7 ANSWER 85 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 22 Apr 2001
AB The title compds. had valuable neurophysiol. properties and could be used as intermediates in the production of other compds. with similar properties. Glycide 7.4 and L-ephedrine (I) 16.5 added to H2O 0.5, the mixture heated 15 hrs. at 90°, the cooled resin dissolved in Et2O 200, a solution of H2SO4 9.8 in Et2O 100 added at 0°, the Et2O distilled, the residue mixed at 0° with H2SO4 100 parts, the solution poured on ice after 2-3 hrs., the mixture extracted with Et2O, NaOH added to the aqueous phase to an alkaline reaction, the mixture extracted with Et2O, and the extract dried and distilled gave 2-phenyl-3,4-dimethyl-6-hydroxymethylmorpholine. The following substituted morpholines were similarly prepared [substituent, b.p./mm., and (parts) given]: 2-phenyl-3,4-dimethyl-6-ethoxymethyl, 92-4°/0.03, from I (16.5) and glycide Et ether (10.2); 2-phenyl-3,4-dimethyl-5,6-tetramethylene, 9-93°/0.02 (sic), from I (16.5) and cyclohexene oxide (9.8); 2-phenyl-3,4-dimethyl-6-decyl, 139-40°/0.0001, from I (16.5) and 1,2-epoxydodecane (II) (20.3); and 2-(p-chlorophenyl)-3-methyl-6-decyl, 150-2°/0.0005, from 1-(p-chlorophenyl)-2-aminopropanol (18.5) and II (20.3). I 16.5 and propylene oxide (III) 7 parts heated 5 hrs. at 80-90° in a sealed tube and then worked up as in the 1st example gave 2-phenyl-3,4,6-trimethylmorpholine, b0.05 71-2.5°, [α]20D 34.8° (c 1.349, CHCl3); picrate m. 167-72°. 2-(3',4'-Dimethylphenyl)-3,6-dimethylmorpholine was similarly obtained from 1-(3',4'-dimethylphenyl)-2-aminopropanol 17.9, III 6, and H2O 0.5 part. 1-(p-Hydroxyphenyl)-2-methylaminoethanol 16.7 dissolved in HCONMe2 100 and H2O 1 at 100-10°, benzyl ethylene oxide 13.4 added, the mixture heated 20 hrs. at 100-10° and evaporated to dryness in vacuo, and the residue dissolved in 48% HBr 130 parts gave 2-(4'-hydroxyphenyl)-4-methyl-6-benzylmorpholine. I 15, 3-phenoxy-1,2-epoxypropane 13.5, and H2O 1 heated at 50° until dissolved and then 14 hrs. at 100°, the crude product 25 dissolved in iso-PrOH-HCl, the solution evaporated to dryness in vacuo, p-MeC6H4SO3H 0.5 part added to the residue, the mixture heated 10 hrs. at 170°/30-50 mm., and the residue dissolved in aqueous K2CO3 and extracted with Et2O gave 2-phenyl-3,4-dimethyl-6-phenoxymethylmorpholine, b0.0001 117-20°, on distillation of the extract Similarly, 2-(3',4'-dimethoxyphenyl)-3-methyl-6-phenoxymethylmorpholine was obtained from 1-(3', 4'-dimethoxyphenyl)-2-aminopropanol 21.1 and 1-phenoxy-2,3-epoxypropane 15, 2-(4'-methoxyphenyl)-3-methyl-6-vinylmorpholine from 1-(4'-methoxyphenyl)-2-aminopropanol 18.2 and butadiene monoxide 7, and 2-phenyl-3,4-dimethyl-6-phenylthiomethylmorpholine, b0.0004 135-8° from I 16.5 and 1-phenylthio-2,3-epoxypropane 16.6 parts. 2-Phenyl-5,6-dimethylmorpholine (IV) 7.6, BuOH 90, BuBr 5.5, and K2CO3 6.9 parts heated 24 hrs. at 80-90° with stirring, the mixture concentrated in vacuo, and the aqueous solution of the residue extracted with Et2O gave on evaporation of the extract 2-phenyl-4-butyl-5,6-dimethylmorpholine, b0.001 81-2°. 2-(3',4'-Dimethylphenyl)-3,6-dimethyl-4-allylmorpholine was similarly prepared from 2-(3',4'-dimethylphenyl)-3,6-dimethylmorpholine 11 and allyl chloride 3.8 parts. Styrol oxide 48, 1,2-dimethylethanolamine 35.6, and H2O 2 parts heated 3 hrs. at 40-50° and 15 hrs. at 80-90° gave (3-hydroxy-2-butyl-2-hydroxy-2-phenylethyl)amine (V), b0.0002 106°. V 40 dissolved in H2SO4 200 parts with cooling, and the solution kept 24 hrs. at room temperature, poured into ice H2O, made alkaline with NaOH, and extracted with Et2O gave IV, b0.0007 68°.

L7 ANSWER 85 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
ACCESSION NUMBER: 1961:54380 CAPLUS
DOCUMENT NUMBER: 55:54380
ORIGINAL REFERENCE NO.: 55:10481e-i,10482a-c
TITLE: Morpholine compounds
INVENTOR(S): Zimmermann, Markus; Haefliger, Franz
PATENT ASSIGNEE(S): J. R. Geigy Akt.-Ges.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 851311		19601012	GB	

IT **101450-40-2**, Morpholine, 4-butyl-2,3-dimethoxy-6-phenyl-
(preparation of)
RN 101450-40-2 CAPLUS
CN Morpholine, 4-butyl-2,3-dimethoxy-6-phenyl- (6CI) (CA INDEX NAME)



L7 ANSWER 86 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 22 Apr 2001
AB Morpholine derivs., RYN.CHMe.CHPh.O.CH2.CH2, where Y = an alkylene radical, CnH2n (n is less than 9), and R = imido radical, were prepared They were anorectic agents, affected water balance, and were mildly diuretic. Thus, 3-methyl-2-phenylmorpholine 8 and formalin 18 was added to succinimide 9 in absolute alc. 80 parts, the mixture heated 1 hr. at 90°, and H2O added to turbidity to give 3-methyl-2-phenyl-4-succinimidomethylmorpholine, m. 127-30°. Similarly prepared was 3-methyl-2-phenyl-4-phthalimidomethylmorpholine, m. 142-4°. 3-Methyl-2-phenyl-4-(2-succinimidoethyl)morpholine was prepared by refluxing 48 hrs. 3-methyl-2-phenylmorpholine 8, N-(2-bromoethyl)succinimide 9, butanone 40, and powdered anhydrous K2CO3 3 parts, filtering, distilling the solvent, taking up the residue in dilute HCl, washing with ether, evaporating to dryness, and extracting with EtOH; HCl salt m. 287-9°. Also prepared were: 3-methyl-2-phenyl-4-(2-phthalimidoethyl)morpholine and its hydrochloride, m. 247-51°; N-(5-bromopentyl)succinimide; 3-methyl-2-phenyl-4-(5-succinimidopentyl)morpholine and its hydrochloride, m. 167.5-73°; 1-2-(2-hydroxyethylamino)-1-phenylpropanol, from 1-1-hydroxy-1-phenylpropanone, 2-aminoethanol, PtO2, and H; d-3-methyl-2-phenyl-4-succinimidomethylmorpholine, m. 125-34°, [α]D 8.79°. d-3-Methyl-2-phenylmorpholine, b1.0 89°, [α]D 22.2°, was prepared by adding concentrated H2SO4 to 1-2-(2-hydroxyethylamino)-1-phenylpropanol.
ACCESSION NUMBER: 1961:13520 CAPLUS
DOCUMENT NUMBER: 55:13520
ORIGINAL REFERENCE NO.: 55:2697b-e
TITLE: Morpholine derivatives
PATENT ASSIGNEE(S): G.D. Searle and Co.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 831933		19600406	GB	

IT **100028-29-3**, Succinimide, N-[5-(3-methyl-2-phenylmorpholino)pentyl]-, hydrochloride **102600-29-3**, Succinimide, N-[5-(3-methyl-2-phenylmorpholino)pentyl]-
(preparation of)
RN 100028-29-3 CAPLUS
CN Succinimide, N-[5-(3-methyl-2-phenylmorpholino)pentyl]-, hydrochloride (6CI, 7CI) (CA INDEX NAME)



● HCl

L7 ANSWER 86 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 102600-29-3 CAPLUS
CN Succinimide, N-[5-(3-methyl-2-phenylmorpholino)pentyl]- (6CI) (CA INDEX NAME)



L7 ANSWER 87 OF 87 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 22 Apr 2001
AB The toxicity, spasmolytic activity, and local anesthetic effect of the following compds. have been tested on mice and on the surviving guinea-pig ileum, resp.: α-aminophenylacetamide-H Br; α-dimethylamino-, α-diethylamino-, and α-dibutylaminophenylacetamide-HCl; α-dibutylaminophenylthioacetamide-HCl; 1-[(phenyl)carbamoylmethyl]pyridinium bromide; α-piperidinophenylacetamide-HCl; N, N-dibutyl-α-dibutylaminophenylacetamide-HCl; α-diethylamino-, α-piperidino-, and α-dibutylaminodiphenylacetamide; α-dibutylaminodiphenylacetic acid; N,N-dibutyl-α-dibutylaminodiphenylacetamide; N,N-dibutylbenzilamide; benzhydryldibutylamine-HCl; 2-phenyl-4-butyl-3-morpholinone; 2-phenyl-4-isopropyl-3-morpholinone; 2-oxo-3-phenyl-4,4-diethylmorpholinium bromide; α-dibutylaminophenylacetic acid-HCl; isoamyl p-aminophenylacetate-HCl; isoamyl α-aminophenylacetate-HCl; Et α-dibutylaminophenylacetate-HCl; and Et α-(2-diethylaminoethoxy)phenylacetate-HCl. The spasmolytic activity of all compds. was weak.
ACCESSION NUMBER: 1955:40500 CAPLUS
DOCUMENT NUMBER: 49:40500
ORIGINAL REFERENCE NO.: 49:7746h-i,7747a-b
TITLE: Toxic, spasmolytic, and local anesthetic effects of basic phenylacetyl derivatives
AUTHOR(S): Hohensee, Friedrich
CORPORATE SOURCE: Jenapharm., Jena, Germany
SOURCE: Arzneimittel-Forschung (1954), 4, 598-601
CODEN: ARZNAD; ISSN: 0004-4172
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
IT **73816-71-4**, 3-Morpholinone, 4-butyl-2-phenyl- (pharmacol. of)
RN 73816-71-4 CAPLUS
CN 3-Morpholinone, 4-butyl-2-phenyl- (9CI) (CA INDEX NAME)



Ngrazier 10727168

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	430.68	756.56

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-63.51	-63.51

STN INTERNATIONAL LOGOFF AT 14:20:32 ON 24 JUN 2005